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Epidemiology and etiology of ovarian cancer 
Introduction 
Epidemiology and etiology of ovarian cancer 
Ovarian cancer is considered to be a cancer of Western civilization, along with cancers of the 
breast, colon, rectum, pancreas, and prostate The highest incidence rates are reported in North-
western Europe and North-America In these countries more than 15 cases of ovarian cancer are 
diagnosed per 100,000 women per annum (Waterhouse et al 1976) Since 1930 there has been a 
steady increase in the incidence (and mortality) rate of ovarian cancer, in contrast to the decreased 
incidence of other gynecological malignancies such as cancer of the uterine cervix and en 
dometnum (Cutler & Young 1975, American Cancer Society 1981) 
According to recent data on cancer incidence and mortality in the Netherlands the clinical 
incidence of ovarian cancer was 18 7 per 100,000 women in 1985 (Fig 1 ), thus ranking fourth after 
breast cancer (101 3 per 100,000), colon cancer (30 1 per 100,000) and cancer of the uterine cervix 
(25 9 per 100,000) In 1985, 915 women died of ovarian cancer in the Netherlands making it the 
fourth major cause of cancer death in women after breast cancer (3052 deaths), colon cancer (1585 
deaths), and lung cancer (928 deaths) (Campos Cardoso 1987) 
Although ovarian cancer can occur in all age groups, most patients (80%) present between the 
ages of 40 and 70 years, with about half of these being in the sixth decade (Stadel 1982 Weiss 
1982) 
The observation that the incidence of ovarian cancer among Chinese and Japanese women who 
reside in the United States is higher than among their Asiatic counterparts (Weiss & Peterson 1978) 
suggested that environmental factors play an important role in the etiology of ovarian cancer A 
series of environmental factors have been associated with ovarian cancer such as talc/asbestos 
exposure (Longo & Young 1979 Cramer et al 1982), radiation (Annegerset al 1979, Kleinermanet 
al 1982), coffee drinking (Stocks 1970 Trichopoulos et al 1981) and animal fat consumption 
(Cramer et al 1984, La Vecchia et al 1987) However, the significance of these factors awaits 
biological and/or biostatistical confirmation 
Although families in which more than one member developed a malignant tumor of the ovary 
have been reported familial ovarian cancer is more the exception than the rule (Piver et al 1984) 
Numerous studies have shown that nulliparous women have an increased risk of ovarian cancer 
Among women who had been pregnant the incidence of ovarian cancer is 30 60 % lower than 
nulliparous women, and multiple pregnancies lower the risk still further (for review see Green et al 
1984) Early age at first pregnancy is also considered to lower ovarian cancer risk 
Several case control studies have reported that the use of oral contraceptives decreases the risk 
of ovarian cancer Women who have used oral contraceptives have a 30 to 60% lower chance of 
developing ovarian cancer compared with non users (Cramer et al 1983, Rosenberg et al 1982, 
Newhouseetal 1977, Dicker et al 1983, Stolk& Kenemans 1989) This protective effect was even 
seen in women who had used oral contraceptives for as little as three to six months, and it continued 
for 15 years after use had ended (Lee et al 1987) 
In an attempt to explain the 'dose-response effect' of protection by parity, number of pregnancies 
early age at first birth, and oral contraceptive use, Fathalla (1972) offered the concept of incessant 
ovulation' He proposed that each ovulation was traumatic to the ovarian epithelium (which is 
ruptured and repaired as each ovum is extruded) Repair requires epithelial proliferation 
Mechanisms Involved in the repair process might go awry and lead to unrestrained proliferation and 
neoplasia 
Casagrande et al (1979) and Henderson et al (1982) expanded the concept by computing 
'ovulatory age' as the time from menarche to cessation of a woman's ovulation, minus the time the 
ovary was anovulatory or 'protected' (pregnancy, lactation or oral contraceptive use) Results of 
retrospective studies showed that ovarian carcinoma was associated with a relatively high 'ovulatory 
age'(Casagrande et al 1979, La Vecchia et al 1983, Franceschi et al 1982, Hildreth et al 1981, 
Langer et al 1984) 
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First admissions due to mal ignant neoplasms in the Netherlands-1985 
Males Females 
% 
lung 6 783 25 θ 
prostates 109 11 9 
bladder 2 867 10 9 
colon 1 770 7 6 
stomach 1 516 6 7 Ц 
rectum 343 
skin* 1006 
pancreas 653 
leukemia 571 
other 6615 25 
» · • » — 1 .' • 
ί \.У· 
7. 
29 i, 7І21 breast 
8 8 2208 colon 
7 5 1893 cervix 
5Д 1368 ovary 
5 3 1331 uterus 
it 5 1K6 rectum 
3 8 952 stomach 
3 7 9 a lung 
3 1 789 skin* 
28 4 7175other 
all neoplasms all neoplasms 
26,233(100%) 25.200(1007.) 
*excluding melanoma 
higurel Source Maandbmcht ge/ondhcid (CBS) 6, 5-25,1987 
Epidemiological data also suggest a hormone related influence on the development of ovarian 
cancer Pregnancy and the use of oral contraceptives lower ovarian cancer risk and are associated 
with low gonadotropin levels Furthermore, gonadotropin levels increase with age and are particular­
ly high in early menopausal years, correlating with the age-distribution of the incidence of ovarian 
cancer (Stadel 1982, Weiss 1982) In experimental models, excess gonadotropin secretion ap 
peared to be related to the development of ovarian tumors (Weiss et al 1982, Cramer & Welch 1983) 
Since gonadotropins stimulate steroidgenesis, their effect could be indirect through estrogens 
Indeed, menopausal use of estrogens was found in association with ovarian cancer (Weiss 1982) 
Cramer and Welch (1983) have tried to unite the different etiological factors in one theory (Fig 
2) They proposed that the first step towards malignant growth is the formation of an inclusion cyst 
by the entrapment of surface epithelium in the ovarian stroma The second step is the stimulation 
of the included epithelium by gonadotropins and estrogens resulting in differentiation, proliferation 
and sometimes malignant transformation However, the final (and crucial) stimulus to malignant 
transformation remains unknown In this theory all factors that cause inclusion cyst formation, high 
estrogen levels or high gonadotropin levels may increase the risk of ovarian cancer 
Recent advances in molecular biology have provided new insights into the molecular basis of 
neoplasia The study of tumor viruses has led to the identification of oncogenes responsible for the 
tumorigenic potential of these viruses Tumor viruses themselves do not seem to play an important 
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role in most human cancers However, genetic sequences were found in the human genome that 
were homologous to the viral oncogenes (Bishop 1983) By now 60 of these so-called proto-on 
cogenes encoding protein kinases, growth factors, growth factor receptors, and other cellular 
proteins have been identified Considerable circumstantial evidence now exists that alterations in 
either the structures, copy number, or expression of one or another of these genes may play a role 
in the pathogenesis of some human malignancies (Slamon 1987) 
Which proto-oncogenes play a role in ovarian cancer is as yet unclear Examination of the 
ovary 
inclusion 
cyst formation 
f 
ovary with 
inclusion 
cyst 
' 
ovary with 
differention 
proliferation 
of cyst epi­
thelial cells 
malignant 
transformation 
incessant high estrogen 
ovulation and gonadotropin 
foreign body levels 
(talc) 
Figure 2 Etiology of ovarian carcinoma according to Cramer & Welch 1983 
expression of 15 proto-oncogenes at the transcriptional level in 6 ovarian carcinoma specimens 
showed enhanced expression of с fos, с myc, с rasH a and c-rasKl in most samples (Slamon et al 
1984) However, the role of the c-ras gene in ovarian carcinogenesis could not be confirmed (Haas 
et al 1987, Rodenburgetal 1988) Recent studies indicate that the c-erb B2 gene may be involved 
(Slamon et al 1987) This gene encodes a protein that has intracellular transmembrane and 
extracellular domains being consistent with the structure of a growth factor receptor (Coussens et 
al 1985) Patients with multiple copies of this gene in the DNA from their tumors had a poor prognosis 
(Slamon et al 1987) Recently it has been shown that the erb B2 gene is altered in 25 30% of the 
primary ovarian cancers (Slamon et al 1989) 
HJstopathology of ovarian tumors 
The ovary is a complex structure with both reproductive and endocrine function It is composed 
of a coelomic epithelium a supporting stroma, and functional germ cells Each of these tissues can 
give rise to malignant neoplasms though the epithelial tumors account for approximately 90% of 
all ovarian malignancies (Scully 1979) In 1973 the World Health Organisation published a widely 
accepted system for the classification of ovarian tumors (Serov & Scully 1973) wherein individual 
tumors are defined in histological terms on the basis of their known or presumed histogenesis A 
simplified version is listed in Table ι 
Epithelial ovarian tumors are so designated because they are thought to arise from the germinal 
epithelium, which consists of modified peritoneal cells covering the surface of the ovary The 
germinal epithelium of the ovary developsfrom the Mulleran duct, as does the lining of the fallopian 
tube, endometrium and cervix It is thought that indifferent cells in the surface epithelium of the ovary 
can undergo neoplasia while still retaining their embryonic potential to differentiate along various 
Mullenan pathways This is reflected in the histological appearance of the epithelium of ovarian 
tumors Different types of epithelial ovarian tumors can be distinguished The differentiated epi­
thelium of the serous tumors resembles the epithelium of the fallopian tube that of the mucinous 
tumors resembles the endocervical epithelium, and the epithelium of the endometrioid and clear 
cell tumors resembles that of the uterine endometrium In addition, the Brenner tumor resembles 
the uroepithehum and it therefore appears that the cells of the surface epithelium also have the 
potential for differentiation along Wolffian lines 
The reported relative frequencies of histological subtypes of ovarian carcinomas vary widely, 
most likely as a result of inter-observer variation (Stalsberg et al 1988) Based on the series of 
Kottmeieretal (1982), Stalsberg et al (1983),andMalkasianetal (1984) (724,869, and 1938ovanan 
carcinomas, respectively) serous carcinomas constitute 47-60% of the common epithelial types 
and are the most common, followed by the mucinous (13-17%), endometrioid (10 19%), clear cell 
(4-7%), and undifferentiated carcinomas (over 5%) 
Both malignant and benign forms of most ovarian tumor types are known Fortunately the benign 
variants exceed their malignant counterparts in the ratio of 3 1 in the case of serous tumors and 
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Table 1 Summary of the World Health Orgam/alion classification of malignant ovarian tumors 
I Common 'epithelial' tumors 
A Serous 
В Mucinous 
С Endometrioid 
D Clear cell 
E Brenner 
F Mixed 
G Undifferentiated 
H Unclassified 
II Sex cord stromal tumors 
III Germ cell tumors 
IV Miscellaneous primary tumors 
V Metastatic tumors 
over 4 1 in the case of mucinous growths (Kent & Mc Kay 1960) Occasionally a tumor is observed 
showing only a focus of malignancy in an apparently benign tumor Certain carcinomas resemble 
the benign variant to such an extent that the inherent malignant character of the growth is suggested 
only by minimal differences in the appearance of the epithelial element (Zaloudek 1983 Rutgers & 
Scully 1988) In such borderline tumors, the histological diagnosis of carcinoma is often made with 
difficulty and uncertainty 
Spread of the disease 
Ovarian carcinomas characteristically break through the ovarian capsule In the majority of 
ovarian tumors, penetration of the ovarian capsule results in spread beyond the ovary By exfoliation 
of cancer cells, intra-abdominal metastases may appear anywhere from the floor of the pelvis to the 
diaphragm Continuous growth of ovarian carcinoma into adjacent tissues may involve the fallopian 
tubes, uterus, bladder rectosigmoid and its mesentery Lymphatic spread is also important in 
ovarian cancer (Bergman et al 1966) In ovarian cancer patients with disease presumed to be limited 
to the ovaries (stage I), para aortal lymph node involvement is reported in 10 25% (Feldman & Knapp 
1974 Musumecietal 1980 Kmpscheer 1982, Chen & Lee 1978) Haematogenous dissemination, 
observed in approximately 10% of the ovarian cancer patients, may spread ovarian cancer to liver, 
lung, pleura, pancreas, skeleton and central nervous system (Bergman 1966, Mayer et al 1978) 
Ovarian cancer is staged surgically The FIGO staging system distinguishes the following stages 
I ovarian II pelvic III peritoneal or coelomic and IV metastatic disease The five year survival rate 
is 66% for stage I, 45% for stage II, 11% for stage III and 4% for stage IV (FIGO 1979) 
Prognostic factors 
Of the eight most common cancers in women only lung cancer has a worse prognosis than 
ovarian cancer (Fig 3) Approximately two out of three patients will die as a result of their disease 
(Cutler & Young 1975) The poor survival rate has been ascribed to the fact that the means for an 
early diagnosis are extremely limited The most common symptoms in ovarian cancer are uncharac­
teristic lower abdominal pain, abdominal distension, increasing girth and uncharacteristic symp­
toms from the bladder with frequent voiding These vague, nonspecific symptoms and the lack of 
early physical signs do not alarm the patient sufficiently to seek medical care, with the result that at 
the time of diagnosis the majority of patients (70%) already has widespread disease (Barber 1982) 
The major prognostic indicator of ovarian cancer is the extent of the pathological spread of the 
disease Furthermore, total surgical tumor clearance (Griffiths et al 1979, Smith & Day 1979) and 
complete remission at the end of a course of chemotherapy or radiotherapy (Berek et al 1984, 
Copeland et al 1985) are associated with a significant improvement of survival 
Two histological characteristics have been correlated with prognosis of ovarian tumor patients 
type and grade (for review see Baak et al 1987) Mucinous and endometrioid tumors seem to have 
slightly better prognoses than other histological types, but the prognostic difference between these 
types is relatively small Histological grade is probably more important for predicting the outcome 
in an individual patient Although well differentiated tumors are more frequently associated with low 
stage cancer and poorly differentiated tumors with high stages (Swenerton et al 1985), the tumor 
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SURVIVAL 
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figure 3 Fivcycar survival rates for the commonest lypLS of cancer Source Monitor MBI 8 8 ' ! OPCS 
grade is of importance as an independent factor in the prognosis (Malkasian et al 1975 Ozols et 
al 1980 Dembo et al 1982 Sorbe et al 1982) However as a parameter the grade of a tumor is 
continuously variable ranging from benign to extremely malignant Probably as a result grade 
assessments show considerable inter observer variation resulting in marked prognostic variability 
Five year survival rates of patients with well differentiated tumors (grade 1 ) is 50 90% compared to 
30 50% for patients with grade 2 and 20 40% for patients with grade 3 tumors (Baak et al 1986) 
The basic data of the patient such as age performance index intercurrent disease are also of 
prognostic significance 
Treatment of ovarian cancer 
Surgery is still the cornerstone in the management o( ovarian cancer During the first operation 
the extent of the cancer spread is determined and the tumor load is removed Following the 
debulkmg operation patients undergo chemotherapy or radiation therapy The role of radiotherapy 
has been controversial and is yet to be defined During the past few years some progress has been 
made in the treatment of patients with advanced stage disease (stage lll/IV) Ten years ago the 
median duration of overall survival after single agent chemotherapy was approximately 14 months 
and the 5 year survival rate was 10% With cisplatm containing multiple drug regimens the median 
overall survival increased to 30 months with a 5 year survival rate of approximately 30% (Neyt et al 
1984) 
After completing the course of chemotherapy (or radiotherapy) patients may undergo second 
look laparotomy (SLL) to assess their disease status Persistent disease diagnosed by SLL has been 
observed in 45 80% of patients with advanced disease (Curry et al 1981 Copelandetal 1985 Raju 
et al 1982) However negative findings at SLL are not a definitive sign of tumor eradication Within 
5 years, 5 50% of the patients with a negative SLL showed recurrence (Copeland & Gershenson 
1986, Gershenson et al 1985 McCuskeretal 1987) 
Conclusions and perspectives 
Desprte the advances in the field of anti tumor agents ovarian cancer patients still have a poor 
prognosis The poor overall 5-year survival rate (30%) has been ascribed to the lack of an early 
diagnosis and an effective therapy Moreover, there is only little progress in the management of 
ovarian cancer patients Therefore, there is continued interest in the application of newly developed 
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immunological techniques for the management of this disease. The hybridoma technology initiated 
by Köhler and Milstein (1975) made it possible to produce large quantities of homogeneous 
antibodies of a stable quality. Subsequently, various monoclonal antibodies have been developed 
intentionally to improve diagnosis, therapy and management of ovarian cancer patients. The second 
part of this chapter gives an overview of relevant monoclonal antibodies against ovarian carcinoma-
associated antigens and the potential clinical application of these antibodies. 
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Markers of ovarian cancer 
In view of the difficulties in detecting, monitoring and treating ovarian carcinoma, there is a 
continued search for markers of ovarian cancer Each cellular component (enzyme, secretion 
product, cytoskeletal protein, proto oncogene product, or membrane component) that is expressed 
at elevated levels in ovarian carcinoma cells may serve as a marker for ovarian cancer Such a 
marker might improve the diagnosis and management of ovarian cancer patients in several ways 
Firstly, ovarian cancer markers may facilitate a more accurate histological typing and grading of 
ovarian tumors Secondly, when a marker is shed or secreted into the bloodstream, serum level 
determinations may facilitate diagnosis or monitoring of the effectiveness of therapy Thirdly, 
antibodies against a marker molecule that is predominantly or specifically expressed on ovarian 
carcinoma cells could serve as vehicles for specifically targeting drugs, toxins, or irradiation to the 
tumor 
Enzymes, hormones and other molecules as markers of ovarian cancer 
A series of different molecules detectable in serum has been investigated as indicators of ovarian 
neoplasms (table 2) Bhattacharya et al (1976) showed elevated galactosyltransferase activities in 
sera from 11 ovarian cancer patients and suggested that serial determinations of this enzyme activity 
might be of value in measuring tumor progression or regression However these observations could 
only be partially confirmed (Belfield & Pledger 1986) Yazawa et al (1988) showed that 61% of the 
ovarian cancer patients had elevated activities of a(l,3)-Lfucosyl transferase Other enzyme 
activities (nbonuclease placental like alkaline phosphatase, lacto N fucopentaose III Manganese 
superoxide dismutase) have also been shown to be elevated in sera from most ovarian carcinoma 
patients when compared to apparently healthy controls (Sheid et al 1977 Nouwen et al 1985, Cox 
et al 1986, Endo et al 1989) In addition, several studies have demonstrated elevated levels of 
hormones (hCG estradiol, estrone, androstenedione) (Stone et al 1977 Mangoetal 1986, Mahick 
et al 1986, Mahick 1986), and peptides (immunosuppressive substance immunosuppressive acidic 
protein, somatomedm-binding protein PP12) (Mono et al 1986, Sevelda et al 1987 Yamashita et al 
1986) in the sera from ovarian cancer patients These observations add to our knowledge of the 
Tdble2 En/ymes, hormones, and other molecules in serum that have been tested as markers for 
ovarian carcinoma 
marker sensitivity2 reference 
Galactosyltransferase 
Fucosyltransferase 
Ribonuclease 
Placental alkaline phosphatase 
Lacto-N-fucopentaose (LNF III) 
Mn-superoxide dismutase 
Cyclic guanosmemonophosphate3 
Human chorionic gonadotrophm 
Androstenedione 
Estradiol 
Estrone 
Human placental lactogen (HPL) 
Somatomedin binding protein PP12 
Immunosuppressive Substance (IS) 
Immunosuppressive acidic protein 
11 
18 
22 
19 
18 
23 
92 
26 
32 
29 
15 
51 
25 
14 
75 
100% 
61% 
95% 
58% 
67% 
52% 
52% 
50% 
65%4 
59% 
73%4 
76% 
72%4 
43% 
40% 
Bhattacharya et al 1976 
Yazawa et al 1988 
Sheidetal 1977 
Nouwen et al 1985 
Cox et al 1986 
Endo et al 1989 
Luesleyetal 1986 
Stone et al 1977 
Mahick et al 1986 
Hemonenetal 1982 
Mangoetal 1986 
Samaanetal 1976 
lionoetal 1986 
Yamashita et al 1986 
Sevelda et al 1987 
' the number of ovarian carcinoma patients included in the study 
2
 the sensitivity has been calculated as the percentage of ovarian cancer patients with marker levels exceeding the 
mean level + 2 SD as determined in the sera from healthy controls 
3
 cGMP was determined in the urine of the patients 
* data were calculated from the figure present in paper cited 
17 
CHAPTER 1 
biology of ovarian cancer, but more studies are required to assess whether determinations of these 
molecules can be clinically useful None of these markers have been shown to be specific for ovarian 
cancer, since elevations of each of the markers listed in table 1 have been shown to be associated 
with malignancies of various types and with several non neoplastic diseases 
Tumor-Associated antigens as ovarian carcinoma markers 
The assumption that tumors bear neo-antlgens which are not found on normal cells, has been 
a central concept in tumor immunology for a long time Experimental support for this concept began 
to appear in the 1920's with the discovery that tumors arising in one animal were rejected when 
implanted into another animal (Ehrlich 1909) Enhanced rejection was seen if the recipient animal 
had been previously immunized with tumor tissue (Woglom 1929, Gorer 1956) These early studies 
were carried with outbred mice or rats The discovery that normal tissue was rejected also, led to 
the discovery of the major histocompatibility complex, and the idea of tumor antigens came into 
disrepute However, attempts were continued to prepare polyclonal hetero antisera that would react 
with tumor antigens A number of tumor-associated antigens have been described since then 
Tumor-associated antigens can be defined as antigens which are predominantly or exclusively 
expressed on malignant cells These include oncofetal antigens, differentiation antigens and 
histocompatibility antigens The tumor associated antigens expressed on ovarian carcinomas, the 
antibodies that define them, and the clinical significance will be reviewed here 
Carcmoembryomc antigen (CEA) 
One of the first tumor associated antigens described, and probably the one studied in greatest 
detail, is the carcmoembryomc antigen (CEA) Based on polyclonal antisera raised against human 
colon carcinoma preparations, CEA was defined as a tumor associated oncofetal antigen of the 
gastro-mtestmal tract (Gold and Freedman, 1965) CEA is a group of glycoproteins (Mr 200,000 
daltons) composed of approximately 50% carbohydrate The isolation and characlenzation of CEA 
cDNA clones revealed the identification of immunoglobulin like domains and therefore the CEA-
gene is considered a member of the immunoglobulin supergene family (Paxton et al 1987) 
With the development of monoclonal antibodies and sensitive radioimmunoassays, it was shown 
that the expression of CEA is not limited to malignancies of the gastro-mtestmal tract Elevated levels 
of CEA occur in patients with malignant disease of colon and rectum (70%) stomach (61%), 
pancreas (91 %), breast (47%), lung (70%) prostate (40%), bladder (42%) gynecologic carcinomas 
(65%), lymphomas and leukemias (37%), and 30-70% of patients with several non malignant 
diseases (cirrhosis pancreatitis, colitis, pneumonia, а о ) (Greenberg 1976) 
Approximately 40% of the ovarian cancer patients have elevated CEA serum levels (Stall & Martin 
1981Khooetal 1979, Van Nagell et al 1978, Marchand et al 1975 Stanhope et al 1979) In the 
management of ovarian cancer, patient serum CEA determinations have been shown to be useful 
only in a limited number of cases, mainly in patients with mucinous ovarian cancer (Van Nagell et 
al 1975, Rutanenetal 1978) 
Ovarian carcinoma associated antigen (OCAA & OCAA-1) 
Bhattacharya and Barlow (1973) isolated two tumor antigens from ovarian cancer tissue, OCAA 
and OCAA 1 OCAA (ovarian carcinoma associated antigen) was characterized as a high molecular 
weight glycoprotein that is detectable in the serum of 70% of potients with ovarian carcinoma and 
in approximately 30% of the patients with advanced colon, breast and cervical carcinoma (Bhat 
tacharya & Barlow 1979) Serial determinations in 15 patients indicated that OCAA levels correlated 
with clinical disease in approximately 60 70% of the cases (Bhattacharya & Barlow 1978, River et 
al 1979) OCAA-1 was present in 90% of the malignant ovarian tumors and in other gynecological, 
colon, breast and pancreatic neoplasms OCAA-1 is considered to be an oncodevelopmental 
antigen since it is present In human umbilical cord serum and in pregnancy serum in the third 
trimester (Bhattacharya & Barlow 1979) 
Ovarian carcinoma antigen (OCA, NB/70K) 
Knauf and Urbach (1979) raised antisera against tumor-associated antigen fraction OCA (ovarian 
carcinoma antigen) The antigen preparation was isolated from epithelial ovarian tumor specimens 
by respectively perchloric acid extraction, affinity chromatography (Concavallm A, Sepharose-IgG), 
and gelfiltration Further purification of the OCA fraction resulted in the isolation of a 70 kD 
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carbohydrate moiety, NB/70K, being immunochemically distinct from CEA (Knauf & Urbach 1981) 
It could be shown that NB/70K serum levels correlated with increasing stage and tumor size, but 
not with histological type or grade (Chang et al 1984) 
Monoclonal antibodies against different epitopes of NB/70K have been prepared (Knauf et al 
1986) Applying the NB 12123 antibody m a homologous double determinant immunoradiometric 
assay, elevated NB/70K levels were found in 70% of the ovarian carcinoma patients (as opposed to 
6% of the healthy controls) More than 50 % of the patients with early stage ovarian malignancies 
(stage I) showed elevated levels (Knauf 1988a) Although the NB/70K antigen had been isolated 
from ovarian carcinoma specimens, immunoradiometric determinations in 432 serum samples 
revealed that elevated NB/70K levels could be detected also in patients with malignancies of the 
lung (59%), breast (68%), gastro-mtestmal tract (55%), and with benign disorders of the ovaries 
(29%), lung (17%), breast (16%) and gastro-mtestinal tract (35%) (Knauf 1988b) 
Tumor associated trypsin Inhibitor (TATI) 
Immunoabsorbtion using antisera raised against preparations from urine samples from ovarian 
cancer patients and healthy controls led to the identification of tumor associated trypsin inhibitor 
TATI is a 6 kD peptide closely related or identical to the pancreatic secretory trypsin inhibitor (PSTI) 
and elevated concentrations have been found in urine of patients with pancreatic cancer, pan 
creatitis, benign biliary disease and gynecological malignancies (Haglund et al 1986) Studying a 
population of patients with gynecological malignancies revealed urine TATI levels are elevated in 
55 61% of patients with ovarian cancer (Huhtala et al 1983, Halila et al 1988) Unlike most ovarian 
cancer markers this sensitivity is also found in patients with cancers of the mucinous type A 
systematic search for the target protease of TATI recently led to the identification of a trypsm-hke 
protease in cyst fluid of mucinous ovarian tumors (Stenman et al 1988) 
Placental-like Alkaline Phosphatase (PLAP) 
In the placental syncytiotrophoblast plasma membrane PLAP, one of the isoenzymenes of 
alkaline phosphatase is found (McComb et al 1979) This enzyme is also detectable in the sera of 
about 12% of all cancer patients (Nathanson et al 1971) Monoclonal antibodies against this 
tumor associated isoenzyme have been produced and have been designated H317 NDOG2 
(Sunderland et al 1984) and E6 (De Groóte et al 1983) Using a monoclonal antibody based 
enzyme linked immunoassay, elevated serum PLAP levels (>0 1 U/L) were found in 58% of the 
ovarian cancer patients (Nouwen et al 1985) Immunohistochemical studies showed that 59% 
(22/37) (Nouwen et al 1987) to 67% (10/15) (Sunderland et al 1984) of the non mucinous ovarian 
tumors expressed this enzyme PLAP is predominantly localized in the membranes of the tumor 
cells and anti-PLAP monoclonal antibodies have been used as vehicles for in vivo imaging of ovarian 
carcinomas in patients with 70% sensitivity (Davies et al 1985 Cntchley et al 1986) The smallest 
tumors detected in these studies were approximately 2 cm 
Polymorphic Epithelial Mucin (РЕМ, CA 15.3) 
The observation that an antiserum against milkfat globule preparations was not only reactive 
with different types of glandular epithelium but also with a variety of epithelial neoplasms motivated 
a number of groups to investigate in detail the tissue distribution of the target antigens (Heyderman 
et al 1979, Sloaneetal 1983, Gusterson et al 1982) Purification and characterization revealed the 
antigen preparation had the properties of a mucin, being a high molecular weight glycoprotein 
containing more than 50% of carbohydrate, which is attached in О linkage (to the hydroxyl oxygen 
atom of serine or threonine residues) via a linkage sugar N-acetylgalactosamme (Shimizu & 
Yamauchi 1982) 
There has been some confusion In nomenclature, but it now becomes clear that the monoclonal 
antibodies raised against HMFG (Taylor Papadimitnou et al 1981,Arklieetal 1981),MAM 6(Hilkens 
et al 1984), SGA (DeKretser et al 1985, 1986), EMA (Cordeil et al 1985, Heyderman et al 1985), 
DCA (Papsidero et al 1983,1984) and Ca (Ashall et al 1982) (Table 2) are directed against separate 
and distinct epitopes on the same high molecular weight (Mr 300,000) antigen Recently, the gene 
coding for this mucin has shown to be highly polymorphic (Swallow et al 1987), and therefore the 
name, polymorphic epithelial mucin (РЕМ) has been proposed 
Immunohistochemical studies with the anti РЕМ antibodies showed that the antigen is expressed 
on the apical side of most glandular epithelia It is thought that the molecule is processed in different 
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ways in different cells (aberrant glycosylation), explaining the slight differences in immunohis-
tochemical reactivities of the individual monoclonal antibodies. 
Table 3 Monoclonal antibodies directed against distinct epitopes of the polymorphic epithelial mucin 
MAb antigen reference 
HMFG-1,2 
Cal 
F36/22 
115D8, 139H2 
NCRC-11 
E29 
OM-1 
DF3 
HMFG 
Ca 
DCA 
MAM-6 
NCRC-11 
EMA 
SGA 
-
Taylor-Papadimitriou et al. 1981 
Ashalletal. 1982 
Papsidero et al. 1983 
Milkens et al. 1984 
Ellis et al. 1984 
Cordelletal. 1985 
DeKretser et al. 1985 
Sekineetal. 1985 
Abbrevations: HMFG, human milk fat globule; DCA, ductal carcinoma antigen; EMA, epithelial mucin antigen; 
SGA, sebaceous gland antigen. 
Immunohistochemical studies using monoclonal antibodies like 115D8, F36/22, and HMFG-2, 
have shown that more than 90% of the human carcinomas are PEM-positive (for review see: Zotter 
et al. 1988), making these antibodies useful tools for discrimination between epithelial and non-
epithelial neoplasms. However, some reactivity with non-epithelial neoplasms, such as lymphomas 
(1/18), sarcomas (4/24), and brain tumors (2/10), has been reported (Kufe et al. 1984, ¿otter et al. 
1988, Croghan et al. 1983, 1984). 
Carcinomas of the ovary express the monoclonal antibody-defined epitopes of РЕМ in almost 
all cases (95-100% depending on the antibody used) (Arklieetal. 1981, Hilkensetal. 1984, Kufe et 
al. 1984, Ward et al. 1987a). Well differentiated serous and mucinous tumors stain mainly at the 
apical parts of the neoplastic cells. In less differentiated carcinomas this orientation is lost (Friedman 
et al. 1986). 
The most commonly used assay for determing РЕМ levels in sera is the CA 15.3 immunoassay 
(Centocor Malvern) (Hayes et al. 1986) which uses 115D8 (Milkens et al. 1984) as a catcher and DF3 
(Sekine et al. 1985) as a tracer antibody. Elevated CA 15.3 levels have been demonstrated in 60-64% 
of the ovarian carcinoma patients (> 25 U/mL) (Hayes et al. 1986, Geyer et al. 1987). Inthese studies 
15-16% of the patients with benign disease showed elevated levels, indicating CA 15.3 on its own 
cannot be used as a marker for the presence of malignancy. Serial CA 15.3 determinations have 
been proven to be clinically useful for monitoring and follow-up of breast cancer patients (Gion et 
al. 1986, Pons-Anicet et al. 1987). For monitoring ovarian cancer CA 15.3 is only used on a limited 
scale because there are serum markers with better characteristics available for this malignancy. 
Some of the anti-PEM antibodies, especially HMFG-2 have been used for imaging of ovarian 
carcinomas in patients (Granowska et al. 1984, Pateisky et al. 1985, Ward et al. 1987b). Occult 
ovarian cancer nodules of only 0.5 cm in diameter were visualized using 123l-HMFG-2 (Epenetos et 
al. 1985). In a prospective study the accuracy of diagnosis and detection of ovarian cancer with 
123l-labeled HMFG-2 was 95%, taking laparotomy findings as the gold standard (Granowska et al. 
1986, Sheperdetal. 1987). 
Cancer antigen 125 (CA 125) 
The CA 125 antigenic determinant is defined by the monoclonal antibody OC 125. This antibody 
was obtained in 1981 after immunizing mice with the OVCA 433 ovarian carcinoma cell line (Bast 
et al. 1981). With an OC 125-based immunoradiometric assay, elevated CA 125 levels (>35 U/mL) 
could be detected in more than 80% of the women with ovarian cancer (Bast et al. 1983) and CA 
125 has become the most important serum marker of ovarian cancer. 
The CA 125-bearing antigen appears to be an oncofetal antigen since in the fetus it can be 
detected in the Müllehan duct as well as in the coelomic epithelia (Kabawat et al. 1983). In normal 
adult tissues it was detected in derivatives of the Müllerian duct such as the endocervix, en-
dometrium, and fallopian tube, and in coelomic derivatives: peritoneum, pleura and pericardium 
(Kabawat et al. 1983). Originally, other adult tissues were found to be negative (Bast et al. 1981). 
However, OC 125 reactivity has now been reported to be present in the surface epithelium of adult 
ovaries, and in the normal adult lung and respiratory tract (Nouwen et al. 1987). The consensus is 
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now growing that the CA 125 determinant is also expressed (be it only weakly and focally) in epithelia 
of the mammary gland, salivary gland, stomach pancreas, liver, lung and ovary (Zotter et al 1988) 
The expression of CA 125 in human tumor tissues has been described in various Immunohis-
tochemical studies (Kabawat et al 1983, Mainguene et al 1984, Koelma et al 1987, Nouwen et al 
1987, Fnedlander et al 1988) According to these studies most (66-95%) non-mucmous ovarian 
carcinomas express CA 125 The expression in mucinous tumors is somewhat ambiguous, one 
study reports focal expression in 4 of the 7 mucinous samples (Koelman et al 1987), while other 
studies find the mucinous tumors to be unreactive with OC 125 (Kabawat et al 1983, Mainguene et 
al 1986, Nouwen et al 1987) As could be expected from the expression in Mullenan derived normal 
epithelia, the majority of endometrial carcinomas and carcinomas of the fallopian tube clearly 
express CA 125 (Koelma et al 1987) CA 125 was observed occasionally in colon, lung, and breast 
carcinomas (Kabawat et al 1983, Mainguene et al 1984, Koelma et al 1987) 
Biochemical studies have shown that the CA 125 determinant is expressed on a glycoprotein of 
relatively high molecular mass ( > 200,000 daltons) that is often found in heterogeneous protein 
complexes (Mr > 1,000,000 dalton) (Davis et al 1986) Although CA 125 is predominantly found on 
the apical side of the cell the CA 125-bearing glycoprotein is not considered a typical mucin, due 
to its relative low carbohydrate content (24%) and the presence of significant amounts of N linked 
oligosachandes (Davis et al 1986) 
The OC 125 antibody has been incorporated into an immunoradiometnc assay used to detect 
CA 125 levels in serum and other body fluids (Klug et al 1984) CA 125 has been demonstrated in 
cyst fluids of malignant and benign tumors (Fleuren et al 1987a), in ascites of benign and malignant 
origin (Bergman et al 1987), in human milk (Hanisch et al 1985), in seminal plasma (Halila et al 
1985), ammode fluid (O Brien et al 1986), and cervical mucus (De Bruijn et al 1986) 
Serum CA 125 levels are elevated (>35 U/mL) in over 80% of patients with epithelial ovarian 
cancers, while only 1 % of apparently healthy women show elevated levels (Bast et al 1983) Patients 
with adenocarcinomas of endometrium (47%), cervix (32%), fallopian tube (87%), breast (14%), 
lung (32%), colon/rectum (11%), stomach (8%), pancreas (59%), liver (57%) also manifest elevated 
CA 125 levels (for review see Kenemansetal 1988) Consequently CA 125 is not a marker specific 
for ovarian cancer and therefore the diagnosis of ovarian cancer cannot be made in patients with 
malignancies of unknown origin solely on the basis of an elevated CA 125 level 
Elevated CA 125 levels have been described in approximately 20% of patients with certain benign 
diseases (endometriosis, benign ovarian tumors leiomyomas, pelvic inflammatory disease, peri-
tonitis, pancreatitis, liver cirrhosis (Bast et al 1983 Niloffetal 1986a, Einhorn et al 1986 Yedema 
et al 1988), further complicating the clinical interpretation of pre-operative CA 125 levels 
The clinical significance of serial CA 125 determinations during the management of ovarian 
cancer patients is beyond doubt More than two hundred research papers have appeared in the 
clinical literature, describing the various applications of the serum marker (for review see Finkler et 
al 1988) 
• Serial CA 125 levels reflect changes in tumor burden Rising, stable or falling levels have been 
reported to correlate with tumor progression, stability, or regression respectively in approxima-
tely 85% of the cases (Bast et al 1983, Krebsetal 1986, Alvarez et al 1987) 
• CA 125 levels are predictive of the chance for clinical recurrence CA 125 levels will rise prior to 
clinical recurrence in over 90% of patients (Niloff et al 1986b Krebs et al 1986) 
• It has been shown that the CA 125 serum level reflects the extent of the disease and the size of 
the tumor masses (Crombach et al 1985, Brioschi et al 1987, Schilthuis et al 1987) 
Recent data suggest that CA 125 determinations during the first courses of chemotherapy can 
predict the final outcome Measurements of the halflife of CA 125 during chemotherapy might be 
helpful in the discrimination between good and poor responders (Lavm et al 1987, Vergole et al 
1987, Van den Burg et al 1988, Rustin et al 1989) In summary, evaluation of serial CA 125 levels 
during primary chemotherapy is an indicator of the patient's response to such therapy and a 
predictor of clinical outcome CA 125 determinations could be used for selecting patients who need 
a change in the drug regimen or patients who need second-line therapy Unfortunately, such 
treatment options are currently limited Recently Niloff (1988) faced with these facts put it this way 
' an example of our tumor marker technology having exceeded our therapeutic arsenal' 
The characteristics of the CA 125 test, 23-50% sensitivity for detection of early stage ovarian 
cancer (Cruickshank et al 1987, Mann et al 1988, Zurawski et al 1988a) in combination with high 
specificity in a population of healthy postmenopausal women (Zurawski et al 1987,1988b) initiated 
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a few large studies to investigate the value of the incorporation of CA 125 determinations in ovarian 
cancer screening programs (e g Jacobs et al 1988) 
OC 125 F(ab')2 fragments labeled with lodine-131 (Haisma et al 1987) or lndium-111 (Chatal et 
al 1986, Hunter et al 1987) have been used in patients with ovarian carcinoma for imaging purposes 
Positive images were obtained especially in patients with lower CA 125 levels, indicating that the 
presence of circulating antigen might hamper the application of OC 125 in immunoscmtigraphy 
Haisma et al (1988) actually demonstrated the formation of antibody antigen complexes in sera as 
early as 15 mm after injection of 131l-OC 125 F(ab')2 
The safety of intraperitoneal injections of high doses (up to 100 mCi) of 131l labeled OC 125 is 
under investigation with hopes of using it as a second-line therapy in ovarian cancer patients (Fmkler 
et al 1989) 
Ovarian carcinoma-associated antigen 3 (OA 3). 
The monoclonal antibody OV-TL 3 was raised against a tumor cell suspension prepared from an 
endometrioid ovarian carcinoma specimen (Poels et al 1986) Immunohistochemical studies have 
shown that OVTL3 is reactive with more than 90% of the ovarian carcinomas, including mucinous 
ovarian carcinomas (Poels et al 1986, Kuhnel et al 1988, Henzen Logmans et al 1988) The 
expression of the OA 3 epitope as defined by the OV-TL 3 antibody is reported to be restricted to 
gynecological malignancies In addition, OA 3 is expressed in the epithelial linings of the female 
genital tract (Poels et al 1986) The biochemical nature of the OA 3-bearing antigen remains unclear 
The biodistribution of the 125l-labeled F(ab')2 fragments of OVTL 3 and OC 125 in nude mice 
bearing mtrapentoneally growing human ovarian carcinoma xenografts were compared (Mosely et 
al 1988) Twenty four hours after intraperitoneal injection, the tumor uptake of 125l-OV-TL 3 was 11 
times higher than the uptake of 125l-OC 125, indicating that OV-TL 3 is a promising antibody for in 
vivo application Preliminary clinical results are very promising Marked uptake into the tumor areas 
was seen in three ovarian cancer patients following intravenous injection of 111ln labeled OVTL 3 
(Epenetos et al 1987) A clinical trial (phase I II) is currently investigating the potential of ' ^ I n -
labeled OV-TL 3 F(ab )2 in immunoscmtigraphy (Claessens et al 1989 Massugeretal 1989) 
Ovarian carcinoma-associated antigen defined by OV632 
The monoclonal antibody OV632 is secreted by a hybridoma cell line which was produced by 
fusing spleen cells from mice immunized with cyst fluid from a serous cystadenocarcmoma of the 
ovary (Fleuren et al 1987b) Unlike most ovarian tumor associated antigens, the antigen recognized 
by OV632 is localized in the cytoplasm of the tumor cells The antibody stained positively 80% of 
the non-mucmous ovarian carcinomas and was hardly reactive with non-gynecologic carcinomas 
(Fleuren et al 1987b) A recent study indicated that OV632 is a useful tool in surgical pathology 
(Koelma et al 1988) In addition this study demonstrated that OV632 can facilitate the immunocyto-
chemical detection of ovarian carcinoma cells in peritoneal fluids or washings 
Ovarian carcinoma-associated glycoprotein, gp 38. 
Most ovarian carcinoma-associated antigens described have been characterized as high mo-
lecular weight glycoproteins An Italian group, however, have developed monoclonal antibodies 
against tumor-associated glycoproteins of respectively 38 and 48 kD (Miotti et al 1987) While the 
48 kD antigen was found in various epithelial neoplasms, the expression of the 38 kD antigen (gp 
38) was highly specific for ovarian carcinomas, because nearly all non ovarian carcinomas (includ-
ing breast, lung, liver and gastro-mtestmal carcinomas) were negative Two monoclonal antibodies, 
MOv 18 and MOv 19, against different epitopes of gp 38 have been generated 
Biodistribution experiments in tumor-bearing nude mice suggest that MOv 18 is a promising tool 
for in vivo application, because tumor uptake of 125l-labeled MOv 18 was 7 times higher than the 
tumor uptake of 125l-labeled OC 125 (Borras Boneu et al 1989), while preliminary immuno-
scmtigraphical results are encouraging (Miotti et al 1988) Currently the cytotoxicity of bispecific 
antibodies composed of MOv 18 and anti-CD3 monoclonal antibodies is under investigation 
(Mezzanzamca et al 1988) 
Outline of this study 
From the proceeding literature survey it is clear that monoclonal antibodies against ovarian 
carcinoma-associated antigens offer new possibilities in the diagnosis and treatment of cancer 
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However, the suitability of a given monoclonal antibody for a particular clinical application is 
determined by the specific characteristics of the antibody and the antigen it recognizes The aim of 
this study was to develop new monoclonal antibodies against ovarian cancer and to investigate 
whether or not these could be exploited as diagnostic tools. 
Chapters 2 and 3 describe the establishment of monoclonal antibodies against ovarian cancer, 
raised by immunization with respectively ovarian carcinoma cyst fluids and undifferentiated ovarian 
carcinoma extracts. 
In chapter 4, an immunohistochemical study is described investigating the applicability of four 
anti-OCAA monoclonal antibodies as diagnostic tools in gynecopathology. 
Chapters 5 and 6 report the studies to evaluate the potentials of three anti-OCAA monoclonal 
antibodies for in vivo application Antibodies were radiolabeled and tested for their ability to localize 
human ovarian tumors in the nude mouse model 
In chapter 7 and 8 the development of an alternative for the OC 125-based immunoradiometric 
assay for CA 125 determinations in sera from ovarian cancer patients is described 
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Abstract InlraspleniL immuni/ation with ovarian lumour derived cyst fluids was used to 
generate monoclonal antibodies (MAbs) against human ovarian carcinomas Seven MAbs 
were characterized immunocylochcmically using indirect immunofluorescence assays (ΙΓΑ) 
on frozen sections of gynaecologie tumours (n = 85), non gynaecologie tumours (η-50), 
normal human tissues (n = 66), and on 8 ovarian carcinoma cell lines The MAbs reacted with 
67-96% of 49 ovarian carcinoma tissues tested Although six out of seven MAbs showed 
slight reactivity with some endometrial, cervical, and oviductal carcinomas, little reactivity 
with non gynaecologie tumours or normal tissues was found Based on immunoelectron 
microscopy, all the antigenic dctcrmmdiits defined by the MAbs appeared to be associated 
with the lumour cell membrane Among the seven MAbs, OV-Tl 16 (IgCJl subclass) and 
ÜV-TL 23 (IgM class) reacted positivclv with 96'# and 82'ί of the ovarian carcinomas 
respectively Staining of 100% of the ovarian carcinomas examined (n = 49) could be 
achieved by combining OV-TL 16 with 23, as could also other combinations of the MAbs 
It is concluded that a panel of these newly developed MAbs, may be suitable for diagnostic 
purposes in hislopalhology 
Introduction 
Since the introduction of the murine hybndoma technology MAbs have been raised against 
tumour-associated antigens MAbs against ovarian carcinoma associated antigens (OCAAs) have 
been produced in several laboratories (Bast et al 1981 Tsujietal 1985 Poels et al 1986 Miotti et 
al 1987, Fleuren et al 1987a Mattes et al 1987) These MAbs recognize antigens on the majority 
of the ovarian carcinomas tested, but the antigenic heterogeneity of ovarian carcinomas limits the 
use of MAbs not only in differential diagnosis (Borowitz & Stem 1984) but also in serodiagnosis 
(Uoyd 1980), immunoscmtigraphy (Goldenberg 1983) and antibody-mediated therapy (Larson 
1985) Several authors have suggested the use of panels of MAbs to overcome the problems of 
antigenic heterogeneity (Sfakianakis & Deland 1982, Goldenberg 1983, Greiner al 1987) Different 
immunogens were used to produce MAbs against OCAAs, such as ovarian carcinoma cell lines (OC 
125) (Bast et al 1981), ascitic cells (OM-1) (De Kretser et al 1985), cell suspensions prepared from 
a human ovarian carcinoma specimen (OV-TL 3) (Poels et al 1986) and crude membrane prepara­
tions (MOv 16, 18 and 19) (Miotti et al 1987) In this study, human ovarian carcinoma cyst fluids 
were used to immunize mice for the production of MAbs, since these fluids have been shown to 
contain high levels of the tumour-associated antigens, such as TATI (Halila et al 1987), CA 125 
(Fleuren et al 1987b), and CEA (Van Nagell et al 1975) We describe here seven new MAbs 
specifically recognizing membrane bound OCAAs, combinations of which stain 100% of the ovarian 
carcinomas tested We therefore conclude that these seven MAbs used m a panel are potentially 
valuable for the histopathological diagnosis of ovarian carcinomas 
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Table 1 Reactivity of seven MAbs with gynaecologie tumours. 
OV-TL 
16 
OV-TL 
17 
OV-TL 
19 
OV-TL 
22 
OV-TL 
23 
OV-TL 
24 
OV-TL 
27 
Epithelial ovarian carcinomas 
Serous carcinoma 
Mucinous carcinoma 
Endometrioid carcinoma 
Clear cell carcinoma 
Nonclassified carcinoma 
Total 
Benign ovarian cyst 
25/27 
4/4 
6/6 
2/2 
10/10 
47/49 
(96%) 
24/27 
4/4 
6/6 
2/2 
10/10 
46/49 
(94%) 
24/27 
4/4 
6/6 
2/2 
9/10 
45/49 
(92%) 
21/27 
3/4 
2/6 
2/2 
5/10 
33/49 
(67%) 
25/27 
2/4 
3/6 
2/2 
9/10 
40/49 
(82%) 
22/27 
1/4 
3/6 
2/2 
9/10 
37/49 
(76%) 
21/27 
1/4 
3/6 
2/2 
10/10 
37/49 
(76%) 
2/7 3/7 0/7 0/7 1/7 0/7 0/7 
Sex cord-stromal tumours 
Granulosacell tumour 
Fibrothecoma 
Other gynaecologie carcinomas 
Tubal carcinoma 
Endometrial carcinoma 
Cervical carcinoma 
- adeno carcinoma 
- squamous cell carcinoma 
- oat cell carcinoma 
Vaginal sq. cell carcinoma 
Vulva sq. cell carcinoma 
0/2 
0/3 
2/2 
4/12 
1/3* 
0/4 
0/1 
0/1 
0/1 
0/2 
0/3 
2/2 
7/12* 
1/3 
3/4* 
0/1 
1/1* 
1/1 
0/2 
0/3 
1/2 
9/12 
2/3* 
1/4* 
0/1 
1/1* 
1/1 
0/2 
0/3 
1/2 
0/12 
0/3 
0/4 
0/1 
0/1 
0/1 
0/2 
0/3 
2/2 
2/12* 
2/3 
0/4 
0/1 
0/1 
0/1 
0/2 
0/3 
2/2 
2/12* 
2/3 
0/4 
0/1 
0/1 
0/1 
0/2 
0/3 
2/2 
8/12* 
2/3 
0/4 
0/1 
0/1 
0/1 
IFA was earned out on frozen sections of primary or metastatic tumours The numbers indicate the number of positive­
ly scored tumour tissues, as a part of the total number of tumour tissues tested At least two samples per patient were 
assayed 
very weak reactivity 
Abbreviation sq, squamous 
Materials and Methods 
Tissues and cyst fluids 
Samples from gynaecologie tumours (n = 85), ποπ-gynaecologic tumours (n = 50) and normal 
human tissues (n = 66) were obtained freshly from surgery, frozen in liquid nitrogen and stored at 
-80oC until use Ovarian cyst fluids (CF785 and CF861) were obtained by thin needle aspiration 
CA 125 determinations 
The CA 125 contents of the cyst fluids were determined immunofluorometrically as described 
previously (Boerman et al. 1987). 
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Cell lines 
The following human ovarian carcinoma cell lines were used in this study OTN 11 (Poels et al 
1989) and OTN 14 (Van Niekerk et al 1988) isolated in our laboratory, cell lines EFO 21 and EFO 
27 (Simon etal 1983), kindly provided by Prof Dr Holzel (FRG), cell lines OAW 42 and OAW 28+ 32 
(Wilson 1984), kindly provided by Dr Wilson (UK), the NIH OVCA 433 cell line (Bast et al 1981), 
kindly provided by Dr Zurawski Jr (USA), and the NIH О VC AR-3 cell Ime (Hamilton et al 1983) 
obtained from the American Type Culture Collection (USA) Ovarian carcinoma cell lines were 
adapted to and maintained in RPM11640 based culture medium (Gibco, Paisly, U К ), supplemented 
with 15% PCS The Balb/c myeloma cell line Sp2/0 was maintained in the same medium 
Immunization and fusion 
The limited amounts of cyst fluids available necessitated a short immunization protocol Balb/c 
mice were immunized once mtrasplemcally, as described by Spitz et al (1984), using 0 1 ml of cyst 
fluid per mouse Three days later, 5 χ 107 immune spleen cells were fused with 2 χ 107 Sp2/0 myeloma 
cells, according to the protocol described by Lane (1985) Fused cells were seeded in 96 well plates 
(Costar Cambridge, MA), grown in HAT medium and further processed as described earlier (Poels 
etal 1986) 
Indirect immunofluorescence assay 
Hybridoma supernatants were initially screened on frozen sections of the same ovarian car­
cinoma tissue from which the cyst fluid - used for immunization - was obtained (Poels et al 1986) 
Subsequently, the carcinoma positive supernatants were screened and selected for a negative 
reaction on sections of colon carcinoma and normal gastric tissue The most promising hybndomas 
were selected and cloned by repeated limited dilution The MAbs were isotyped in a double diffusion 
assay (Hudson & Hay 1980) 
Table 2 Percentages of the ovarían carcinoma tissues (n = 49) stained positively by pairs of MAbs 
OV-TL OV-TL OV-TL OV-TL OV-TL OV-TL OV-TL 
16 17 19 22 23 24 27 
OV-TL 16 94 
OV-TL 17 
OVTL 19 
OV TL 22 
OV TL 23 
OV TL 24 
OV-TL 27 
Integersindicate the percentage ol ovarian oarcmoma samples staining positively with at least one of the two MAbs (100% = 49) 
Immunocytochemical studies 
These were carried out using hybridoma culture, or ascitic fluids appropriately diluted to optimal 
concentrations, as determined by titration experiments (Vandesande 1979) The number of posi 
tively stained cells in a section was arbitrarily scored in 3 categories, namely a positive reaction 
with more than 50% of the carcinoma cells in a section (cat I), a positive reaction with less than 
50% of the carcinoma cells in a section (cat II), or no positive reactivity at all (cat III) MAb OVTL 
12-5 (antl-keratm 5, 7,14 & 19), which stains all carcinoma cells in a section (Van Niekerk et al 1988 
Poels et al 1989) was used as a positive reference, while myeloma cell culture supernatant was 
used as a negative control For assaying the reactivity of the MAbs on ovarian carcinoma cell lines, 
cells were seeded in culture chambers of 8-well tissue culture slides (4 χ 104 cells per well) (Miles, 
Naperville, IL) and incubated for 2-3 days to allow cluster formation The cells were then fixed in 
cold methanol (-20°C) for 2 min before being air dried and processed as described (Poels et al 
1986) 
98 
92 
100 
100 
92 
98 
100 
100 
67 
100 
100 
100 
88 
82 
100 
100 
too 
86 
84 
76 
100 
100 
96 
80 
84 
84 
76 
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Immunoelectron microscopy 
In order to establish the subcellular localization of the OCAAs, a freshly obtained sample from a 
serous ovarian carcinoma was fixed in periodate lysme-paraformaldehyde-glutaraldehyde solution 
(PLPG) for 1 5 h (Gendelman et al 1983), and further processed for immunoelectron microscopy 
as described by Van Niekerk et al (1988) 
Results 
Origin of the hybridomas and MAbs 
Three cell fusion experiments yielded 6,000 growth-positive hybridoma clones The screening 
strategy was based on the assumption that supernatants should display positive reactivity with the 
carcinoma cells m cryostat sections of ovarian carcinomas and nonreactivity with any tissue 
component in sections of a colon carcinoma and normal gastric tissue Consequently 28 hybridoma 
cell lines were selected for further immunocytochemical characterization on a series of cryostat 
sections of different carcinomas and normal tissues Subsequently, seven cloned hybridoma cell 
lines were selected for the studies described here The MAbs OVTL 16 17 and 19 were raised by 
mtrasplenic immunization with cyst fluid CF785, obtained from a poorly differentiated ovarian 
carcinoma, containing 68,000 U/ml of CA 125 The MAbs OV-TL 22, 23, 24 and 27 were raised by 
immunization with cyst fluid CF861, derived from a well differentiated serous ovarian carcinoma 
This fluid contained 24,000 U/ml of CA 125 By double diffusion assay it was shown that the 
anti CF785 antibodies (OVTL 16, 17 and 19) and the OVTL 22 antibody belonged to the IgGl 
subclass, while the isotype of the remaining anti-CF861 antibodies was IgM 
Table 3 RuaUivitv of the MAbs with cullurul ovarian carcinoma cell lines 
OV-TL OVTL OV-TL OV-TL OV-TL OV-TL OV-TL 
Cell line 16 17 19 22 23 24 27 
OTN11 
OTN14 
NIHOVCA433 
NIH OVCAR 3 
EF0 21 
EF0 27 
OAW28 + 32 
OAW42 
+ 
+ 
+ 
+ + 
+ 
t-
+ + 
+ 
-
-
+ 
+ 
+ 
-
•1-
+ 
-
+ 
-
+ 
+ 
+ + 
+ 
Reactivity was scored arbitrarily as negative ( ) weak to moderate ( + ) or moderate to strong ( + +) according to 
the intensity of the staining and the number of positive cells 
π d not done 
Immunocytochemical reactivity on gynaecologie tumours 
Serially cut frozen sections from a total of 49 ovarian carcinomas, seven benign ovarian cysts, 
5 sex cord-stromal tumours and 24 other gynaecologie carcinomas, were tested in IFA for reactivity 
with the seven MAbs, as shown in Table 1 
Reactivity with ovarian carcinomas 
The anti-CF785 MAbs (OV-TL 16 17 and 19) each stained positively more than 90% of the ovarian 
carcinoma specimens Theanti-CF861 MAbs stained positively 67% to 82% of the ovarian carcinoma 
samples No indications were found that any of the MAbs selectively stained any particular 
histological type of ovarian carcinoma Every ovarian carcinoma sample reacted positively with at 
least one of the seven MAbs tested Therefore, combinations of the MAbs can be selected to allow 
reactivity with all ovarian carcinoma specimens, as shown in Table 2 Serially cut sections of tumour 
specimens showed different staining patterns with each antibody, as illustrated in Fig 1 In most 
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Figure I Immunocytochcmical staining pattern (IFA) of OV-TL 12-5 (a), OV-TL 16 (b), OV-TL 17 
(c), OV-TL 19 (d), OV-TL 22 (e), OV-TL 23 (0 , OV-TL 24 (g) and OV-TL 27 (h) on serially 
cut frozen sections of a serous ovarian carcinoma tissue (600 x). 
samples, the anti-CF785 MAbs (OV-TL 16,17 and 19) stained the majority of carcinoma cells diffusely, 
and homogeneously (Fig lb , lc, id). The anti-CF861 antibodies OV-TL 23, 24 and 27, showed a 
focal and more granular staining pattern on most tumour cells in the majority of sections (Fig. If, g, 
h) The OV-TL 22 antibody stained less than 50% of the tumour cells in most sections (Fig 1e) The 
percentages of samples stained with each antibody and the percentages of samples in which more 
than 50% of the cells were stained, are shown in Fig. 2. Significant differences between the staining 
patterns of primary versus metastatic ovarian carcinoma samples of the same patient were not 
observed with any of the MAbs. 
CHAPTER 2 
Ultrastructural localization 
of the МАЬ-defined OCAAs 
Ultrastructural localization studies of the 
MAb-defined tumour-associated antigens 
were carried out on specimens of a serous 
ovarian carcinoma All MAbs reacted with sur­
face antigens on the tumour cells. An example 
of electron-dense deposits indicating a posi­
tive immunoperoxidase reaction is shown in 
Fig. 3a and 3b. The OV-TL 27 antibody posi­
tively stained antigens in the cytoplasm as well 
(Fig. 3c). 
Reactivity with other ovarian tumours 
Within the group of anti-CF861 MAbs, OV-
TL 23 stained the epithelial cells of just one out 
of seven benign ovarian cysts, while the 
remaining MAbs were nonreactive with cyst 
epithelium. In the anti-CF785 group, OV-TL 19 
also showed no reactivity with benign ovarian 
cysts, while OV-TL 16 and 17 stained 2 and 3 
out of the seven cysts, respectively. None of 
the antibodies showed any immune reactivity 
with the sex cord-stromal tumours examined 
(Tablet). 
Reactivity with other gynaecologie tumours 
As shown in Table 1, the OV-TL 22 antibody did not show any reactivity with endometrial 
carcinomas, while the remaining antibodies in the anti-CF861 group showed slight reactivity on a 
small number of endometrial and other gynaecologie carcinomas. The anti-CF785 antibodies 
showed more positive reactivity on these carcinomas than the anti-CF861 antibodies Significant 
Figure3 Immunoclcctron microscopy of malignant cells from a serous ovarian carcinoma. A 
continuous electron-dense deposit of peroxidase reactivity on the microvillous membranes 
stained with OV-TL 16 (a), (3500 x). A detail of this staining pattern shows that cell 
organdis like ribosomes, junctional complexes and mitochondria are not stained (b), (9500 
x). Cytoplasmicreactivity of the tumour cell is observed after staining with OV-TL 27(c), 
(9500 x). 
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Jreactivity < 5 07o of the carcinoma cells 
I reactivity > 507e of the carcinoma cells 
OV-TL 16 17 19 22 23 1U 27 
Figure 2 Diagram showing for each MAb, the per­
centage of ovarian carcinoma samples 
stained positively, and the percentage of 
ovarian carcinoma samples of which more 
than 50% of the carcinoma cells in the 
section were stained positively. 
Discussion 
reactivity was found on tubal carcinoma cells. Antigen expression was also found on some of the 
cervical carcinomas. 
Reactivity with ovarian carcinoma cell lines 
The individual reactivities of the seven MAbs on ovarian carcinoma cell lines is summarized in 
Table 3. Most antigens were found expressed on NIH:OVCAR-3 cells, and on OAW 42 cells. The 
Table 4 Reactivity of the MAbs with non-gynaecologic tumours . 
S«e diagnosis OV-TL OV-TL OV-TL OV-TL OV-TL OV-TL OV-TL 
(no. of specimens 16 17 19 22 23 24 27 
examined) 
stomach 
ileum 
colon 
rectum 
pancreas 
kidney 
urethra 
bladder 
breast 
testis 
testis 
penis 
skin 
bone marrow 
adenocarc 
adenocarc 
adenocarc 
carcinoma 
carcinoma 
renal care 
carcinoma 
carcinoma 
carcinoma 
seminoma 
teratoma 
sq cell care 
melanoma 
' lymphoma 
(2) 
(1) 
(12) 
(4) 
(2) 
(9) 
(1) 
(7) 
(4) 
(3) 
0) 
(1) 
(2) 
(1) 
-
-
1* 
2* 
-
-
-
-
-
-
-
-
1 
1 
2* 
2 
-
3 
-
1* 
-
1 
-
-
-
-
-
1 * 
2* 
-
-
3* 
1 
2* 
4* 
-
-
-
1 * 
1 * 
Integers indicate the number of sections reacting positively with the MAbs in an IFA on cryostat sections 
* very weak reactivity 
Abbreviation* care carcinoma, sq squamous 
MAb OV-TL 16 reacted positively with all cell lines. The antigenicity was not affected by the short, 
mild fixation procedure. 
Reactivity with non-gynaecologic tumours 
The staining results for 50 non-gynaecologic malignant lesions are summarized in Table 4 Most 
anti-CF861 MAbs did not show reactivity with these tumours, although traces of fluorescence were 
noticed in one colon carcinoma section after incubation with OV-TL 27 The anti-CF785 antibodies 
showed some reactivity with non-gynaecologic tumours. OV-TL 16 focally stained one colon 
carcinoma sample and two renal cell carcinoma specimens The OV-TL 17 and 19 antibodies reacted 
weakly with 20 and 30% of the tumours tested 
Reactivity with normal tissues 
Significantly, no strong reactions on normal tissue sections were observed using any of the MAbs, 
as shown in Table 5. With the exception of OV-TL 22, all MAbs showed weak staining with oviductal 
epithelial cells. Weak reactivity with endometrial cells was limited to a few samples stained by OV-TL 
16, 19,23 and 27. Traces of fluorescence on epithelial cells of the colon were found upon staining 
with OV-TL 16 and 17 only. OV-TL 16, 19, 22 and 23 weakly stained the glomeruli of some of the 
kidney samples. OV-TL 19, also showed focal staining in sections of human lung and spleen. 
Discussion 
MAbs to ovarian carcinoma-associated antigens can be used in cancer diagnosis and therapy, 
as well as in basic studies on the pathogenesis of ovarian cancers. In this chapter we have described 
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Table S Reactivity of the MAbs with normal human tissues 
OV-TL OV-TL OV-TL OV-TL OV-TL OV-TL OV-TL 
(no. of specimens examined) 16 17 19 22 23 24 27 
female genital tract 
ovary 
fallopian tube 
endometrium 
cervix squamous epithelium 
cervix glandular epithelium 
vagina 
vulva 
placenta 
other tissues 
diaphragma 
oesophagus 
stomach 
duodenum 
jejunum 
ileum 
colon 
liver 
testis 
kidney 
lung 
adrenal gland 
spleen 
skin 
tonsil 
(6) 
(8) 
(9) 
(2) 
(2) 
(1) 
(1) 
(2) 
(1) 
0) 
(4) 
(1) 
(1) 
(1) 
(4) 
(3) 
(1) 
(6) 
(3) 
(1) 
(2) 
(5) 
0) 
-
T 
2 
4' 
V 
2 
1 
1* 6 5* 5* 
1* - 1* - 2* 
IFA on (rozen sections ot normal human tissue Integers indicate the number of specimens reacting positively 
* very weak reactivity 
the immunocytochemical characterization of seven potentially valuable MAbs for histodiagnosis 
and other clinical applications The antibodies were raised by a single intrasplentc immunization 
with cyst fluids obtained from ovarian carcinomas and the appearence of 4 IgM-producmg hy-
bridoma cell lines might be related to this short immunization procedure 
Additionally, the observation that all MAbs recognize epitopes located on the tumour cell 
membrane, may be related to the use of membrane vesicle containing cyst fluids for immunization 
These MAb-defmed antigenic determinants were detectable in cyst fluids (manuscript in prepara-
tion), however, preliminary results (not shown) have indicated that none of the determinants are 
detectable in sera from ovarian carcinoma patients It would therefore appear that these MAbs are 
not suitable for serodetectton of circulating OCAAs On the basis of the staining patterns on serially 
cut ovarian carcinoma sections and reactivity on normal tissues, non-ovarian tumours and cell lines, 
it would appear that the seven MAbs are directed against different epitopes The anti-CF785 MAbs 
(OV-TL 16,17 and 19), raised against a poorly differentiated ovarian carcinoma, reacted with more 
than 92% of the ovarian carcinoma samples This is comparable to percentages reported for other 
anti OCAA MAbs, such as OC 125 (Kabawat et al 1983, Shishi et al 1986), OV 632 (Fleuren et al 
1987b), and MOv 18 (Miotti et al 1987) In contrast to these described antibodies, which are only 
focally reactive with a minority of mucinous ovarian carcinomas, the anti-CF785 antibodies seem 
to be equally reactive with mucinous ovarian carcinomas and ovarian carcinomas of other histologi-
cal types Although tested on a limited number of samples, this reactivity in mucinous carcinomas 
indicates that the anti-CF785 antibodies are directed against new OCAAs Since OV-TL 16 is less 
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reactive with non-ovarian carcinomas, this MAb may be more suitable for histodiagnostic purposes. 
The other anti-CF7e5 antibodies (OV-TL 17 and 19) which react strongly with membrane-associated 
antigens on nearly all ( >90%) ovarian carcinomas, but only to a limited degree on normal human 
tissues, may be tested for application as in vivo targeting vehicles. Although tumour heterogeneity 
is a major obstacle in effective treatment, the use of combinations of these MAbs might circumvent 
this problem. The anti-CF861 MAbs raised against a well differentiated serous ovarian carcinoma 
do not react with non-gynaecologic tumours. Moreover, the OV-TL 22 antibody displays a highly 
ovarian carcinoma-specific reactivity Even carcinomas derived from tissues with the same em­
bryologie origin as ovarian carcinomas, such as endometrial and (endo)cervical carcinomas did 
not express the antigenic determinant defined by this antibody. In spite of the fact that each 
anti-CF86l antibody is nonreactive with about 20% of the ovarian carcinomas, their use in surgical 
pathology can be maximized by using these four antibodies combined in a panel This panel stained 
96% of the ovarian carcinoma samples examined In this study. However, the anti-CF86l antibodies 
are probably less suitable for in vivo applications, since it is assumed that IgM antibodies are less 
capable of infiltrating tumours in vivo. Since several antibodies (OV-TL 19, 22, 24 and 27) did not 
stain the epithelial cells in the sections of the seven benign ovarian cysts, we are currently evaluating 
their use in the discrimination between benign, malignant and borderline-malignant ovarian tumours 
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Abstract Three hvbridoma cell lines producing monoclonal anliboclies (MAbs) against 
ovarian eartmomas, were obtained after immum/mg mice with an undifferenlialed human 
ovarian cystadcnocarcinoma extract The hybridoma cell supernatants were initially 
screened for a positive immunohistochcmical re iclion with ovarian carcinomas con 
comitant with a negative reactivity with a benign ovarian cysladenoma 
The antibodies OV TL 15 (IgM), OV TL ЭО (IgGl) and OV TL 31 (IgM) reacted 
positively with M'A, 84'Л and 74';!? of the ovarian carcinoma samples (n = 76) respectively 
Reactivity with ovarian cysts and evstadenomas (n = 21), wilh поп ovarian carcinomas 
(n = 77), and with normal human (issue samples (n = 63) was absent or limilcd to weak 
reactivity on incidental samples 
All three antibodies were shown by immunoclcctron microscopy to react with surface 
antigens (OA 15, О A 30 and OA 31) of ovarian carcinoma cells Cross reactivity between 
OV TL 15, OV TL 30, OV TL 31 and ОС 125 monoclon il antibodies was excluded by 
competitive binding assays on NI H OVC AR 3 cells 
Antigen levels (OA 15 and OA 31) in tumour extracts and cyst fluids were quantified by 
immunoradiomclric assays and compared to the CA 12e· antigen levels High levels of С A 
125 OA 15 and OA 31 were found in cyst fluids from ovarian cancers In benign ovarian 
cyst fluids, however the CA 125 conlenl was also high while OA 15 antigen was hardlv 
delectable The OA 31 antigen was present tt relatively low levels 
The IRMA data confirmed the minninohistochcmical data showing th it, in eonlr ist to 
OC 125, the newly developed MAbs OV TL 15 OV TL 30 and OV Π 31 disciimin ile 
between benign ovarian cystadenomas and malignant ovarian cancers 
Introduction 
Monoclonal antibodies (MAbs) against ovarian carcinoma associated antigens (OCAAs) have 
been developed m several laboratories (Taghbue et al 1985 Poels et al 1986 Miotti et al 1987 
Fleuren et al 1987a M< ttes et al 1987 Boermanetal 1989) and have been shown to be useful in 
the discrimination between ovarian and non ovarian carcinomas (Poels et al 1986 Nouwen et al 
1987, Koelma et al 1988) A tew antibodies may be useful for assessing the histologic type 
(mucinous versus other common epithelial types) of ovarian carcinomas (Tsup et al 1985 Saka 
kibaraetal 1988) 
The biological behaviour of ovarian tumours may range from benign to extremely malignant with 
a number of steps in between Antibodies described so far are directed against antigens expressed 
in benign as well as in malignant ovarian tumours OC 125 has been reported to stain 45% of the 
benign serous ovarian tumours positively (Kabawat et al 1983), MOv 18 stained 100% (Miotti et al 
1987) and OV 632 stained 56% (Fleuren et al 1987) of the benign serous ovarian tumours 
MAbs against antigens expressed exclusively in malignant ovarian tumours may facilitate an 
accurate discrimination between benign borderline malignant and malignant ovarian tumours In 
this study we report the development of MAbs reacting positively and almost exclusively with 
malignant ovarian cancer cells 
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Materials and Methods 
Tissues, cyst fluids, cell lines and tumour extracts 
Human tissue samples were obtained freshly from surgery, snap-frozen in liquid nitrogen and 
stored at -80°C Cyst fluids from ovarian carcinomas (n = 13) and from benign ovarian tumours 
(n = 32) were obtained by thin needle aspiration and centrifuged at 3,500 g (10 mm, 40C) The 
supernatants were stored at -80°C 
The NIH OVCAR-3 ovarian carcinoma cell Ime (Hamilton et al 1983) obtained from the American 
Type Culture Collection, was grown in RPMI-1640 medium (Gibco, Paisly, U К ) supplemented with 
10% PCS (foetal calf serum, Flow Labs, Herts, U К ) 
Tumour extracts were prepared by homogenizing 0 1 g tissue/ml PBS containing 5 mM EDTA 
(ethylenediammetetraacetate, E Merck, Darmstadt, FR G ), 1 mM PMSF (phenylmethylsulphonyl-
fluonde, Sigma, St Louis, MO) in a glass homogenizer with a Teflon pestle After centnfuging the 
crude homogenate (20,000 g for 30 mm at 4°C) the supernatants were stored in small aliquots at 
-80oC until use 
Production of anti-ovarian carcinoma monoclonal antibodies 
Balb/c mice were immunized by four intraperitoneal injections given at 1 month intervals, with 
0 5 ml tumour extract prepared from an undifferentiated ovarian carcinoma (code no 86-753) Four 
days after the final injection, 5 χ 107 immune spleen cells were fused with 2 χ 107 myeloma cells 
(Sp2/0 Ag-14), using polyethylene glycol 4000 (E Merck, Darmstadt, FRG) as fusogen, as 
described (Fazekas St Groth & Scheidegger 1980, Lane 1985) The hybndoma supernatants were 
initially screened using an indirect immunofluorescence assay (IFA) on frozen sections of the same 
ovarian carcinoma as used for immunization, as described (Poels et al 1986) The supernatants 
reacting positively with the carcinoma cells in these sections were further selected for a negative 
reaction on sections of a serous ovarian cystadenoma The hybndomas were recloned by repeated 
limiting dilution 
Three hybndoma cell lines (OV-TL 15, OV-TL 30 and OV-TL 31), were selected for further 
characterization The hybndomas were grown in pnstane-pnmed Balb/c mice for production of 
ascites containing antibodies according to standard procedures 
The MAbs were isotyped m a double diffusion assay (Hudson & Hay 1980) 
Solubihzed tumour proteins were subjected to SDS-gelelectrophoresis, Western blotting and 
immunodetection using MAbs as described (Towbm et al 1979), with minor modifications 
Immunohistochemistry 
Reactivity of MAbs on unfixed cryostat sections of human tissue samples was tested both in 
immunofluorescence (IFA) (Poels et al 1986) and in immunoperoxidase assays (IPO) (Vandesande 
1979), using undiluted hybndoma supernatant or optimally diluted hybridoma-mduced mouse 
ascitic fluid A broad spectrum anti-keratin MAb, OV-TL 12-5 (Poels et al 1989, Van de Molengraft 
et al 1989), staining all epithelial cells in a section was used as a positive control The IFA and IPO 
staining were scored arbitrarily ( + ) for clearly positive, (±) for weakly positive and (-) for negative 
staining 
Immunoelectron microscopy 
A freshly obtained sample from a serous ovarian carcinoma was fixed in penodate-lysme-parafor-
maldehyde-glutaraldehyde solution (PLPG), for 1 г h (Gendelman et al 1983) and further processed 
for electronmicroscopy as described previously (Van Niekerk et al 1988) 
Radioiodmation of the antibodies 
The IgM isotype MAbs OV-TL 15 and OV-TL 31 were purified by 45% ammomumsulphate 
precipitation from hybridoma-mduced ascitic fluid (Vandesande et al 1979), followed by gel filtration 
on a G-200 column (Pharmacia, Uppsala, Sweden) (Parham et al 1982) The IgGi isotype MAb 
OV-TL 30 was purified by affinity chromatography on a Protein A-Sepharose column (Pharmacia, 
Uppsala, Sweden) (Ey et al 1978) 
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Purified MAbs were radioiodmated by the chloramme-T procedure (Greenwood et al 1963) 
followed by chromatography on Sephadex G-25 (Pharmacia, Uppsala, Sweden), resulting in a 
specific radioactivity of 10-15 Ci/g 
Competitive binding assay 
NIH OVCAH-3 cells were grown in 8-well strip plates (Costar, Cambridge, MA) until 90% 
confluency After the cells were fixed in 0 25% glutaraldehyde (E Merck, Darmstadt, F R G ) (10 mm, 
20°C) the wells were washed and saturated (1 h, 20oC) withO 5% BSA (bovine serum albumin, Sigma, 
St Louis, MO) in PBS After washing, the cells were incubated with 50 ^L of a fixed amount of 
125l-labelled MAb (50 ng/ml) in the presence of various dilutions of the unlabelled MAbs OV-TL 15 
OV-TL 30, OV-TL 31, as well as OC 125 (Bast et al 1981 ), for 4 h at 20°C From the displacement of 
the labelled antibodies by the corresponding unlabelled antibody, the affinity constants of the 
antibodies were calculated as the reciprocal of the molar concentration of unlabelled MAb required 
for 50% displacement (Giacomim et al 1985) 
Immunoradiometric assays 
Two-step IRMAs were developed essentially as described previously for an OC 125-based 
immunofluorometric assay (Boerman et al 1987) The wells of 12-well EIA/RIA strips (Dynatech, 
Bilhngshurst, UK ) were coated by overnight incubation with 200/(L purified, unlabelled MAb (1-25 
//g/ml in PBS) Wells were saturated with 250 /iL 0 5% BSA (Sigma, St Louis, MO) in PBS for 2 h 
and subsequently incubated for 4 h with 100 //L tumour extract or cyst fluid and 100/<L assay buffer 
(50 mM Tris HCl, pH 7 75, 150 mM NaCI, 0 5% BSA) 125l-labelled MAb in 200 ¡iL assay buffer (50 
ng/ml) was incubated in each well for 2 h All incubations were carried out at room temperature and 
after each incubation the wells were washed 4 times with PBS containing 0 05% Tween 20 (E Merck, 
Darmstadt, FR G ) Finally, the bound portion of the tracer was determined in a gamma counter 
Serial dilutions of an ovarian carcinoma extract (code no 86-753) were used as standard 
preparations in each assay, and equivalent antigen (OA15 and OA 31) concentrations for experimen-
tal samples were determined by interpolation of the standard curve run on each assay plate using 
the RIA Cale software package (Pharmacia-Wallac Oy, Turku Finland) on an IBM-XT compatible 
personal computer The OA 15 and OA31 contents of the 86-753 ovarian carcinoma extract were 
calibrated as 100 arbitrary Units per ml (100 arb U/ml) As a rule the standard error of triplicates 
(mtra-assay precision) remained within 10% of the mean, while the inter assay precision for the same 
samples on five different occasions remained within 15% of the mean Wells retaining a radioactivity 
less than the 99% upper confidence limit of the control (assay buffer) were considered below the 
limit of the assay sensitivity 
To investigate whether the epitopes defined by OV-TL 15, OV-TL 30, OVTL 31 and OC 125 are 
located on the same molecule we performed double determinant I RMAs In these assays the antigen 
preparation (ovarian carcinoma extract or cyst fluid) was incubated in wells coated with one 
antibody, and a second, different antibody was used as a tracer 
CA 125 determinations 
Levels of CA 125 in cyst fluids were assayed m an OC 125-based IRMA as described by Klug et 
al (Klug et al 1984) To avoid the high-dose 'hook effect' (Miles et al 1974), a two step incubation 
protocol was applied Forali samples multiple dilutions up to 1/10,000 were assayed Dilutions were 
made using a standard serum diluent The reagents were obtained from Centocor Ine (Malvern, 
PA) 
Statistical methods 
As antigen levels In cyst fluids were not normally distributed, non-parametric statistical methods 
were used A Mann-Whitney U-test was used for comparison of antigen levels in benign and 
malignant ovarian tumour cyst fluids 
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Results 
Characterization of three anti-ovarian carcinoma monoclonal antibodies 
Based on the strategy of immunization with an extract of an undifferentiated ovarian carcinoma, 
followed by a differential screening for a positive reaction on the same carcinoma concomitant with 
a negative reaction on sections of an ovarian cystadenoma, three hybndoma cell lines were selected 
Radial immunodiffusion analysis indicated that the hybndomas OV-TL 15 and OVTL 31 produced 
IgM antibodies, while OV-TL 30 produced IgGl antibodies 
The immunoreactivity of the tumour antigens (OA 15, OA 30 and OA 31) defined by the three 
monoclonal antibodies OV-TL 15, OV-TL 30 and OV-TL 31 respectively, was not preserved after 
SDS-gelelectrophoresis followed by immunoblottmg The immune reactivity of these antibodies was 
lost on paraffin processed tissue blocks, but resisted cold methanol as well as PLPG fixation 
Immunohistochemical reactivity of ovarian tumours 
The immunohistochemical reactivity of the three monoclonal antibodies on ovarian tumours was 
studied in combination with the reference MAb OC 125 A broad spectrum anti-keralm monoclonal 
antibody OV-TL 12-5, was applied in order to stain all epithelial cells in the tissue sections The results 
as summarized in Table 1 show that OV-TL 15, OVTL 30 and OV-TL 31 hardly reacted with benign 
ovarian tumours Figure 1a shows an example of OV-TL 15 staining negatively a serous ovarian 
cystadenoma Weak and heterogeneous staining was seen with these antibodies in only three 
Table 1 Immimohistochemical reactivity of anti ovarian carcinoma monoclonal antibodies () V-TL 15, 
OV TL 30, OV-TL M and OC 125 with ovarian tumours 
Tumours OV-TL 15 OV-TL 30 OV-TL 31 OC 125 
Cystoma simplex 
Cystadenomas 
Borderline tumours 
Serous carcinomas 
Mucinous carcinomas 
Endometrioid carcinomas 
Clear cell carcinomas 
Non-classified adenocarcinomas 
Total carcinomas 
Granulosa cell tumours 
Fibrothecomas 
0/8a 
3/14b 
2/4b 
37/42 (88%) 
3/5 
6/8 
5/6 
13/15 
64/76 (84%) 
' 0/2 
0/4 
0/8 
3/14b 
3/4b 
39/42 (93%) 
3/5 
6/8 
4/6 
12/15 
64/76 (84%) 
0/2 
0/4 
0/8 
3/14b 
2/4b 
35/42 (83%) 
2/5 
5/8 
4/6 
10/15 
56/76 (74%) 
0/2 
0/4 
6/8 
10/14 
3/4 
41/42 (98%) 
2/5 
5/8 
5/6 
15/15 
68/76 (89%) 
0/2 
0/4 
The number ol positively reacting samples per total number of samples 
ь
 Weak immunoreactivity was found on the indicated number of samples 
All specimens were assayed by both immunofluorescence and immunoperoxidase assays 
cystadenoma samples, while ОС 125 (Fig 1 b) stained the majority of benign ovarian tumours clearly 
positively 
A few of the samples of the borderline tumours were stained focally (10 25% of the epithelial cells 
in a section) and heterogeneously However, in these samples both the obviously proliferating areas 
as well as the areas showing no atypical features displayed immune reactivity 
OV TL 15 reacted with 88% of the 42 serous ovarian cancers and with 84% of the 76 ovarian 
carcinoma samples tested On the same samples OV-TL 30 reacted with respectively 93% and 84% 
and OV-TL 31 with 83% and 74%, while ОС 125 stained with 98% of the serous ovarian cancers and 
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Figure 1 Immunohistochemical staining pattern (IPO) of a serous ovarian cystadenoma (250x) stained 
with OV-TL 15 (a) showing no immune reactivity, OC 125 (b) and OV-TL 12-5 (c). 
89% of all ovarian carcinomas examined In most samples OV-TL 15 showed a homogeneous, diffuse 
positive staining pattern (Fig. 2d), OV-TL 30 usually displayed a heterogeneous pattern (Fig 2e), 
while OV-TL 31 reactivity was confined to the apical side of the tumour cells (Fig. 2f). 
Immunoelectron microscopy showed that the three antibodies reacted with the tumour cell 
membrane (Fig. 3). OV-TL 15, however, also showed some submembranous cytoplasmic staining 
(Fig. 3b), indicating the OA 15 antigen is not exclusively localized in the cell membrane. 
Immunohistochemical reactivity of non-ovarian carcinomas 
With regard to the gynaecologie carcinomas (Table 2), all three antibodies positively stained both 
carcinomas of the fallopian tube examined, while OV-TL 15 and OV-TL 30 positively stained three of 
Table 2 Immunohistochemical reactivity of anti-ovarian carcinoma monoclonal antibodies OV-TL 15, 
OV-TL 30 and OV-TL 31 with non-ovarian tumours. 
TUMOURS OV-TL OV-TL OV-TL OC 125 
15 30 31 
Gynaecologie carcinomas 
Tubal carcinomas 2/2a 
Endometrial carcinomas 3/13 
Cervical carcinomas Adeno carcinomas 2/4 
Squamous cell carcinomas 0/4 
Non-gynaecologic tumors 
Breast carcinomas 0/10 
Renal cell carcinomas 0/9 
Colon carcinomas 0/12 
Other carcinomas 
stomach, ileum, pancreas, bladder, rectum, a.o. 0/17 
Non-epithelial tumours 
seminomas, melanomas, lymphomas 0/8 
a
 The number of positively reacting samples per total number of samples 
b
 1/2 positively reacting pancreascarcmoma 
All specimens were assayed using both an immunofluorescence and an immunoperoxidase assay 
2/2 
3/13 
1/4 
2/4 
3/10 
5/9 
0/12 
0/17 
0/8 
2/2 
0/13 
0/4 
0 4 
0/10 
0/9 
0/12 
0/17 
0/8 
2/2 
5/13 
2/4 
0/4 
2/10 
0/9 
1/12 
1/17b 
0/8 
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Figure 2 Immunohislochemical staining (IPO) of serial sections of a serous ovarian carcinoma (250x), 
stained with OV-TL 12-5 (b), OC 125 (с), OV-TL 15 (d), OV-TL 30 (e) and OV-TL 31 (f). 
Sections were counterstained withhacmaloxylin. A negative control section (lOOx) is shown in 
figure 2a. 
the 13 endometrial carcinomas tested OV-TL 31 did not react with either endometrial carcinomas 
or cervical carcinomas 
The OV-TL 15 and OV-TL 31 antibodies did not show any reactivity with any of the non-gynae-
cologic tumours {(n = 48), including breast (n = 10) and gastrointestinal carcinomas (n=21)}. 
OV-TL 30 reacting with some renal cell carcinomas (five out of nine specimens) and breast 
carcinomas (three out of ten specimens). 
Immunoreactivity with normal human tissues 
Staining sections of 64 samples of different types of normal human tissues with the three 
antibodies indicated that the MAb-defined antigens were hardly expressed In normal human tissues 
(Table 3). Sections of ovarian tissue clearly showed the antibodies to be non-reactive with the 
germinal epithelium. Mesothelial linings in sections of three non-ovarian samples also stained 
negatively. OV-TL 15 displayed weak positive reactivity with the apical side of oviductal epithelium 
and traces of reactivity were observed on some renal tubules. OV-TL 30 stained faintly positive the 
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glomerular mesangial cells (two out of six samples), while tubules remained negatively. OV-TL 31 
stained positively with less than 10% of the renal tubules, probably the Henie loops. 
Competitive binding assay 
We investigated whether the MAbs compete for the binding of identical epitopes on the ovarian 
carcinoma cell line NIH;OVCAR-3 The binding of 125l-labelled MAbs was measured in the presence 
of varying concentrations of unlabelled antibodies. As shown in Table 4 the binding of labelled 
Figure 3 Immunoelectron micrograph showing immunoperoxidase reaction on a sample of a serous 
ovarian carcinoma stained with OV-TL 15 (a,b) and OV-TL31 (c,d) at the tumour cell surface. 
The microvillous cell membranes are stained clearly positive. Some submembranous cytoplas-
mic immune reactivity is observed with the OV-TL 15 antibody (Fig. 3b). Magnification Fig. 
3a,c (8,000x) and Fig. 3b,d (16,000 x). 
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Table 3 Immunohistochemical reactivity of anti-ovarian carcinoma monoclonal antibodies OV-TL 15, 
OV-TL 30 and OV-TL 31 with normal human tissue 
Tissues (#samples examined) OV-TL OV-TL OV-TL 
15 30 31 
5/8a 
Mesothelium 
Ovary, uterus, cervix, vulva, vagina 
Oviductal epithelium 
Digestive tract epithelium 
Liver, Gallbladder, Pancreas 
Respiratory tract epithelium 
Kidney, glomeruli 
tubules 
Testis, prostate 
Adrenal gland 
Spleen, tonsil 
Skin 
(3) 
(18) 
(8) 
0) 
(4) 
(3) 
(6) 
(6) 
(3) 
(2) 
(3) 
(5) 
216a 
3/6a - 1/6a 
All specimens were assayed using both an immunofluorescence and an immunoperoxidase assay 
antibody could only be inhibited by using the identical unlabelled antibody, indicating that each 
antibody recognized a unique epitope on the cell surface 
From these displacement studies the affinity constants of the three MAbs were calculated as the 
reciprocal of the molar concentration of unlabelled MAb required for 50% displacement of the 
homologous l-labelled antibody The affinity constants of the three antibodies were in the same 
range, being highest for OV-TL 30 (16 χ 108 M"1), and lowest for OV-TL 31 (1 4 χ 10e M"1). 
Immunoradiometric assays 
To investigate whether the MAb-defined antigenic determinants could be quantified in tumour 
extracts and ovarian cyst fluids, three 'sandwich'-type IRMAs based on the three MAbs (OV-TL 15, 
OV-TL 30 and OV-TL 31) were developed 
The optimized standard curve of the OA 15 IRMA, using serial dilutions of the 86-753 ovarian 
carcinoma extract as standards, is shown in Figure 4A The curve of a serially diluted cyst fluid was 
similar to the standard curve, indicating OA 15 is ¡mmunochemically similar in both cyst fluid and 
tumour extracts. Similar data were obtained with the OV-TL 31-based IRMA (not shown) With the 
OV-TL 30-based IRMA, wells did not retain significant amounts of radioactivity, neither after 
incubation with ovarian carcinoma extracts nor with ovarian carcinoma cyst fluids, suggesting that 
the OA 30 antigenic determinant was not preserved during the procedure or does not appear as a 
repetitive epitope on the antigen. 
Figure 4B shows that using the OV-TL 15-based IRMA, no significant OA 15 levels could be 
detected in extracts of a selection of 14 non-ovarian cancers exhibiting no OA 15 expression as 
determined immunohistochemically, while significantly elevated antigen levels were found in the 
extracts of ovarian cancers (n = 17). The immunohistochemical reactivity of the MAb OV-TL 15 in 
sections of the ovarian carcinoma samples was arbitrarily scored on a range from negative (-) to 
strongly positive (+ +) and corresponded well to the IRMA data (Figure 4B) Ovarian carcinomas 
of different differentiation grade (well, moderately and poorly differentiated), were used to prepare 
the tumour extracts measured in the IRMA, but no relationship between OA 15 content and 
differentiation grade as assessed histologically, was observed (data not shown). Analogous results 
were found for the level of OA 31 antigen in extracts of ovarian carcinoma extracts. 
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The ovarian carcinoma associated antigen OA 15 was also detectable in 12 out of 13 cyst fluids 
from ovarian cystadenocarcinomas significantly lower levels were found in the fluids from 32 benign 
ovarian tumours (p < 0 001, Mann-Whitney U test) In fact, only 2 benign ovarian tumour cyst fluids 
showed detectable OA 15 levels as shown in Figure 5A These findings, again, are in line with the 
immunohistochemical assays on tissue sections ol the corresponding tumour specimens 
Although the OA 31 antigen was not detected immunohistochemically in sections of benign 
ovarian tumours, relatively low OA 31 levels were found in some cyst fluids from these tumours 
(n = 27) as determined in the IRMA (Figure 5B) Significant higher levels, however, were found in the 
fluids of cystadenocarcinomas (n = 11 ) (p<0 001, Mann-Whitney U-test) Cyst fluids from only two 
ovarian carcinomas contained OA 31 concentrations that were in the range of the benign tumour 
cyst fluids (0 10 arb U/ml) In these two ovarian carcinoma samples no OA 31 expression could be 
demonstrated with immunohistochemical staining techniques 
The CA 125 levels in cyst fluids from ovarian carcinomas were not significantly higher than CA 
125 levels in benign ovarian tumour cyst fluids, as determined in the Mann-Whitney U test (p = 0 091 ) 
(Figure 5C) 
In contrast to the homologous IRMAs, no significant antigen levels could be detected with double 
determinant IRMAs in tumour extracts in the presence of 10 mM CHAPS (3-[3 cholamideopropyl) 
dimethylammomo] 1 1 propanesulfonate Boehnnger Mannheim, FRG) This indicates that the 
MAb-defmed epitopes (OA 15, OA30, OA31 and CA 125) are located on different molecules 
t u m o u r e x t r a c t OA 15 
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Figure4 A: Standard curve of the OA 15 IRMA ( · ) and ihc curve of a serially diluted ovarian 
carcinoma cyst fluid (o) Serial dilutions of an ovarian carcinoma extract were used as 
standards (Error bars represent -J ( Xi + X2 )/2 ) 
B: Relative OA 15 levels in tissue extracts of 17 ovarian carcinomas and extracts of 14 
non ovarian carcinomas (four colon, three breast, three renal, two endometrial and two 
cervical carcinomas) I FA scores of the corresponding samples are indicated + + = strong 
positive 1FA reactivity on cryostat sections, + = positive 1FA reaction, ± - weak 1FA 
reaction, - = negative IFA reaction 
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Table 4 Competitive inhibition of binding of radiolabcllcd M Abs on ovarian carcinoma cells 
125l-MAb Unlabelled MAb % Inhibition at ΛμΜ unlabelled MAb Affinity constant ( M 1 ) 
0V-TL15 
0V-TL15 
OV-TL 30 
OV-TL31 
OC 125 
97 
0 
0 
0 
6.8 x 1 0 8 
OV-TL 30 
OV-TL 15 
OV-TL 30 
OV-TL 31 
OC 125 
0 
96 
0 
0 
160x10® 
OV-TL 31 
OV-TL 15 
OV-TL 30 
OV-TL 31 
OC 125 
0 
0 
92 
0 
1 4X10' β 
The binding studies were carried out on NIH OVCAR-3 cells as described in 'Materials and Methods All numbers rep­
resent the mean of three different experiments (1>iM IgG = 0 1Sg/L, ' м 'Э^ = OBg/L) 
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Figure 5 Relative levels of the ovarian carcinoma-associated antigens OA 15 (A), OA 31 (B) and CA 
125 (С) in cyst fluids from malignant and benign ovarian tumours. If a frozen tissue sample of 
the corresponding tumour was available, the IFA score is indicated: + + = strongly positive, 
+ = positive; ± = weakly positive, - = negative staining. 
54 
Discussion 
Discussion 
In this chapter we describe the generation and characterization of three monoclonal antibodies 
against ovarian carcinoma associated antigens The MAbs OV-TL 15, OV-TL 30 and OV-TL 31 were 
obtained after immunization with an undifferentiated ovarian carcinoma extract followed by screen-
ing of the immunoreactive hybridoma culture supernatants fora negative reactivity on the epithelium 
of a serous ovarian cystadenoma 
Based on competitive binding assays on NIH OVCAR 3 cells, the three MAbs are directed against 
different epitopes No cross reactivity was found with CA 125 as defined by the OC 125 antibody 
Experiments using double determinant assays indicated that the epitopes defined by the MAbs 
used are located on different molecules The antibodies exhibited differing affinity constants, being 
highest for OV-TL 30 (16x108 M 1) This might be related to the subclass of this antibody (IgGl ), the 
other antibodies belonged to the IgM class 
Monoclonal antibodies against ovarian carcinoma-associated antigens described until now, 
suchas OC 125 (Bast et al 1981, Koel ma et al 1988), MOvI, MOv2 (Taglibueet al 1985),MT179, 
MW162, MW207, MX35 (Mattes et al 1987), MOv 18, MOv 19 (Miotti et al 1987) and OV 632 (Fleuren 
et al 1987a, Koelma et al 1988) have all been reported to react with most benign ovarian tumours 
as well The ovarian carcinoma associated antigens defined by these antibodies are expressed in 
endometrial and endocervical epithelium and are thought to be antigens expressed in the Mullenan 
duct, the embryologie origin of the epithelia of the ovaries, the fallopian tubes and the endocervix 
In contrast, the MAbs described here are directed against antigens apparently not expressed on 
endometrial and cervical epithelium, and thus may be non Mullenan duct related antigens This may 
explain the observation that these anti ovarian carcinoma antibodies (OV TL 15, OV TL 30 and OV-TL 
31) are non reactive with benign ovarian tumours 
It has been suggested that ovarian carcinogenesis starts with inclusion cyst formation from the 
germinal epithelium of the ovary Ovarian cystadenomas arising from these cysts are thought to 
give rise to ovarian carcinomas (Cramer & Welch 1983) According to this concept, OA 15, OA 30 
and OA 31 expression is triggered during malignant transformation 
The negative or low immunohistochemical reactivity of the MAbs OV TL 15, OV-TL 31 with benign 
ovarian tumours was supported by IRMA determinations in cyst fluids from a larger series of ovarian 
tumours high concentrations of OA 15 and OA31 were found in ovarian carcinoma cyst fluids, but 
the antigens were absent or found at low levels in cyst fluids from benign ovarian lesions Although 
no OA 31 antigen was found by immunohistochemical methods m the tissue sections of the benign 
ovarian tumours, the antigen was detectable in the cyst fluid of the corresponding samples This 
might be due to accumulation of shed antigen in cyst fluids CA 125 determinations in cyst fluids of 
benign and malignant ovarian tumours revealed comparable CA 125 levels being in line with the 
data reported by Fleuren et al (1987b) They proposed the basal membrane in benign ovarian 
tumours to be an effective barrier for CA 125, explaining the observation that, in spite of the high 
CA 125 contents of cyst fluids from behign tumours, elevated CA 125 serum levels are observed 
only occasionally in patients with benign ovarian lesions (Einhorn et al 1986) 
The OV TL 15 and OV-TL 31 -based IRMAs, facilitated quantitative determination of the OA 15 and 
OA 31 contents of ovarian carcinoma specimens High levels were found in ovarian carcinomas, 
while the antigens were hardly expressed in benign ovarian tumours thus suggesting that the 
expression levels of the MAb-defmed antigens are related to the biological behaviour of the tumour 
However, a clear relationship between the differentiation grade of ovarian carcinomas as determined 
histologically, and their OA 15 or OA 31 content as determined immunoradiometrically, was not 
observed Further studies are required to determine whether these antibodies can be used to assess 
the malignant potential of ovarian tumours 
The antibodies OV-TL 15 and OV-TL 31 showed no reactivity with breast and colon carcinomas 
together representing the majority of adenocarcinomas metastatic to the ovary Therefore, these 
antibodies are considered to be useful as additional tools for differential diagnosis between ovarian 
cancers and other cancers 
By immunoelectron microscopy it was shown that the antigens OA 15, OA 30 and OA 31 were 
associated with the membrane of the tumour cells In addition, the antigenic determinants OA 15 
and OA 30 could not be traced in serum from ovarian carcinoma patients (data not shown) It is 
thought that tumour-associated antigens located at the cell membrane and not detectable in serum 
are suitable targets for in vivo application of antibodies Preliminary biodistribution studies of OV-TL 
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30 in tumour-bearing athymic mice support this suggestion. Preliminary studies indicate that the 
OA 31 epitope is detectable in serum of ovarian cancer patients. 
In summary, we have generated three new monoclonal antibodies against ovarian carcinoma-
associated antigens which may be useful adjuncts in differential diagnosis of ovarian tumours. 
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Abstract The monoclonal antibodies ОС 125, OV-TL 3, MOv 18 and OV-TL 23 which 
are directed against distinct ovarian carcinoma-associdled antigens are assessed in the 
present study for their gynecopathological value The expression of the antigens defined 
by these antibodies was studied in serial sections from 8Ü ovarian carcinomas and 103 
non-ovarian carcinomas obtained from 183 patients, using the immunoperoxidasc techni-
que 
Immunoclcctron microscopy demonstrated that the antigens were all localized on the 
lumor cell membrane ОС 125, OV TL3 and MOv 18 reacted posituelv with approximately 
90% of the ovarian carcinoma samples (n = 80), while OV-TL 23 stained 76% ol these 
samples ОС 125, OV-TL 3 and MOv 18 were also reactive with a majority of the 
carcinomas derived from the cervix, cndomelruim and fallopian lube, while OV-TL 23 
reactivity was primarily reslncled to ovarian carcinomas OC 125 and OV-TL 3 reacted 
respectively with 11% and 14% of the non-gynecologic carcinomas tested (n = 64) Positive 
cases included breast, colon and lung carcinomas The antibodies MO\ 18 and OV TL 23 
were found less reactive with non-gynecologic carcinomas 
Introduction 
Approximately 90% of malignant ovarian tumors are of the common epithelial type Epithelial 
ovarian cancers are thought to arise from modified peritoneal mesothelial cells covering the surface 
of the ovary (Dallenbach Hellweg 1984, Rüssel 1984) Since ovarian carcinomas cause symptoms 
only late in the course of the disease, more than 75% of ovarian cancer patients have tumor in the 
pelvis or abdomen outside the ovary at the time of diagnosis (Griffith 1982) Oviductal, lymphatic 
or haematogenous dissemination may spread ovarian cancer to fallopian tube, endometrium, 
distant nodes, liver, lung, pancreas or skeleton (Bergman 1966) Although the histopathological 
differential diagnosis between ovarian and non-ovarian cancers is feasible in most cases about 10% 
of poorly differentiated ovarian tumors cannot be positively identified on basis of morphological 
criteria (Osborn & Weber 1983) In addition, approximately 8% of ovarian tumors arise outside the 
ovary (Kempson & Hendrickson 1978, Fox & Langley 1976) the most common primary sites being 
breast, intestines, and stomach These metastases from occult carcinomas may show an adenoid, 
papillary or cystic structure bearty distinguishable from carcinomas arising in the ovary (Scully 1980, 
Ulbnght et al 1984) Since treatment and prognosis depend on the histologic origin and the spread 
of the tumor (Davis 1982, VogI et al 1979, Klein et al 1985), reliable histopathological typing of 
adenocarcinomas in the abdominal cavity is essential 
Monoclonal antibodies against ovarian carcinoma-associated antigens have been developed in 
several laboratories (Bast et al 1981, Poels et al 1986, Miotti et al 1987) Immunohistochemical 
staining of carcinoma sections using monoclonal antibodies against ovarian carcinoma-associated 
antigens may be a useful supplementary method in surgical pathology In the discrimination between 
(primary and metastatic) ovanan carcinomas and other adenocarcinomas The ideal target for an 
antibody for application to gynecopathological practice would be an antigen which is abundantly 
expressed in ovarian carcinomas, but is not expressed in those of non-ovarian origin In this study 
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we evaluated the reactivities of four anti-ovarian cancer monoclonal antibodies (OC 125, OV-TL 3, 
MOv 18 and OV-TL 23) using serial sections from a wide range of carcinoma specimens in order to 
assess their potential value in surgical pathology 
Materials and Methods 
Tumors 
Tumors were obtained at the time of surgery from 183 patients Small blocks of fresh tissue were 
frozen in liquid nitrogen and stored at -80°C Diagnosis had been made from both cryostat and 
paraffin sections stained with haematoxylm/eosin Epithelial tumors of the ovary (n = 80) were 
histologically classified according to the WHO criteria In addition three adenocarcinomas of the 
fallopian tube, 21 endometrial carcinomas, 11 cervical carcinomas, and 5 gynecologic squamous 
cell carcinomas were tested Furthermore, 64 carcinomas from ten different organs (including 16 
breast, 11 colon and 10 lung carcinomas) were studied 
Table 1 Immunohistodiemical sldining of ovarian carcinomas 
histological type 
serous 
mucinous 
endometrioid 
clear cell 
mixed epithelial 
undifferentiated 
non classified 
total 
(42)a 
(5) 
(8) 
(6) 
(3) 
(3) 
(13) 
(80) 
OC 125 
4 1 Ь 
2 
6 
4 
3 
3 
13 
72(90%) 
OV-TL 3 
41 
3 
5 
6 
3 
3 
12 
73(91%) 
MOv 18 
39 
3 
7 
3 
3 
3 
12 
70(88%) 
OV-TL 23 
36 
2 
5 
3 
3 
3 
9 
61 (76%) 
Motal number of samples examined 
'' Number ol positively reacting samples 
Specimens were assayed in an immunoperoxidase assay Staining was scored by two independent observers 
Monoclonal antibodies 
The following murine monoclonal antibodies were used in this study (1) ОС 125 was raised 
against a serous ovarian carcinoma cell line (NIH OVCA 433) (Bast et al 1981) (2) OV-TL 3 was 
obtained after immunization with a cell suspension prepared from an endometrioid ovarian car­
cinoma specimen (Poels et al 1986) (3) MOv 18 was raised against a crude membrane preparation 
of a poorly differentiated ovarian carcinoma (Miotti et al 1987) (4) OV-TL 23 was isolated after 
immunization with cyst fluid from a serous ovarian carcinoma (Boerman et al 1989) (5) OV-TL 12-5 
an anti keratin antibody (directed against keratin 5 7,14 and 19) (Van Niekerk et al 1988, Ramaekers 
et al 1990) was used as a positive control The antibodies were purified from ascitic fluid using a 
Protein A Sepharose column (Ey et al 1978) For immunohistochemistry purified monoclonal 
antibodies diluted in PBS (20/<g/ml) were used 
Immunohistochemical studies 
Serial unfixed cryostat sections (4-6μη) were incubated with purified monoclonal antibody (20 
¿<g/ml PBS) for 30 mm at room temperature The sections were then washed and treated with 
peroxidase conjugated rabbit-anti-mouse immunoglobulins (DAKO, Denmark) diluted 1 /100 in PBS, 
0 05% Tween-20 (E Merck, Darmstadt FRG) After washing peroxidase was revealed with 3 mM 
З'.З'-diaminobenzidine (Sigma St Louis, MO) and 0 01% H2O2 in PBS, 0 05% Tween-20 The 
sections were counterstamed with haematoxylm and mounted in Eukitt Negative control staining 
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Figure 1 Diagram showing for each MAb ihe percentage of ovarian carcinoma samples (n = 80) stained 
strongly posilivc, moderalcly positive, and weakly positive 
was performed on adjacent sections by replacing the first antibody by PBS Sections of an ovarian 
carcinoma sample (code no 86 753) reactive with all antibodies used in this study served as a 
positive control in each staining session 
Staining was scored arbitrarily by two independent observers as negative (-), weak (±) moderate 
( + ) or strong ( + + ) according to the intensity of the staining and the percentage of tumor cells in 
a section stained The monoclonal antibody OV TL 12 5 which stains all carcinoma cells in a section, 
was used as a reference in the estimations of the percentage of the positively stained cells The 
sensitivity and specificity of the antibodies lor staining ovarian carcinomas was calculated as follows 
. . no ovarian carcinoma samples stained positvely . „ „ „ , 
sensitivity = — — е ¡ е з ^ х 100% total no ovarian carcinoma samples examined 
. . no non-ovarian carcinoma samples stained negatively . 
specificity = —-—: ^ : a—-r1- χ 100% total no non-ovarian carcinoma samples examined 
Immunoelectron microscopy 
A freshly obtained sample from a serous ovarian carcinoma was fixed in penodate-lysme-parafor-
maldehyde-glutaraldehyde solution (PLPG), for 11/2 h (Gendelman et al 1983) Frozen sections (30 
μπι) were cut and incubated with the monoclonal antibodies (20,ug/ml) followed by incubation with 
anti-mouse IgG antibody conjugated with peroxidase (1 100) (DAKO, Denmark) Following a 10 mm 
fixation in 2% glutaraldehyde in 0 1 M phosphate buffer (pH 7 4), a second 15 mm incubation was 
carried out using 1% a'.S'-diaminobenzidine-HCI with 0 0 1 % H2O2 Sections were postfixed in 1% 
osmium tetroxide, dehydrated in an ascending series of ethanols and embedded in Epon 812 After 
polymerization, ultrathm sections were cut with a diamond knife on a Reichert ОМ U3 ultramicrotome 
(Reichert, Vienna, Austria) Sections were double contrasted with uranylacetate and leadcitrate, and 
examined in a Philips EM 300 electron microscope (Philips, Eindhoven, The Netherlands) 
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Results 
Immunohistochemical staining of ovarian carcinomas 
The four monoclonal antibodies were used to stain sections of epithelial ovarian cancers from 
80 patients. The results are listed in Table 1 The highest sensitivity for staining of ovarian carcinomas 
was found for OV-TL 3 (91%), while OC 125 and MOv 18 scored 90% and 88%, respectively. The 
lowest sensitivity (76%) was found for OV-TL 23 
In addition to sensitivity, the intensity of the staining may also be a criterium for selecting 
antibodies for use in surgical pathology. Figure 1 summarizes the staining intensities of the 
antibodies in sections from the 80 ovarian carcinoma specimens. OC 125, OV-TL 3, and MOv 18 
showed intense staining in more than 60% of the tissues, while OV-TL 23 strongly reacted with only 
Figure 2 Immunohistochemical staining paltern (IPO) of OC 125 (a), OV-TL 3 (b), MOv 18 (c), and 
OV-TL 23 (d) on serially cut frozen sections of a serous ovarian carcinoma sample (250x). A 
section stained with the anti-keratin antibody OV-TL 12-5 is shown as a positive control (e). 
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Table 2 Immunohislochemicdl staming of non-ovarian carcinomas 
gynecologic carcinomas 
SITE 
fallopian tube 
endometrium 
cervix adenocarcinoma 
cervix squamous cell 
vulva 
vagina 
(n = 39) 
(3)a 
(21) 
(4) 
(5) 
(5) 
(1) 
OC 125 
3 b 
16 
2 
-
2 
1 
OV-TL 3 
3 
14 
3 
2 
3 
1 
MOv18 
3 
15 
2 
-
2 
-
OV-TL 23 
3 
2 
2 
-
-
-
non-gynecologic carcinomas (n = 64) 
SITE 
breast 
stomach 
ileum 
colon 
rectum 
pancreas 
lung 
kidney 
urethra 
bladder 
(16) 
(3) 
(1) 
OD 
(4) 
(2) 
(10)C 
(Θ) 
0) 
(8) 
3 
-
1 
-
1 
2 
-
-
-
5 
1 
-
1 
1 
-
1 
-
-
-
total (103) 31 35 24 
•' Total number of samples examined 
ь
 Number of positively reacting samples 
c
 including three small cell carcinomas three squamous cell carcinomas three adenocarcinomas and one carcinoid 
Specimens were assayed in an immunoperoxidase assay Staining was scored by two independent observers 
25% of the samples Moreover, OV-TL 23 weakly stained about 20% of the tissue specimens while, 
with the other antibodies a weak reaction was only observed in a small number (5 6) of samples 
ОС 125 stained 41 of the 42 serous carcinomas distinctly positively An example of a positive 
reactivity is shown in figure 2a One moderately differentiated serous ovarian carcinoma stained 
negatively ОС 125 showed a characteristic pattern of staining, with the intraluminal and peripheral 
cell surfaces reacting most intensively The mucinous ovarian carcinomas showed less ОС 125 
reactivity than the other histological types one mucinous carcinoma stained distinctly positive, one 
sample stained focally while three were negative 
OV-TL3stainedpositively41 of the 42 serous tumors An example is shown in figure 2b Additional 
staining of tumor stroma was observed occasionally, but was not scored The serous tumor which 
was negative to OV-TL 3 reacted positively with the other three antibodies OVTL 3 stained 
approximately 50% of both mucinous and endometrioid carcinomas 
MOv 18 stained positively 39 of the 42 serous carcinomas (Fig 2c) In addition three out of five 
mucinous carcinomas stained distinctly positive, while only 50% (three out of six) of the clear cell 
type tumors were positive 
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Figure3 Immunoclcctron micrograph showing Immunoperoxida.se reaction on a sample of a serous 
ovarian carcinoma stained with OC 125 (a), OV-TL 3 (b), MOv 18 (c), OV-TL 23 (d). The 
cell membranes arc stained clearly positive with each of the antibodies. Magnification figure 
3a, 3b, 3c (3,50()()x) and figure 3d (9,5(Юх). 
OV-TL 23 reactivity was found on 36 ( = 86%) serous tumor samples (Fig 2d) In addition, 
approximately 60% (11 of 19) of the non-serous tumors stained positively In general OV-TL 23 
staining was heterogeneous, ranging from a localized to uniform distribution This resulted in a less 
intense staining of most sections in comparison with that observed with the other antibodies (of 
figure 1). 
Immunoelectron microscopy on a sample of a serous ovarian carcinoma showed that all 
antibodies are directed against antigens localized in the membrane of the neoplastic cells (Fig 3). 
OV-TL 23 reactivity appeared to be restricted to the luminal cell surface (Fig 3d), while the antigens 
recognized by ОС 125, OV-TL 3 and MOv 18 were demonstrated at the basal, the lateral and the 
apical site of the cells, resulting in circumferential staining (Fig 3a, 3b, 3c). Additional cytoplasmic 
immune reactivity was not observed with any of the four antibodies, while the sections stained with 
the anti-keratin antibody (OV-TL 12-5) showed dense cytoplasmic reactivity (not shown) 
Immunohistochemical staining of non-ovarian carcinomas 
ОС 125, OV-TL 3 and MOv 18 showed positive staining with the majority of the 39 other 
gynecologic carcinomas examined (Table 2). OV-TL 23 showed markedly less reactivity with these 
samples than the other antibodies ОС 125, MOv 18 and OV-TL 3 stained the majority of the 
adenocarcinomas of the fallopian tube, endometrium and cervix Additionally these antibodies 
positively stained some of the squamous cell carcinomas of the vagina and/or the vulva The OV-TL 
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23 antibody stained only 25% of the non-ovarian gynecologic adenocarcinomas examined (7 of 28) 
and did not react with the squamous cell carcinomas of the cervix uteri, vulva and vagina 
The reactivity of the four monoclonal antibodies on 64 non-gynecologic carcinomas (including 
16 breast 20 gastro-mtestmal and 10 lung carcinomas) is reported in Table 2 OV-TL 23 showed no 
reactivity with these samples Positivity for OC 125 was detected in adenocarcinomas of the breast 
(3 of 16), colon (1 of 11), pancreas (1 of 2) and lung (2 of 10) OVTL 3 positively stained a third of 
breast cancer samples (5 of 16), while 3 (of 19) gastro-mtestmal carcinomas and one adenocar 
cmoma of the lung also stained positively MOv 18 reacted positively with two non-gynecologic 
cancer samples one ductal breast carcinoma and one mucinous adenocarcinoma of the colon 
The highest specificity (93%) was found for OV-TL 23, while the specificities of OC 125, OV TL 3 
and MOv 18 were significantly lower 70%, 66% and 77%, respectively The relevance of the absolute 
value of these calculated specificities is limited since the range of non ovarian carcinomas we used 
in this study does not reflect the population based incidence figures However the reported 
specificities do represent a relative indication of the specificity of the antibodies for staining ovarian 
carcinomas 
Discussion 
To investigate their application in histopathological differential diagnosis of cancer, we studied 
the immune reactivity of four anti ovarian carcinoma monoclonal antibodies in sections from a broad 
series of carcinomas The immunohistochemical reactivity on cancer tissues of each of these four 
monoclonal antibodies has been previously described (Kabawat et al I983ab, Poels et al 1986 
Miotti et al 1987, Boerman et al 1989) However an actual comparison of their immunohistochemi-
cal reactivities requires an evaluation on serially cut sections from a wide range of cancer samples 
Immunohistochemistry on 80 ovarian carcinoma specimens revealed that OC 125 OV TL 3 and 
MOv 18 each reacted with approximately 90% of the ovarian carcinomas examined while each 
antibody stained 98% 98% and 93% of the serous ovarian carcinomas respectively In tho present 
study the frequencies of OC 125 and MOv 18 positivity were higher than reported earlier 62% for 
OC 125 (Kabawat et al 1983a) and 69% for MOv 18 (Miotti et al 1987) However more recent studies 
with OC 125 are in line with our observations (90%) (Nouwen et al 1987 Koelmaetal 1988) The 
sensitivity of OV-TL 23 for staining ovarian carcinomas was significantly lower than the sensitivity of 
the other antibodies, and is in agreement with earlier observations (Boerman et al 1989) 
It was originally reported that OC 125 was unreactive with mucinous ovarian carcinomas 
(Kabawat et al 1983a), however, in this study OC 125 positivity was found in a proportion of the 
mucinous samples CA 125 expression in mucinous ovarian tumors has been reported in previous 
studies (Koelmaetal 1987, Shishietal 1986) and is in line with the high CA 125 levels in cyst fluids 
from mucinous ovarian tumors (Fleuren et al 1987, Boerman et al 1990) and m sera from patients 
bearing mucinous ovarian carcinomas (Di Xia et al 1988) We found the mucinous samples also 
reactive with MOv 18 Probably as a result of the limited number of mucinous samples previously 
examined, this reactivity has not been observed earlier (Miotti et al 1987) 
For application in surgical pathology the antibodies should not only stain ovarian carcinomas 
but should also be nonreactive with non ovarian carcinomas with similar histological appearances 
The epithelia of normal endometrium, fallopian tube and endocervix have been shown to weakly 
express the antigenic determinants recognized by OC 125 (Kabawat et al 1983b) OVTL 3 (Poels 
et al 1986) and MOv 18 (personal observation) In this study the majority of adenocarcinomas 
originating from these epithelia also showed OC 125, OV-TL 3, and MOv 18 positivity Consequently 
these antibodies do not facilitate discrimination between the various adenocarcinomas arising from 
the gynecologic tract OV-TL 23, however, reacted with only 10% of the endometrial carcinomas, 
and may be helpful in the discrimination between ovarian and endometrial carcinomas 
The expression of the antigens defined by OC 125, OV-TL 3, and MOv 18 in carcinomas of the 
vagina and/or vulva shows that their expression is not restricted to adenocarcinomas, but also can 
be observed in squamous cell carcinomas 
The immune reactivity of OC 125 with breast and colon carcinomas corresponds with that of 
earlier reports (Kabawat et al 1983b, Poels et al 1986, Mainguené et al 1986) OV-TL 3 positivity in 
breast carcinomas has not been reported previously (Poels et al 1986, Kuhnel et al 1988) but sample 
numbers in these investigations were limited The reactivity of OC 125 and OV TL 3 with carcinomas 
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of the breast, colon and lung limits the use of these antibodies in differential diagnosis since these 
carcinomas comprise a major proportion of the secondary ovarian tumors Application of a 
combination of OV-TL 3 and anti-keratin 7 antibodies has been shown to facilitate the discrimination 
between ovarian and colon carcinomas (Ramaekers et al. 1990) MOv 1 θ showed only very limited 
reactivity with the non-gynecologic carcinomas (2 of 64), while OV-TL 23 was completely unreactive 
with these samples, making these antibodies suitable tools for application in gynecopathological 
practice 
The monoclonal antibodies OC 125, OV-TL 3, MOv 18 and OV-TL 23 are useful adjuncts for 
discriminating ovarian carcinomas from non-gynecologic carcinomas OC 125, MOv 18 and OV-TL 
3 display very high sensitivity for staining ovarian carcinomas and thus a negative reactivity with 
these antibodies in an adenocarcinoma section makes it unlikely to be an ovarian carcinoma 
However, the occasional reactivity of OC 125, OV-TL 3 (and to a lesser extent MOv 18) with 
non-gynecologic carcinomas must be kept in mind when interpreting such results 
OV-TL 23 in this study was the only antibody to be totally unreactive with the 64 non-gynecologic 
carcinomas In addition, OV-TL 23 was the only antibody being only poorly reactive with endometrial 
carcinomas On the other hand OV-TL 23 displayed lowest sensitivity for staining ovarian carcinomas 
and stained them in a heterogeneous manner An adenocarcinoma sample displaying a positive 
reactivity therefore with OV-TL 23 is likely to be an ovarian carcinoma 
From the immunohistochemical characteristics of these antibodies, it can be concluded that the 
use of only one antibody as a diagnostic tool in surgical pathology is limited since (1 ) the antibodies 
are occasionally reactive with non-ovarian carcinomas, (2) the antibodies frequently reveal hete­
rogeneous staining Therefore, combinations of antibodies seem more informative 
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Abstrait The intcraclions of fíiur monoclonal diilibodiLS (OV 1 L 3 OV TI 16, OV TL 
Mi and OC 125) Willi ovarian carcinoma cells (Nil) OVC AR 3) were compared in \ilroas 
well as in a nude mouse model The affinilv conslanls of the antibodies ranged from l u x 
IO9 M ' (OC 125) lo 3 χ IO9 M ' (OV TL 30) The cell binding kinetics of the antibodies 
were studied in vilro OV TL 30 associated faslesl (4i0/r binding after 24 min) OV TL 3 
and OV TL 16 associated slower (50% binding after 75 mm) while the association rale of 
OC 125 was slowest (50% binding after 120 mm) Dissociation rates of the antibodies also 
differed OC 125 displayed the slowest dissociation rale ((Иг - Vi) mm) The OV TL 
antibodies showed a fasler, biphasic dissociation characlenstic The biodislribution ol the 
radioiodinatcd antibodies in NIH OVCAR 3 xenograft bearing athvnnc mice following 
intravenous injection, was compared I lighest tumor accumul ilion 48 h ρ ι was found with 
OV TL 3 (13 3 ± 2 1 % ID/g) and OV TL 16 (11 0 ± 2 0 'A Il)/g) while the uptakes of 
OV TL 30 and OC 125 were mirkedly lower (4«) ± 0 4 '/, md 6 0 ± 1)9 'A IDg, 
respectivelv) The faci that in this experimental model (he in vivo lumor accumul ilion ol 
OV TL 3 and OV TL 16 was approximately twice as high as the tumor accumulation ol 
OC 125 could not be fully ascribed to parameters of the antibodies determined in vitro 
(immunoreaelive fraction, affinity constant antigen density association ind dissociation 
rale) It is suggested thai because the antigens recogm/ed b) OV TL3 and OV TL 16 are 
not shed from the tumor cells these antibodies may be belter tools for clinical r idiomi 
munodeleclion of ovarian carcinomas 
Introduction 
Monoclonal antibodies (MAbs) against tumor associated antigens are widely applied diagnostic 
tools in histopathological diagnosis serodiagnosis and immunoscmtigraphy Several MAbs have 
been successfully used in clinical trials for immunoscmtigraphic detection of ovarian carcinomas 
(Granowska et al 1986 Hunter et al 1987 Epenetosetal 1987 Massuger et al 1989) The outcome 
of radioimmunotargetmg of tumors with MAbs is affected by many factors such as the density 
accessibility, and fate of the target antigen the kinetic and thermodynamic characteristics of the 
antibody used the radionuclide used and the amounts to be injected (Gremer et al 1987 Haisma 
et al 1987) Since comparative studies to select the most suitable vehicle for in vivo imaging are 
impracticable in humans extensive use has been made of nude mouse models In a previous study 
the biodistribution of the F(ab )2 fragments of OC 125 and OVTL 3 was evaluated in a nude mice 
model with mtrapentoneally growing human ovarian tumors (Mosely et al 1988) It was shown that 
OVTL 3 accumulated to higher levels in the xenografts than OC 125 In addition to OVTL 3 a new 
series of MAbs against ovarian carcinoma-associated antigens has been developed in our 
laboratory (Boerman et al I989ab) From this series we have selected two IgGi antibodies (OVTL 
16 and OVTL 30) directed against different epitopes localized on the cell membrane of ovarian 
carcinoma cells In order to select the most suitable antibody for radioimmunotargetmg we 
investigated the in vitro cell binding characteristics as well as the biodistribution 48 h after 
intravenous injection of the three OV-TL antibodies in comparison with OC 125 
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Materials and Methods 
Monoclonal antibodies 
The following MAbs against ovarian carcinoma-associated antigens were used in this study 
OV-TL 3 (Poels et al 1986), OV-TL 16, OV-TL 19 (Boerman et al 1989), OV-TL 30 (Boerman et al 
1990) and OC 125 (Bast et al 1981, Kabawatetal 1983) All MAbs reacted with tumor celi membrane 
antigens and showed minimal reactivity with normal human tissues All five MAbs belong to the lgG1 
subclass Ascitic fluids containing the various MAbs were generated by intraperitoneal (ι ρ ) 
inoculation of approximately 1 χ 1(r hybndoma cells into pristane-primed Balb/c mice The ascitic 
fluid was harvested and clarified at 1,000 g for 10 mm before storage at -20oC The antibodies were 
purified from ascitic fluid by protein A-affmity chromatography (Ey et al 1978) The IgG containing 
fractions eluted at pH 4 5 were neutralized, pooled and buffer-changed to PBS in an Amicon 
concentrator using an YM 10 filter (Amicon, Danvers, MA) The concentration of the purified 
preparations was adjusted to 3 5 mg/ml as determined by the method of Lowry et al (1951) using 
BSA (bovine serum albumin, Sigma Co , St Louis, MO) as a standard The preparations were stored 
at - г с с until use 
Radioiodination 
Purified antibodies were radioiodlnated using the lodogen method (Fraker & Speck 1978) Briefly, 
100/(1 aliquots of lodogen (1,3,4,6-tetrachloro3a,6a diphenylglycoluril, Pierce Chemical Co , Rock-
ford, IL) at 150 /ig/ml in chloroform were evaporated to dryness in 8 χ 60mm glass tubes One 
hundred μ\ of purified IgG (adjusted to 1 mg/ml in 50 mM sodiumphosphate buffer pH 7 2) and 0 3 
mCi of Na1 2 5 l (Amersham Int UK) were added After five mm the reaction mixture was applied 
on a 55 χ 200mm Sephadex G-25 (Pharmacia Sweden) column to separate the labeled protein from 
the unincorporated 1 2 5 l The labeled antibody in the void of the column was pooled and adjusted 
to 25 /ig/ml and used within 4 h for in vivo studies For in vitro studies the labeled antibody solution 
was stored at 40C in the presence of 1 % BSA and 0 05% NaNa Label incorporation was approximate­
ly 80%, resulting in a specific radioactivity of approximately 2 Ci/g IgG 
The maximum binding of each radiolabeled antibody batch for use in the in vivo experiments 
was assessed by titration of a fixed amount of antibody with increasing numbers of ovarian 
carcinoma cells (ranging from 104 to 107) until a plateau of bound activity was reached The 
immunoreactive fraction of the batches was calculated as described by Lmdmo et al (1984) 
Cell line and tumor growth 
The NIH OVCAR-3 human ovarian carcinoma cell Ime (Hamilton et al 1983) was obtained from 
the American Type Culture Collection and grown in RPMI 1640-based culture medium (Gibco, 
Paisley, U К ) supplemented with 10% FCS The cell line was routinely subpassaged weekly at a 1 5 
split ratio This cell line was used because it can be grown in vitro as well as subcutaneously in 
athymic mice It expresses the epitopes defined by the MAbs OV-TL 3, OVTL 16, OV-TL 30 and ОС 
125 
Subcutaneously growing tumors were induced by subcutaneous (s с ) injection of 3 χ 107 cells 
on the back of 1-2 months old female athymic Balb/c mice (nu/nu) These tumors were resected 
asceptically, cut into 2-3 mm blocks and transplanted subcutaneously Approximately 6 weeks later, 
the tumors had grown to 1 0-1 5 cm in diameter (corresponding to 0 5 - 2 0 g) These tumor-bearing 
mice were used for biolocahzation studies From each in vivo passage a tumor tissue specimen was 
subjected to standard histological and immunohistochemical procedures In contrast to reports on 
the original cell line (Hamilton et al 1984) in our hands, intraperitoneal inoculation of up to 4 χ 107 
cells did not give rise to ι ρ growing ascitic tumors 
Immunofluorecense assay 
The expression of the MAb defined antigens on cultured NIH OVCAR 3 cells was qualitatively 
determined using an indirect immunofluorescence assay (IFA) as described in a previous study 
(Boerman et al 1989) 
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OV-TL 3 
OV-TL 16 
OV-TL 19 
OV-TL 30 
OC 125 
+ + 
+ + 
-
+ -
+ + 
Table 1 Expression of the MAb-defined antigens on cultured NIH:OVCAR-3 cells and affinity 
constants of the MAbs 
IFA1 Number of determinants per cell (x10'4) Ka (M 1) 
120 1 4 X 1 0 9 
100 1 1 χ 1 0 9 
n.s. 
9 3 X109 
490 1 0 x 1 0 9 
η s not significant 
1
 The immunofluorescence assay was done on in vitro cultured NIH OVCAFW cells Reactivity was scored arbitrarily as negati­
ve (-), weak (±), moderate ( + ) or strong ( + + ) according to ttie intensity of the staining and the number of positive cells 
Quantification of the cell binding of the MAbs at equilibrium 
The affinity constants (Ka) of the antibodies and the number of epitopes per cell (N) were 
determined as described (Parham et al 1982) NIH OVCAR-3 cells were briefly fixed in 0 25% 
glutaraldehyde (E Merck, Darmstadt, FR G ) (10 mm, 20oC) and suspensions of 106 cells were 
incubated with eight 1 5-fold dilutions of labeled antibody in 1 ml PBS, 0 5% BSA in Eppendorf-type 
centrifuge tubes After 24 h, tubes were centnfuged, supernatants aspirated, and the cell pellet 
counted for radioactivity bound Unbound radioactivity was calculated as the total bmdable 
radioactivity added minus the bound radioactivity Values obtained with a control cell line (Sp2/0 
Ag-14) were subtracted as background The affinity constants and the number of MAb-defined 
antigenic determinants per cell were calculated from Scatchard plots (Bound/Free versus Bound) 
CA 125 determinations 
To further characterize the nude mouse model, six tumor-bearing mice from different in vivo 
passages were bled and their CA 125 serum levels were determined using an immunofluorometric 
assay, as described in a previous study (Boerman et al 1987) 
Solid phase binding assay 
NIH OVCAR-3 cells were grown (at least 48 h) in 8-well strip plates (Costar, Cambridge, MA) until 
90% confluence After fixing the cells in 0 25% ^Paraldehyde (10 mm, 20ÉC), the wells were saturated 
with 100 ml of 0 5% BSA in PBS for 1 h at 20EC For association rate determinations, monolayers of 
fixed cells were incubated with 50 ml labeled antibody (0 5 mg/ml) in PBS, 0 5% BSA. After different 
incubation periods (from 5 min up to 24 h) the amount of bound antibody was determined The amount 
of antibody bound after 24 h of incubation was used as the maximum binding (100%) reference For 
dissociation rate determinations, monolayers of fixed cells were incubated overnight with labeled 
antibody (0 5 mg/ml PBS, 0 5% BSA) After washing, excess unlabeled antibody was added (100 mg/ml) 
to prevent rebmding of dissociated labeled antibody At different incubation intervals (between 15 mm 
and 24 h) the portion of labeled antibody remaining bound to the cells was determined 
Biolocalization studies 
NIH OVCAR-3 xenograft-bearina nude mice received 150/ig/kg bodyweight (corresponding to 
approximately 5 /ig per mouse) l-labeled MAb (IgG) in the tail vein (injected volume 0 2 ml) 
Animals were housed in special cages in order to collect urine and feces to monitor the125 l excretion 
during the experiments. The clearance of the labeled antibodies from the blood was determined by 
taking 20-40 μ\ blood samples from the retro-orbital vein Mice were bled and sacrificed 48 h ρ i (3 
or 4 mice for each determination). Tumors and selected tissues were removed, weighed, washed 
once in PBS and analyzed in a gamma counter. The results were expressed as (a) the percentage 
of the injected dose per gram of tissue (% ID/g), (b) the ratio of radioactivity in tumor to that in normal 
mouse tissues (tumor/non-tumor ratios), and (c) the specificity index, i e , the ratio of the uptake of 
the specific MAb (OV-TL 3, OV-TL 16, OV-TL 30 or OC 125) to the uptake of a non-specific antibody 
(OV-TL 19). 
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Figure 1 A. Kinetics of the binding of the antibodies to NIH:OVCAR-3 cells. 
Monolayers of glularaldehyde-fixed cells were incubated with dilu-
tions of the radioiodinatcd antibodies at room temperature for diffe-
rent time periods, washed and counted in a gamma counter. 
B. Kinetics of the dissociation of the antibodies from NlH:OVCAR-3 
cells. Monolayers of glularaldehyde-fixed cells were incubated over-
night with the radioiodinatcd antibodies al room temperature, washed 
and cold antibody was added at lOO/ug/ml. At different time intervals 
the wells were washed and counted in a gamma counler. 
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Figure 2 Tissue dislribulion of l-labclcd OV-TL 16 antibodies in NIH: 
OVCAR-1 bearing nude mice 4Й h after injection of lour different 
antibody doses. The mean of three animals is presented. SD was less 
than 20% of the mean for all tissues 
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Figure 3 Tissue distribution of 125I-Iabcled antibodies in NIH:OVCAR-3 bea­
ring nude mice 48 h p.i. The mean of three animals is presented. SD 
was less than 20% of the mean for all tissues. ISO/ig/kg bodyweight 
of each antibody was injected intravenously. 
CHAPTER 5 
Results 
Binding of the MAbs to the NIH:0VCAR-3 cells 
The expression of the MAb-defmed antigens on cultured NIH OVCAR-3 cells was studied in an 
immunofluorescence assay (Table 1) OV-TL 3 and OV-TL 16 showed intense staining of more than 
90% of the cells OV-TL 30 reactivity was limited to a weak staining of less than 50% of the cells 
Strong staining of most cells was observed with the OC 125 antibody With OV-TL 19 no staining of 
the cells was observed No significant staining differences were observed using cells from different 
in vitro passages 
The affinity constants were calculated from the slopes of the Scatchard plots of NIH OVCAR-3 
cell suspensions incubated with varying concentrations of the 1 2 5 l labeled MAbs The affinity 
constants of the antibodies were similar (Table 1 ), being highest for OV-TL 30 (3 χ 109 M 1) and lowest 
for ОС 125 (1 0 χ 109 IVI1) The numbers of the various MAb defined antigenic determinants per cell 
were derived from the x-axis intercepts of the Scatchard plots (Table 1) The numbe1- of OVTL 
3-defined determinants (OA 3) was comparable to the number of determinants recognized by OV-TL 
16 (OA 16) (respectively 1 2 χ IO6 and 1 0 χ 106 det /ceil) while CA 125 expression was about 4 
times higher (4 9 χ 106 det /cell) Expression of the OV TL 30 defined determinant (OA 30) was more 
than 10 times lower than OA 3 and OA 16 expression (9 χ 104 det /cell) As in the IFA no significant 
binding of 125l-labeled OV-TL 19 to the NIH OVCAR-3 cells was observed, making this antibody a 
suitable control antibody in the biolocalization studies 
CA 125 determinations 
The CA 125 levels in the sera of the tumor-bearing mice were less than 7 0 U/mL 
7· dose/mouse 
г50 
Кіциге 4 Blood clearance of '"^I labeled OV-TL 16 antibodies (o) 
in nude mice bearing human ovarian carcinoma xenografts 
Mean ± SD At least three animals were used for each lime 
point Excretion of the " I label each mouse was injected 
with " I-labeled monoclonal antibodies (l^O/ig/kg) The 
amounts of label excreted per mouse arc plotted cumulati­
vely ( · ) 
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Association and dissociation rates of the antibodies 
Association rates of the antibodies were determined in vitro on fixed cells (Fig ι A) Association 
of OC 125 was slowest, reaching 50% of maximum binding in 120 mm The association rates of 
OV-TL 3 and OV-TL 16 were similar, with 50% binding in 75 minutes OVTL 30 associated fastest, 
with 50% binding in 25 minutes 
Dissociation of the antibodies was measured at different time intervals by determining the portion 
of antibody remaining bound to fixed cells after the addition of excess (100 лд/ml) of unlabeled 
antibodies (Fig 1B) Dissociation of OC 125 was slowest (tV2 = 360 mm) For the OV-TL series of 
antibodies a biphasic dissociation was found The biphasic dissociation characteristic of OV-TL 3 
was similar to the dissociation characteristic of OV-TL 16, with tVz = 15 and 360 mm For OVTL 30 
halflives of 30 and 360 mm were found, resulting in a dissociation rate faster than OC 125 but slower 
than OV-TL 3 and OV-TL 16 
Biolocalization studies 
The immunoreactive fraction of each batch of each radiolabeled MAb used in the biodistnbution 
studies was found to range between 0 82 and 0 91 As a rule the coefficients of variation (CV) of the 
triplo determinations of the % ID/g were less than 20% for all tissues examined 
Dose-dependency of the biodistnbution of 125l-labeled OV-TL 16 
To investigate the relation between the amount of injected antibody and the biodistnbution four 
doses (10, 30,150 and 750/<g'kg bodyweight) of 1 2 5 l labeled OVTL 16 from the same radioiodma-
tion batch were injected intravenously Mice were sacrificed and analyzed 48 h later Fig 2 shows 
that higher doses provided higher tumor accumulation reaching 13 8 ± 2 6% ID g after the injection 
of the highest dose However doses higher than 150 ng'kg did not significantly improve tumor'non 
tumor ratios (T/NT), due to increased label uptake in kidney spleen and lung Based on these 
observations, doses of 150 /<g/kg (T/NT 3 7-15 48 h ρ ι ) were administered during subsequent 
experiments 
Comparison of the biodistribution of different MAbs 
The biodistnbution of OV TL 3, OV TL 16, OV TL 19 OV TL 30 and OC 125 at day 2 (injected dose 
150/<g/kg) is shown in Fig 3 The highest tumor accumulation was found with the MAbs OVTL 3 
and OVTL 16 (13 3 ± 2 1 % ID/g and 11 0 ± 2 0 % ID/g respectively) Tumor/blood ratios reached 
1 1 for these antibodies 48 h ρ ι 
Tumor localization of OV-TL 30 and OC 125 was significantly lower (4 9 ± 0 9 % ID/g and 6 0 ± 
0 9 % ID/g, respectively) with tumor/blood ratios of 0 5 and 0 6, respectively The label uptake into 
the tumor presented here were found in tumors weighing 0 5 2 0 g A few mice however beared 
subcutaneous micrometastases as well Label uptake into these small tumors (less than 0 2 g) was 
higher 20 8 % ID/g OV-TL 16 uptake m a tumor weighing 0 071 g was found 
The label uptake in most normal tissues or organs was about the same after the administration 
of different antibodies for all antibodies lowest uptake was found in muscle tissue (0 8 ± 0 1 % 
ID/g), while highest uptake was found in lung tissue (3 0 ± 0 4 % ID/g) 
For OV-TL 3 and OVTL 16 tumor/non-tumor ratios 48 h ρ ι for some organs (musclo gut 
pancreas) exceeded 10, while tumor/ lung, tumor/liver and tumor/kidney ratios reached 4 OVTL 
30 and OC 125 revealed tumor/non-tumor ratios exceeding 5 for some organs while for liver kidney 
and lung T/NT ratios were 2 
The OV-TL 19 antibody used as a control antibody in these experiments showing no binding to 
the NIH OVCAR-3 cells in vitro according to the IFA and Scatchard analysis revealed the lowest 
tumor uptake (1 9 % ID/g, 48 h ρ ι ) Considering the biodistnbution of 1 2 5 l labeled OVTL 19 as the 
distribution of a non-specific antibody, the specificity index for the localization of the other antibodies 
could be calculated as the ratio of the uptake of the specific antibody and the uptake of OV-TL 19 
OV-TL 3 provided the highest specificity Index of the tumor localization (7 0) OV-TL 16, OVTL 30 
and OC 125 exhibited specificity indices of the tumor localization of 5 8 2 6 and 3 2 respectively, 
proving that there is an antigen-dependent accumulation of antibodies in the NIH OVCAR-3 
xenografts The specificity indices of the localization of the antibodies in the non-tumor tissues 
ranged from 0 77 to 1 31 
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Clearance and excretion of the antibodies 
Mice received 150/¿g/kg bodyweight of the labeled antibodies ι ν and blood samples, feces and 
urine were gamma counted at different time points The clearance rates of the four 125l-labeled 
antibodies from the blood were similar during the three hours ρ ι clearance was relatively fast 
(tV2 = 4 h) Thereafter, the halflife of the 1 2 5 l label in the circulation was 42 ± 4 h (Fig 4) Gamma 
counting of the urine and feces of the animals revealed that after 1,2 and 3 days, 21, 35 and 44%, 
respectively of the injected dose was excreted per mouse (Fig 4) Separate counting of urine and 
feces revealed that more than 95% of the excreted radioactivity was excreted via the urine 
Discusssion 
In this study we have described the in vitro binding characteristics and the biodistribution 
following intravenous (ι v) injection in athymic mice bearing s с human ovarian carcinoma xeno­
grafts of the recently developed monoclonal antibodies (OV-TL16 and OV-TL 30) in comparison with 
OV-TL3andOCl25 
The affinity constants of the antibodies as determined by Scatchard analysis were similar, ranging 
from 1 0 χ 10 M 1 (ОС 125) to 3 χ 109 M"1 (OV-TL 30), while the number of MAb-defmed determinants 
per cell varied considerably Despite the relative high CA 125 expression level of the NIH OVCAR-3 
cells, the CA 125 levels in the sera of the tumor-bearing mice were very low, being in contrast with 
the high CA 125 levels (up to 12,500 U/mL) found in the sera of nude mice with intraperitoneally 
growing NIH OVCAR-3 xenografts (Hamilton et al 1984) 
The biphasic dissociation characteristics as displayed by the OV-TL antibodies suggest that these 
antibodies recognize two kinds of epitopes on the target cells, or that a portion of the antibodies 
binds to the fixed tumor cells monovalently Furthermore, OC 125 displayed the slowest association 
and dissociation rates However, these determinations only partly reflect the kinetics of the binding 
of the antibodies to the tumor cells in vivo In our hands these assays could only be performed 
reproducibly on fixed cells where phenomena such as modulation of antigen expression, internaliza­
tion of bound antibody, and shedding of antigens do not occur For instance, the dissociation of OC 
125 from live carcinoma cells might be faster because of shedding of the CA 125 bearing antigen 
(Masuhoetal 1964) 
The biodistribution studies indicate that the radioiodmated MAbs OV-TL 3, OV-TL 16, OV-TL 30 
and OC 125 show specific tumor localization First, because uptakes of the radiolabeled MAbs into 
the tumors exceeded those found in highly vascularized normal tissues Secondly, the tumor uptake 
of the antibodies was much higher than the uptake of an isotype matched non-specific antibody 
(OV-TL 19) Thirdly, the clearance of the antibodies from the blood and normal tissues was much 
faster than from the tumor (data not shown) 
The tumor uptake of the different antibodies differed significantly High tumor accumulation 48 
h ρ ι was found with OV-TL 3(133 % ID/g) and OV TL 16 (11 0 % ID/g), while the tumor localizations 
of OC 125 and OV-TL 30 were markedly lower (6 Oand 4 9% ID/g, respectively) Tumor/blood ratios 
ranged from 1 1 toO Satday 2 ρ ι Highertumor uptake was observed in smaller tumors (< 0 2 g ) , 
being in line with earlier observations with other antibodies (Pedley et al 1987) 
Our data show that the different MAbs had quite comparable uptake in normal tissues after 
injection of different types of antibodies, reaching highest uptake in organs with an active reticulo­
endothelial system (liver, lung), and lowest uptake in muscle tissue 
It has been assumed that antibodies with higher affinity constants accumulate better in tumors 
in vivo (Haskell et al 1983, Larson et al 1984, Beaumier et al 1985, Powe et al 1985, Colcher et al 
1988) However, the relatively high tumor uptake of OV-TL 3 and OV-TL 16 into the xenografts cannot 
be ascribed solely to the affinity constants of the MAbs since the Ka's of OV-TL 3, OV-TL 16 and OC 
125 were similar (1 0 1 4 χ 10 M 1 ), while the Ka of OV-TL 30, providing lowest tumor uptake, was 
higher (3 χ ΙΟ9 M 1) These observations are in line with the results reported by other investigators 
(Jones et al 1986, Sakaharaetal 1988, Sharkey et al 1988), who also found no clear-cut relationship 
between the affinity constant and tumor accumulation of radiolabeled antibodies 
The expression levels of the MAb-defmed antigens cannot fully explain the outcome of the 
biolocahzation studies either, since the number of CA 125 determinants on NIH OVCAR-3 cells was 
about four times higher than the number of OA 3 and OA 16 determinants On the other hand, the 
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low uptake of OV-TL 30 might be related to the relatively low OA 30 expression levels of the 
NIH:OVCAR-3 cells. 
The in vivo tumor uptake of OV-TL 3 and OV-TL 16 was found to be approximately twice as high 
as the tumor uptake of OC 125 in this experimental model. High levels of target antigens in the 
circulation may decrease the tumor uptake of antibodies (McKay et al 1989). However, it is unlikely 
that antibody-antigen complex formation following i.v. Injection of OC 125, as observed in ovarian 
cancer patients (Halsma et al. 1988), caused decreased OC 125 uptake into the xenografts, since 
CA 125 serum levels of the tumor-bearing mice were very low. The lower tumor uptake of OC 125 
may be a result of the different cell binding kinetics of the antibodies. OC 125 displayed the slowest 
association rate in this study Moreover, the CA 125-bearing antigen, unlike the antigens recognized 
by the OV-TL antibodies, is actively shed from the tumor cells (Masuho et al. 1984) 
Our observation that lower doses of 125l-labeled OV-TL 16 (less than 150/*g IgG/kg) resulting in 
less favorable tumor/tissue ratios and lower tumor uptake are in accordance with the results reported 
for other antibodies (Larson et al 1984, Murray et al. 1985). This phenomenom might be a result of 
saturation of other antibody binding sites (Fc receptors, cross-reacting epitopes) at higher doses 
Ι π summary we conclude that OV-TL 16 and OV-TL 3 are suitable candidates for in vivo application 
in man. The relatively low tumor accumulation of OV-TL 30 in this study may be ascribed to the low 
OA 30 expression in the xenografts Therefore, It may be worthwhile to investigate the biodistribution 
of OV-TL 30 in a nude mouse model with xenografts exhibiting higher OA 30 expression, since the 
parameters of this antibody determined in vitro indicate good in vivo behavior 
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Abstract The monoclonal antibody OV-TL 3, directed against an ovarian carcinoma-as­
sociated antigenic determinant, was tested as a vehicle for radioimmunolocahzation of 
ovarian carcinomas in athymic mice bearing NIH OVCAR 3 xenografts 
The biodistribution of intact OV TL 3 was compared with the distribution of ОС 125 
Tumor uptake with OV TL 3 was significantly higher than with ОС 125, and almost seven 
times higher than with a non specific control antibody (OV TL 19) Administration of a 
mixture of intact OV TL 3 and ОС 125 did not improve tumor uptake in comparison with 
OV TL 3 alone 
Subsequently, intact OV TL 3 and its КаЬ')2 fragments were labeled with either In 
or
 1 2 5 I Highest tumor uptake was obtained with In labeled intact OV-TL 3 (14 7 % 
ID/g, 4β h ρ ι ) For both antibody forms uptake of In in liver, spleen and kidneys was 
very high as compared to the uptake of the I label Furthermore, In cleared slower 
from most tissues than l 2 5 I As a result, tumor/tissue ratios with In-labeled OV TL 3 
were lower than with 1 2 5 l labeled OV TL 3 F(ab')2 fragments cleared from the blood and 
tissues more rapidly than the intact antibodies Highest tumor/tissue ratios (6 9 to 53) were 
obtained with I labeled OV TL 3 F(ab')2 fragments 4S h after injection 
Introduction 
Radiolabeled monoclonal antibodies (MAbs) directed against tumor associated antigens are 
currently used by many investigators to assess non mvasively the disease status in cancer patients 
(Machetal 1981, Epenetosetal 1982, Goldenberg 1987) Theoutcomeoftheseradioimmuno im­
aging studies is affected by several factors such as tumor type, MAb used, form of the antibody 
(IgG or fragments), radionuclide and labeling method (Gremer et al 1987, Haisma et al 1987) 
The MAb OV-TL 3 is a promising candidate for immunotargetmg of ovarian cancer (Poels et al 
1986) It is directed against a cell surface antigenic determinant present on more than 90% of human 
ovarian carcinomas of different histological types (Poels et al 1986 Kuhneletal 1988) Theantigenic 
determinant can not be detected in sera from ovarian cancer patients probably because it is not 
shed from the ovarian cancer cells In nude mice bearing mtrapentoneally growing ovarian 
carcinoma xenografts, OVTL 3 F(ab')2 showed higher tumor accumulation than OC 125 F(ab')2 
(Mosely et al 1988) Recently, a clinical trial (phase I & II) was initiated to evaluate the safety and 
clinical applicability of 1 1 1 ln OV-TL 3 F(ab')2 for immunoscmtigraphy in ovarian cancer patients 
Preliminary results are most promising (Claessens et al 1989) To select the most optimal agent to 
image ovarian carcinomas, we studied the pharmacokinetics and biodistribution of OV TL 3 (IgG 
and F(ab')2) labeled with either 1 2 5 l or 1 1 1 ln in athymic mice bearing human ovarian carcinoma 
xenografts 
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Materials and Methods 
Cell line 
The ovarian carcinoma cell line NIH OVCAR 3 (Hamilton et al 1983) was used for its ability to 
grow in vitro as well as in athymic mice, expressing the epitopes defined by both the MAbs OV-TL 
3 and OC 125 The cell line was grown in RPMI 1640-based culture medium (Gibco, Paisly, U K ) , 
supplemented with 15% fetal calf serum 
Monoclonal antibodies 
The MAb OV-TL 3 was raised against a cell suspension prepared from a human endometrioid 
ovarian cancer specimen (Poels et al 1986) The well characterized OC 125 antibody (Bast et al 
1981 ) was used as a reference in this study Both MAbs (IgGI subclass) are directed against distinct 
antigenic determinants localized on the tumor cell membrane The MAb OV-TL 19 (IgGI ) (Boerman 
et al 1989) showing no significant binding to the NIH OVCAR-3 cells was used as a control antibody 
The antibodies were purified from ascitic fluid generated by inoculation of hybndoma cells into 
pnstane primed Balb/c mice, using a Protein A Sepharose column (Pharmacia Sweden) (Ey et al 
1978) F(ab')2 fragments were prepared as described by Parham et al (1982) Protein concentra­
tions were determined according to Lowry et al (1951 ) The preparations were stored at -20oC until 
use 
Radiolabeling and quality control 
Radioiodmation of purified whole IgG and F(ab')2 fragments with lodine-125 was performed 
according to the lodogen method (Fraker & Speck 1978) Briefly, 100/tg of purified antibody or 67 
/гд of F(ab')2 was adjusted to 10ΟμΙ with 50 mM sodium phosphate (pH 7 2) and added to a lodogen 
(Pierce Chem Co , II) coated tube (15^g/100^l) Approximately 250μΟ of Na1 2 5 l (Amersham Int, 
U К ) was added and five mm later the reaction mixture was applied on a Sephadex G-25 column 
(Pharmacia, Sweden) and eluted with PBS The fractions containing the labeled antibody were 
pooled and used for in vivo studies within two hours 
Whole IgG and F(ab')2 fragments were labeled with Indium 111 using bicyclic anhydride of 
diethylenetriammepentaacetic acid (cDTPA) as a bifunctional chelating agent (Hnatowich et al 
1983) Briefly, to 1 ml of protein (3 mg/ml in 0 1 M NaHCOs pH 8 2) a five fold molar excess of cDTPA 
dissolved in 10^1 anhydrous dimethylsulfoxide was added After removing unconjugated DTPA by 
Sephadex G-25 column chromatography, ^00μg of DTPA-conjugated protein was mixed with 400 
μ Ο 1111 пСІз (Amersham I nt, U К ) and an equal volume of 0 2 M citrate buffer (pH 5 0) After 20 mm 
incubation, the labeling efficiency was determined by ITLC, using 0 1 M citrate buffer (pH 5 0) as 
solvent 
The maximum binding of each radiolabeled antibody preparation was assessed by titration of a 
fixed amount of antibody with increasing numbers of ovarian carcinoma cells (ranging from Ю4 to 
107) until a plateau of bound activity was reached (Lmdmo et al 1984) 
Xenografts 
Female nude mice (Balb/c nu/nu, 25-30 g) bearing a subcutaneously (s с ) growing human 
ovarian carcinoma xenograft (NIH OVCAR 3) were used The tumor model was established by 
subcutaneous injection of 3 χ 107 NIH OVCAR-3 cells Tumors were resected aseptically, minced 
into small pieces of 2-3 mm diameter and serially transplanted subcutaneously at the left lumbar 
region in 20-30 mice This procedure was performed under ether anaesthesia Tumor growth was 
seen in 90% of the mice Six to eight weeks after transplantation tumors measured 1 0 to 2 0 cm in 
diameter (corresponding with 0 8-2 5 g) At that time mice were used for biodistribution studies 
Biodistribution 
Distribution studies were performed in tumor-bearing mice Antibody preparations were injected 
through the tail vein (0 2 ml/animal) A minimum of three mice was used per data point The mice 
were sacrificed by exsangumation and cervical fracture under ether anaesthesia Blood, liver, spleen, 
kidneys, intestine (stomach to rectum), muscle, bone (femur), lung and tumor were removed Solid 
tissues were washed, blotted dry, weighed and assayed for radioactivity The results were expressed 
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Figure 1 Tissue distribution of intact 125I-labeled OV-TL 3, OC 125 
and d mixture of both antibodies in NIH OVCAR-3 bea­
ring nude mice 48 h ρ i. The mean (± SD) of three animals 
is presented. 
as percentage of the injected dose per gram of tissue (% ID/g) and tumor/tissue uptake ratios were 
calculated 
A The biodistributions of intact OV-TL 3, OC 125 and the control antibody OV-TL 19 were 
determined Radioiodinated intact antibodies (10/ig/ammal) were injected and mice were sacrificed 
48 h post injection To determine whether label uptake into the tumor could be enhanced by using 
a combination of MAbs directed against different epitopes, in the same experiment mice were 
injected with a mixture of 125l-OV-TL 3 and 125l-OC ^25(5μg + 5 /<g per animal) both labeled to 
the same specific radioactivity (2 Ci/g) The biodistribution of the mixture was compared with the 
biodistribution of either antibody administered alone 
В The biodistributions of four different formulations of OV-TL 3 were compared Mice were 
injected with intact OV-TL 3 (10/<g/animal) and its F{ab')2 fragments (6 7/<g/animal) labeled with 
either 1 2 5 l o r 1 1 ' in and dissected 4, 24 and 48 h post injection. 
Blood clearance 
At five different intervals (15 min, 1,4,24 and 48 h ρ i ) during the biodistribution experiments 30 
μ\ blood samples were obtained by retro-orbital vein puncture These samples were measured in a 
well type gamma counter (Compugamma LKB, Wallac Oy, Finland) and the count rate per gram 
blood was expressed as a percentage of the first sample, which was taken 15 min after injection 
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Excretion of the radiolabels 
To monitor the activity excreted with urine and feces, mice were housed Individually during the 
biodistribution experiments. Urine and feces were collected and assayed for radioactivity 
Results 
Radiolabeling and quality control 
The specific activities of the radiolodlnated OV-TL 3 preparations, calculated from the amount of 
1 2 5 l recovered in the voided fraction of the column, with the assumption that 100% of the MAb was 
% ID/g 
16-
12 
J 
10 
Δ — Δ 1 2 5 l - IgG 
о — о " Ч п - l g G 
~2Ô 30 ¡0 
hours post injection 
A_._A '2S|-F(ab')2 
• · " M n - F l a b ' h 
Figure 2 Label uptake into the tumor 4,24 and 48 h post injection of 
125I or ñ 'in-labeled OV-TL 3 (intact IgG or F(ab')2 frag-
ment) in NIH:OVCAR-3 bearing nude mice. 
Θ8 
also recovered, ranged from 1.5 to 2.5 Ci/g. ITLC analysis of the Ίη-labeled preparations revealed 
that more than 95% of the 1 '11n label was bound to the protein, yielding a specific radioactivity of 4 
Ci/g. 
The four radiolabeled OV-TL 3 formulations did not show significant differences in the percentage 
of the preparation that retained its original antigen-binding activity (70-80%). 
A. Biodistribution of 125l-labeled intact OV-TL 3, OC 125 and the mixture of both antibodies. 
The biodistribution data obtained 48 h post injection of 125l-labeled OV-TL 3, OC 125 and the 
mixture of both MAbs are shown in Fig. 1. Highest tumor uptake was observed with OV-TL 3 (12 9 
± 2.1 % ID/g) Injection of 125l-OC 125 resulted in an uptake of 6 9 ± 1.0 % ID/g in the tumor 48 h 
p.i, which is significantly lower than the tumor uptake obtained with OV-TL 3 (p<0 011, student 
t-test). For the non-specific control MAb (OV-TL 19) tumor uptake was 1 9 ± 0 3 % ID/g 
Injection of a mixture of intact OV-TL 3 and OC 125 resulted in a tumor uptake of 9.7 ± 0.6 % 
ID/g, which is in between the tumor uptake obtained with both antibodies individually Label uptake 
(umor/ l issue ratio 
25 
t u m o r / t i s s u e ratio 
" I Ir. " I I r " | 
blood l.vtr l i idnty mleslme 
¡4 1» • IL Лг Щ Li hr • î.nr B - S M 
Figure 3 A. Tumor/tissue ratios 4,24 and 48 h post injection of 1 and 
'"in-labeled intact OV-TL 3 in NIH:OVCYVR-3 bearing nude 
mice. The mean of Ihree animals is presented. 
B. Tumor/tissue ratios 4, 24 and 48 h posi injection of I and 
"'in-labeled F(db')2 fragments of OV-TL 3 in NlH:OVCAR-3 
bearing nude mice. The mean of three animals is presented. 
in various non-tumor tissues with the mixture was similar to uptake after administration of the 
individual antibodies (Fig. 1). 
B. Biodistribution of four different formulations of OV-TL 3. 
1. Intact OV-TL 3 labeled with either 125l or111ln. 
Animals bearing NIH:OVCAR-3 tumors were given injections of 125l or111ln-labeled intact OV-TL 
3 and were dissected 4, 24 and 48 h p.i. (Table 1). Both radionuclides accumulated in the tumors 
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during the first 48 h p i . (Fig. 2). Highest tumor uptake was obtained with the In-labeled intact 
, 2 5 l -
OV-TL 3 (13.3 ± 2.2 % ID/g). For all solid tissues examined two days after injection, 1 1 1 ln uptake 
was higher than 1 2 5 l uptake. Following injection of 111ln-OV-TL 3, the label accumulated In liver, 
spleen and kidneys to a relatively high level persisting throughout the study. This phenomenon was 
not observed with the 125l-labeled preparation. Consequently, tumor/tissue ratios obtained with 
125l-OV-TL 3 for these organs were much higher than obtained with 111ln-OV-TL 3 (Fig. ЗА) In 
addition, 111ln-labeled OV-TL 3 showed markedly higher uptake into bone (marrow) and intestine. 
For all solid tissues, tumor/tissue ratios 48 h p.i. were higher using the 125l-labeled preparation In 
contrast, tumor/blood ratio 48 h p i . was higher for the 111ln-labeled preparation. 
% of peak a c t i v i t y 
80 
60 
40-
20 
10 "2Ö" 30 40 
hours post injection 
Δ — Δ ' " [ . [ g o A _ _ A '«i-F(ab')2 
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Figure 4 Blood clearance of 1 2 5I and '"in-labeled OV-TL 3 (intact 
and F(ab')2) at 1, 4, 24 and 48 h p.i. in NIH:OVCAR-3 
bearing nude mice, expressed as the percentage of the 
blood levels measured IS min p.i. 
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Table 1 Tissue levels of radioactivity 4, 24 and 48 h after injection of mice bearing NIH OVCAR-3 
xenografts with intact OV-TL 3 labeled with either ' 2 5 I and ш І п (% ID/g ± SD, η = 3) 
4 h 24 h 48 h 
125, 1 1 1 | n 125, 1 1 1 , n 125, 1 1 1 , n 
Blood 
Liver 
Spleen 
Kidney 
Intestine 
Muscle 
Lung 
Bone + Marrow 
Tumor 
591 ±5 6 
1 5 1 ± 1 5 
152±1 2 
1 4 5 ± 1 3 
4 4±0 9 
2 9±0 3 
21 3±1 5 
2Θ±0 2 
7 4±2 3 
43 9±2 1 
32 1 ±5 3 
159±1 8 
174±24 
2 6±0 6 
2 1 ±0 7 
171±17 
5 4±0 5 
4 8 ± 1 0 
20 1±1 5 
4 1 ±0 1 
4 3±0 3 
5 4±0 1 
1 7±0 3 
3 2±0 2 
8 4±0 3 
2 6±0 1 
1 0 0 ± 2 9 
13 6±0 1 
34 5±2 0 
1 4 4 ± 0 7 
23 6±2 4 
3 5±0 2 
2 4 ± 0 2 
7 1 ±0 3 
5 6 ± 1 0 
128±1 5 
1 4 4 ± 2 8 
3 4±1 0 
3 3±0 8 
3 3±0 8 
1 2±0 2 
1 6±0 5 
4 5±0 9 
1 9±0 2 
13 3+2 2 
7 3 ± 1 4 
31 4±2 5 
151±1 6 
21 2±5 1 
4 4±0 2 
2 4±0 3 
6 3±0 2 
5 4±0 3 
1 4 7 ± 0 9 
Table 2 Tissue levels of radioactivity 4, 24 and 48 h after injection of mice bearing NIH OVO AR 3 
xenografts with F(ab )? fragments of OV TL 3 labeled wilh either 1 2 5 I or l l ГІп (% ID'g ± SD, 
n = 3) 
4 h 24 h 48 h 
125, 1 1 1 , n 125, 1 1 1 , n 125, 1 1 1 | n 
Blood 
Liver 
Spleen 
Kidney 
Intestine 
Muscle 
Lung 
Bone + Marrow 
Tumor 
20 3±3 3 
4 1 ±0 3 
4 0±0 5 
172+02 
2 7±0 3 
1 1±0 2 
121±1 1 
2 1+03 
1 9+0 1 
26 2±9 6 
9 9±0 8 
6 7±0 4 
53 0±0 9 
2 1 ±0 5 
14±0 6 
9 8±0 8 
2 1+01 
3 3+0 1 
3 5±0 5 
0 8±0 1 
0 9±0 2 
2 5±0 1 
0 6+0 1 
0 4±0 1 
1 8±0 4 
0 5±0 05 
3 7±0 9 
4 1 ± 1 4 
9 9±0 9 
7 8±0 2 
53 4±3 8 
2 1 ± 0 7 
1 3±0 4 
2 4±0 5 
1 7±0 4 
7 1 ±2 4 
0 6±0 2 
0 2±0 1 
0 3±0 2 
0 5±0 2 
0 08±0 03 
0 08+0 01 
0 5±0 2 
0 2 ± 0 1 
4 1±2 4 
0 7±0 3 
7 3 ± 0 6 
5 8±0 2 
54 1 ±7 5 
1 2±0 2 
1 7±0 8 
1 2 ± 0 2 
2 5 ± 0 3 
6 0 ± 1 1 
2. F(ab')2 fragments of OV-TL 3 labeled with either 1 2 5l or 1 1 1ln. 
Tumor bearing mice were Injected with OV-TL 3 F(ab')2 fragments labeled with ^ ^ n o r 1 2 5 l and 
were dissected 4, 24 and 48 h ρ I (Table 2) For both radionuclides accumulation in tumor tissue 
was seen (Fig 2) The highest amount of tumor uptake (7 1 ± 2 4 % ID/g) was obtained with the 
111ln-labeled fragment at 24 h p i As observed with the 1 1 1 ln labeled IgG 1 1 1 ln labeled F(ab)2 
caused relatively high label uptake in liver, spleen and kidneys persisting throughout the whole 
study In the case of intact IgG the highest levels were observed in liver (35 % ID/g) whereas with 
F(ab')2 fragments the highest levels were seen in kidneys (53 % ID/g) Again 48 h ρ ι for all solid 
tissues, the highest tumor/tissue ratios were obtained with the 1 2 5 l labeled preparation (Fig 3B) 
These tumor/tissue ratios ranged from 6 3 to 53 and were higher than those obtained with intact 
OV-TL 3 As observed with intact IgG, tumor/blood ratio for F(ab')2 fragments (48 h ρ ι ) was higher 
for the 111ln-labeled preparation Uptake In bone (marrow) and intestine was also markedly higher 
with the 111ln-labeled F(ab')2 preparation 
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Blood clearance 
Blood clearance of both radionuclides of the F(ab')2 fragments was much faster than that of the 
intact IgG as shown in Fig. 4. For F(ab')2 fragments more than 90% of both labels had been cleared 
at 24 h p.i. For intact IgG a difference in 1 1 ^n and 1 2 5 l clearance was seen from 24 h p.i. onwards, 
with 1 1 1 ln being cleared faster. 
Excretion of the radiolabels 
Gamma counting of the urine and feces during the blolocalization experiments revealed that 
excretion of the label of 125l-F(ab')2 was much faster than the excretion of the labels of the other 
cumulative excretion (% ID) 
80 
60 
ДО 
20-
10 
Δ — Û 1 2 S I -IgG 
о — о Mn-IgG 
20 30 ¿0 
hours post injection 
A—A 125I-F(ab'h 
• · "Mn-Flab'h 
Figure S Cumulative excretion (urine and feces) of the radiolabels 
of 125I or n'in-labeled (intact and F(ab')2) OV-TL 3 pre-
parations in NIH:0 VCAR-3 bearing nude mice. The mean 
of three animals is presented 
92 
Discussion 
three OV-TL 3 preparations (Fig 5) More than 70% of the I label of the F(ab')2 fragment was 
excreted 24 h ρ ι , whereas only 20% of the label of the other three preparations was excreted at 
that time From 24 h onwards, excretion of the label o f 1 1 1 ln-F(ab')2 was faster than from both labeled 
forms of intact IgG 
Discussion 
To evaluate the potential for tumor imaging of OV-TL 3-based radioimmunoconjugates, we 
studied the pharmacokinetics and biodistribution of this MAb and its F(ab')2 fragments labeled with 
two radionuclides The well characterized OC 125 and a non-specific control antibody (OV-TL 19) 
were used as references 
Biodistribution studies showed the specific tumor uptake of intact 125l-labeled OV-TL 3 and OC 
125, as compared with the radioiodmated isotype-matched control antibody Tumor uptake obtained 
with OV-TL 3 was significantly higher than with OC 125 These results are in agreement with the 
findings of Mosely et al (1988), comparing the biodistribution of ι ρ injected F(ab')2 fragments of 
OV TL 3 and OC 125 in a nude mouse model 
Munz et al (1986) reported that a mixture of MAb fragments resulted in enhanced tumor uptake 
compared to the individual fragments as determined by external scintigraphic analysis We found 
highest tumor uptake with OV-TL 3 alone and no additional uptake with a mixture of OV-TL 3 and 
OC 125 Our results are in agreement with previous studies using mixtures of intact anti CEA MAbs 
(Sharkey et al 1988) and mixtures of F(ab')2 fragments (Kabawata et al 1988) also finding no 
enhanced tumor uptake of the mixture into the tumor Nevertheless, (he sensitivity of immunoscm-
tigraphy In patients may be increased using combinations of MAbs as shown by Chatal et al (1984) 
in colorectal carcinoma patients In addition, mixtures of MAbs may be useful in order to create a 
more uniform distribution of the label within a tumor 
Cell binding tests demonstrated similar immunological reactivity of the four different radiolabeled 
OVTL 3 preparations However, major differences in the in vivo behavior were observed For both 
labels F(ab')2 fragments cleared from the blood and tissues more rapidly than intact IgG which is 
in line with previous studies (Buchegger et al 1983, Khawetal 1984 Wahl et al 1983) On the other 
hand, tumor uptake obtained with F(ab')2 fragments was lower than with intact IgG, probably due 
to the more rapid decline of the antibody concentration gradient between blood and tumor Despite 
the lower tumor accumulation, F(ab')2 fragments yielded the highest tumor/tissue ratios indicating 
their preferential use in Immunoscintigraphy 
Despite the more rapid clearance of the F(ab')2 fragments from most tissues 1 l 1 l n OV-TL 3 
F(ab')2 showed higher In retention in the kidneys than was observed using intact IgG It has been 
shown that in contrast to intact IgG, F(ab')2 fragments are susceptible to glomerular filtration 
(Wochner et al 1967), explaining the shift in distribution of the 1 '11n label when antibody fragments 
are used 
With respect to the radionuclide used, tumor accumulation was higher for both antibody forms 
when " ' i n was used as a label, in line with previous animal studies (Brown et al 1987 Andrew et 
al 1988) Apparently, radioiodmated antibodies are dehalogenated at the tumor site and the free 
1 2 5 l label is rapidly removed via the blood In contrast, with 1 1 1 ln labeled antibodies virtually all of 
the label is retained in the tumor The comparison of the levels of both radiolabels in the other tissues 
at consecutive time points after injection suggests that this phenonenon also occurs m non tumor 
tissues The retention of ' " i n in various tissues maybe caused by (a) transcomplexation of 1 1 1 ln 
from DTPA to metal binding proteins in the tissues, (b) precipitation of free1111n in situ as '111ndium 
hydroxide, (c) Intracellular storage of (colloidal) 1 1 1 ln, (d) retention of non-catabohzed 1 nln-labeled 
antibody Studies with endogeneously labeled 75Se-MAb have shown that these antibodies in vivo 
behave very similarly to 11'in-labeled antibodies (Halpern et al 1983), being in favor of the fourth 
mechanism However, based on our data the other mechanisms cannot be ruled out The rapid 
removal of the 1 2 5 l label from the tissues to the blood may explain the higher blood levels for I 
(as compared to 1 1 1 ln levels) following injection of radiolabeled intact OV-TL 3 (Fig 4) 
The high persistent uptake of ' " i n into liver, spleen and kidneys is in striking contrast with the 
clearance of 1 2 5 l from these organs for both forms of the antibody The accumulation of 1 1 1 ln in 
liver, spleen and kidneys may obscure tumor deposits in the vicinity of these organs It has been 
suggested that 1 1 1 ln is retained in the liver following dissociation of the covalent bond attaching 
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DTPA to the protein (Sakahara et al. 1987). However, deconjugatlon of 1 '11n-DTPA from the antibody 
is unlikely, since it is known that DTPA-chelated In is excreted in the urine very rapidly (McAfee 
et al. 1979, Jakowatz et al. 1985). 
Several mechanisms can be postulated to explain the high1111n uptake into the liver as compared 
with the " ' i n uptake In other tissues, (a) transchelatlon of 1 1 1 ln from the antibody to serum 
transferrin and subsequent transportation to the iron storage protein (ferritin) in the liver, (b) since 
antibodies are glycosylated proteins they may enter поп-parenchymal cells of the liver by a 
receptor-mediated process (Schlesinger et al. 1978). Subsequent intracellular catabolization of the 
labeled antibodies could result in hepatic retention of n i l n . 
As often in animal experiments, one has to be reluctant to translate these observations to the 
situation inpatients. In the present study the 111ln-OV-TL3 F(ab')2 preparation yielded the highest 
label uptake in the kidneys (15 % ID), while hepatic uptake accounted for 10 % of the injected dose. 
However, clinical studies with 1111n-OV-TL 3 F(ab')2 have indicated that only 5% of the administered 
dose accumulated In each kidney, while 20% of the injected dose accumulated in the liver (Massuger 
et al. 1989). Possible explanations for the difference in hepatic accumulation in patients are the 
formation of HAMA-antibody complexes and the recognition of foreign (murine) proteins by the liver. 
In summary, all radiolabeled formulations of OV-TL 3 retained their specific antigen binding 
activity However, important differences in the in vivo behavior were observed. Overall, the 
radiolodinated F(ab')2 fragments revealed the most optimal distribution in the nude mouse model, 
suggesting the possible use of 123l-labeled OV-TL 3 F(ab')2 in clinical radioimmunodetection of 
ovarian cancer lesions. However, the quality of images with 1 2 3 l will be severely degraded due to 
its short physical halflife. This can only partly be compensated for by administering higher doses of 
labeled antibody Taken these considerations into account, 1 2 3 l and 111ln-labeled OV-TL 3 F(ab')2 
may both be useful agents In imaging ovarian cancer. Major disadvantages with regard to 1 un­
labeled antibodies are the overall lower tumor/tissue ratios and the inability to detect tumor deposits 
in the upper abdominal region, while imaging with 123l-labeled antibodies will suffer from poor 
counting statistics. 
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Abstract A lime-resolved immunofluorometric assay (IFMA) is described for quantifying 
the ovarian carcinoma-associaled antigenic determinant CA 125 in human scrum. 
Monoclonal antibody lo CA 125 is immobilized onto a microliter well, and ihe same 
anlibody labeled with an europium chelate is used as a tracer. After the immunoreaction 
the bound portion of the labeled anlibody is quantified by dissociating the Eu + in a 
fluorescence-enhancement solution and measuring ils fluorescence with a lime-resolved 
fluorometer. The dctcclion limil of the IFMA is 1.5 arb. unils/mL, being about the same 
as thai of a commercially available immunoradiomctric assay (IRMA) for CA 125 (1.4 arb. 
units/mL). The analytical range of the IFMA extends to 20(X) arb. units/mL, whereas the 
range of the IRMA is 500 arb. units/mL. For 30 scrum samples from ovarian cancer patients 
measured simultaneously in the IFMA and IRMA, orthogonal regression analysis gave the 
equation CA 125 (IFMA) = 0.9937 CA 125 (IRMA) -1.211 arb. units/mL (Sy, = 6.8681, 
r = 0.9932). Apparently, the IFMA for CA 125 is a convenient allcrnalive to the IRMA 
for CA 125 because of shorl counting times, the uscof nonradioaclivc, stable reagents, and 
(he much extended measuring range. Additionally, the microliter formal should lend itself 
lo mure fully automated procedures in laboratories doing many such analyses. 
Introduction 
Monoclonal antibodies generated against antigens associated with a broad range of malignan-
cies (Sell & Reisfeld 1985) have been used to develop sérodiagnostic immunoradiometric assays 
(IRMAs) for gastro-intestinal carcinoma (carbohydrate antigen CA 19-9) (Del Villano et al. 1983), for 
breast carcinoma (cancer antigen CA 15-3) (Hayes et al. 1986), for cervical squamous cell 
carcinoma (SCC) (Kato et al. 1979), and for ovarian carcinoma (cancer antigen CA 125) (Bast et al. 
1983, Klug et al. 1984). 
The specificity and the sensitivity of the CA 125 IRMA have sufficed to support its evaluation in 
several clinical applications for ovarian cancer patients, including detection of disease prior to 
second-look surgery (Niloff et al. 1986, Schilthuis et al. 1987), monitoring patients' response to 
therapy (Lavin et al. 1987), differential diagnosis (Einhorn et al. 1986), and even early detection of 
ovarian carcinoma (Zurawski et al. 1987). The consensus has been that increased concentrations 
of CA 125 in serum are a reliable indicator of the presence of disease. Such concentrations have 
been measured in most cases with the one-step IRMA (Klug et al. 1984) in which 125l-labeled 
antibody to CA 125 is used as a tracer. An enzyme immunoassay for CA 125 determinations has 
also been developed by Abbott Laboratories (Chicago, IL), in which anti-CA 125-horseradish 
peroxidase (EC 1.11.1.7) conjugate is a tracer. 
Here we take advantage of recent developments indicating the widespread applicability in 
immunoassays of an europium chelate; the time-resolved fluorescence signal can be measured 
with high accuracy and low background (Hemmilä et al. 1983, Soini & Kojola 1983). We describe a 
two-step immunofluorometric assay (IFMA) for the quantitative determination of CA 125 concentra-
tions in serum. The use of dissociation-enhanced lanthanide fluorescence provides an assay with 
sensitivity equivalent to the already available IRMA, with no need for radioactive reagents. 
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Materials and Methods 
Labeling the monoclonal antibody 
The anti-CA 125 monoclonal antibody (OC 125) was purified by affinity chromatography on 
Protein A-Sepharose (Pharmacia, Uppsala, Sweden) ÍEy et al 1978) OC 125 was labeled with 
Eu3+-N'-(p-isothiocyanatobenzyl)diethy1enetriamine-N ,N2,N3,N3-tetraacetate, resulting in the in-
corporation of 7 7 Eu atoms per antibody molecule, as described by Hemmila et al (1983) 
Sera and standards 
Serum samples from 30 ovarian cancer patients were included in the present study As a 
reference we used the standards from a commercially available IRMA kit (Centocor, Malvern, PA) 
These standards, in a matrix of calcium-supplemented human plasma, contain respectively 7 7,30, 
80, 200, and 500 arb units of CA 125 per milliliter (The units In which the CA 125 concentrations 
are expressed are not internationally standardized ) As a diluent for patients' sera and standards, 
we used fetal calf serum (batch no 11639, Flow Labs, Herts, U К ) 
Preparation of ovarian carcinoma extract 
We prepared an extract of a human ovarian carcinoma tissue by homogenizing 1 0 g of a serous 
cystadenocarcmoma in 20 mL of 1 0 mmol/L phosphate buffered (pH 7 4) saline containing 137 
mmol of NaCI per liter in a glass homogemzer with a Teflon pestle After centnf ugmg the homogenate 
(30 000 χ g, 20 mm, 40C), we stored the supernate in small aliquots at -70°C 
Coating of the microtitration strips 
Monoclonal antibody ОС 125 was absorbed to the walls of polystyrene microtitration wells (Eflab 
Oy, Helsinki, Finland) by incubating overnight at room temperature 200 /iL of purified antibody 
(0 1-5 0 mg/L) in sodium bicarbonate buffer (50 mmol/L pH 9 6) per well After the incubation we 
washed the strips saturated them overnight with 250//L of bovine serum albumin (Sigma Chemical 
Co , St Louis, MO) solution - 5 0 g of albumin, 50 mmol of Tris (pH 7 75), 154 mmol of NaCI, and 
7 5 mmol of №N3 per liter - and stored them in a humidified atmosphere at 4°C 
Immunofluorometric assay. 
Pipet100^Lof CA 125 standard or serum sample and 100 μ ι of assay buffer (the albumin solution 
above, plus 0 2 mL of Tween-20 surfactant per liter) into the coated microliter wells After incubation 
overnight at room temperature, aspirate the reaction mixture and wash the wells four times with 
wash solution (0 5 mL of Tween 20 surfactant and 7 5 mmol of №N3 per liter of isotonic saline), 
using a 12-channel washer (LKB-Wallac Oy, Turku, Finland) In the second step, add to each well 
210 fit of Eu-labeled OC 125 antibody (diluted to 100 ¿<g/L in assay buffer) After incubating the 
strips for 1 5 h at room temperature, aspirate the contents of the wells and wash the plates seven 
times with wash solution Finally, dispense into each well 200//L of enhancement solution (contain-
ing 1 0 g of Triton X-100 surfactant, 6 8 mmol of potassium hydrogen phthalate, 100 mmol of acetic 
acid, 50 /¿mol of tn-n octyl phosphmoxide and 15/imol of 2 naphtoyltrifluoroacetone per liter) 
Shake the strips for 5 mm on a microshaker (Dynatech, Zug, Switzerland), and after another 10 mm 
measure the fluorescence in a 1230 Arcus time resolved fluorometer (LKB Wallac Oy) using a 1s 
counting time and a 400^s time delay (Somi & Kojola et al 1983) 
Immunoradiometric assay 
The simultaneous (one-step) immunoradiometric assay was performed as described by Klug et 
al (1984) Reagents, buffers and standards from the Centocor CA 125 IRMA kit were used The kit 
contained 125l-labeled anti-CA 125 (specific activity approximately 10 Ci/g), standards, anti-CA 125 
coated polystyrene beads 
125l-labeled OC 125 (100 μΐ, 1 χ 105 cpm) was incubated (20 h, room temperature) with 
polystyrene-immobilized OC 125 and sample (100 /iL) The beads were washed three times and 
their radioacitivity was counted m a gamma scintillation counter 
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Results 
Standardization 
We tested the suitability of various 
CA 125-containing preparations as 
standards by using the standards from 
the CA 125 Centocor IRMA kit as a 
reference. We determined analytical 
recoveries from a human serum 
sample with a very high CA 125 con­
centration as well as from an extract of 
human serous ovarian carcinoma tis­
sue in saline, using fetal calf serum as 
a diluent. The curves for the serum and 
the tissue extract dilution series paral­
leled the Centocor standard curve 
(Figure 1). In subsequent determina­
tions we therefore used the ovarian 
carcinoma tissue extract diluted in 
fetal calf serum as a working CA 125 
standard. 
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105: 
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10 100 
tumor extract/serum amount (μι) 
Figure 1 Parallel assay curves for Centocor standard series 
(O), tumor extract dilution series ( · ), and a hu­
man-scrum dilution scries (•) 
Assay optimization 
To determine the effect of the am­
ount of immobilized OC 125 antibody 
(solid phase) on the assay charac­
teristics, we coated strips with 50 
mmol/L sodium bicarbonate buffer 
(pH 9 6) containing amounts of OC 
125 ranging between 0.1 and 5 0 mg 
per liter Each strip was incubated 
overnight at room temperature with a 
series of tissue extract standards The 
assay was then completed according 
to the standard protocol described 
above Each coating concentration 
gave a different standard curve (Figure 
2). The optimal standard curve was 
reached at an antibody concentration 
of 0 5 mg/L in the sodium bicarbonate 
buffer Use of lower coating concentra­
tions decreased the measuring range 
of the assay, whereas use of antibody 
concentrations >0.5 mg/L decreased 
the sensitivity of the assay 
In contrast, variation of the amount 
of Eu-labeled antibody negligibly af­
fected the standard curve (data not 
shown). Therefore, we used an ar­
bitrary concentration of 20 ng of Eu-
labeled OC 125 per well in further test­
ing. 
fluorescence intensity (cps)-
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ION­
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I f I I Г | — 
10 100 
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1000 
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Figure 2 Dose-response curve for various coating concen­
trations of the immobilized ОС 125 antibody. 
0.1 mg/L (O), 0.5 mg/L ( · ), 1.0 mg/L (•), 5.0 
m g / L « 
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Table 1 Intra and Inlcr-assay Precision of the I F M A 
Intra-assay precision 
Mean SD 
(arb units/mL) (arb units/mL) 
5 9 0 5 
20 10 
184 5 0 
1864 53 
3600 354 
cv 
(%) 
85 
5 0 
2 7 
2 8 
10 
Inter-assay precision 
Mean SD 
(arb units/mL) (arb units/mL) 
56 4 0 
200 16 4 
1000 86 
CV 
(%) 
7 2 
8 2 
8 6 
Intra assay precision was calculated from five replicate determinations of each serum sample inter assay precision 
from five separate duplicate assays of each serum sample 
Assay sensitivity 
The lower detection limit of the IFMA was 1 5 arb units/mL, as determined by calculating the 
mean plus 3 SD for 10 replicates of the zero dose standard prepared from assay buffer or fetal calf 
serum 
Dynamic range 
The apparent working range of the 
IFMA was determined by assaying a 
series of CA 125 tissue extract stand­
ards covering the concentration range 
from 0 to 7200 arb units/mL Fluores­
cence intensity was plotted vs the con­
centration of standard CA 125 (Figure 
3) Above 2000 arb units/mL we saw 
no further proportional increase of 
fluorescence signal Thus the working 
range ol the IFMA ranges from 1 5 to 
2000 arb units/mL 
Precision 
Intra-assay precision was deter­
mined by assaying fivefold replicates 
of five different human sera with 
various amounts of CA 125 in the same 
run (Table 1 and Figure 3) Inter-assay 
precision was estimated by determin­
ing, in duplicate CA 125 in three serum 
samples on five different occasions 
lluorebcencp intens ly (cpsl о 
1000 
CA 125 [un ts m I 
Figure 3 Standard curve and precission profile for the CA 
125 ігмл Determinations were done in duplicate 
Error bars represent ( Χ ι — X 2 ) v'S" 
Correlation with immunoradiometric assay 
We assayed, in duplicate, the CA 125 in serum samples from 30 patients, by both the present 
method (IFMA) and the IRMA Orthogonal regression analysis of these data gave the linear equation 
CA 125 (IFMA) = 0 9937 CA 125 (IRMA) -1 1211 arb units/mL, with a standard error of estimate 
(Syx) of 6 8681 arb units/mL and a Spearman rank correlation coefficient (r) of 0 9932 
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Discussion 
Radioimmunoassays are valuable tools in the clinical laboratory, but they have their own set of 
limitations The limited maximum radioactivity possible for labeled haptens or proteins may have an 
important effect on the specifications of a particular assay In terms of its sensitivity, specificity, 
broadness of the analytical range, etc Furthermore, the shelf life of a 125l-labeled protein, which 
depends on radiation damage, will be shortened as increasing numbers of I atoms are incor­
porated into the protein, and it is generally limited to six to 10 weeks Together with radiation hazards 
and the special requirements for laboratories, these limitations have stimulated the investigation of 
alternative labels in immunoassay methodology In the case of the CA 125 assay, Abbott 
Laboratories have recently made available an enzyme immunoassay based on the sandwich' 
principle In our laboratory a method comparison analysis has shown that it is less sensitive than 
the Centocor IRMA (7 5 arb umts/mL vs 1 4 arb umts/mL, respectively) As an alternative the 
present report deals with the development of an immunoassay for CA 125 based on the DELFIA 
principle with the same sensitivity as the IRMA (Klug et al 19Θ4) 
Our results indicate that high sensitivity can be achieved by optimizing the amount of immobilized 
OC 125 antibody on the solid phase If coating concentrations exceed 0 5 mg of OC 125 per liter 
the sensitivity of the assay is remarkably decreased Perhaps at higher coating concentrations all 
the available epitopes present on the CA 125-Ьеаппд antigen are captured or masked by the solid 
phase antibody, which would limit the numbers of these CA 125 determinants available to bind the 
Eu labeled antibody 
The wider measuring range of the IFMA offers obvious important practical advantages This 
advantage is probably principally ascnbable to the assay design the IRMA is performed as a 
one-step assay (Klug et al 1984), whereas the IFMA follows a two step procedure This leads to a 
broader measuring range and avoidance of the high-dose hook effect (Miles et al 1974)charac 
tenstic for one step assays The sensitivity of the IFMA (1 5 arb umts/mL) does not differ significantly 
from that of the one step IRMA (1 4 arb umts/mL) as reported by Klug et al (1984) With use of 
Eu labeled antibodies, increased sensitivity has been reported for the immunoassays for epidermal 
growth factor (Pesonen et al 1986), insulin (Toivonen et al 1986) and choriogonadotropin (Alfthan 
1986) Especially the IFMA for choriogonadotropin has been performed under exactly similar 
conditions as the IRMA, and the author showed the IFMA to be more sensitive than the IRMA because 
of a higher specific activity of the tracer molecule Regarding the similar detection limits of the CA 
125 IRMA and IFMA, the gam in sensitivity by applying Eu labeled antibodies may be counteracted 
by the introduction of a two- instead of a one-step assay design leading to a decreased assay 
sensitivity This is in line with Klug et al (1984), who showed that the IRMA was less sensitive in its 
two-step configuration 
The parallelism between the curves of the IRMA strandards and the dilutions of the ovarian 
carcinoma extract or the human serum sample shown in Figure 1 demonstrated that the CA 
125-bearing antigen in serum and the CA 125 bearing antigen extracted from tissue behave in an 
immunochemically similar fashion in the IFMA This suggests that the epitopes of the CA 125 tissue 
antigen remain well preserved upon release into the circulation Recently, Davis et al (1986) 
reported that CA 125 antigen isolated from the culture supernate of an ovarian carcinoma cell line 
was biochemically indistinguishable from CA 125 antigen in human serum, also supporting the 
notion that the number and immunochemical nature of the CA 125 epitopes remain relatively intact 
in antigen derived from different sources 
In conclusion, the use of Eu-labeled instead of 125l-labeled OC 125 allows construction of an 
immunoassay with an extended shelf life and reduced analysis time with no loss of sensitivity and 
an extended analytical range It will be of interest to test this assay on a more extensive set of clinical 
specimens to see if the IFMA matches the IRMA in its ability to monitor regression and progression 
of disease (Bast et al 1983) and identify patients with residual disease after first line therapy (Niloff 
et al 1986, Schilthuis et al 1987) 
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Abstract An in-housc OC 125 monoclonal anlibody-based "sandwich" immunofluor-
omclric assay (IFMA) described previously (Boerman el al 1987) gd\e high results for CA 
125 in 37 of 123 scrum samples, as compared with determinations by a commercially 
available immunoradiomclnc assay (IRMA) Discordant results between the two assays 
became concordant when measurements of the samples were repeated with normal mouse 
scrum (100 mL/L) included in the IFMA reagent The murine immunoglobulins arc 
thought to block the ability of the heterophilic antibodies in the human ^crum samples to 
cross link the labeled antibody withthc solid phase antibody Using an en/ymt immunoas­
say, we demonstrated human anti mouse anlibodics (HAMA) in most of the discordant 
samples examined We tested the ability of nonimmune sera from other animal species to 
lower the apparent CA 125 concentrations of the spurious samples and observed that rat, 
goal, and sheep serum were less effective lhan mouse serum One serum sample was 
disco\crcd to give a falsely increased CA 125 result with ihe IRMA, but this increase could 
be prevented by adding murine serum lo the IRMA reagent We conclude that falsely 
increased CA 125 results arc best prcvenlcd by adding murine serum (or murine an­
tibodies) to the assay buffer 
Introduction 
The monoclonal antibody-based assay for CA 125 (cancer antigen 125) in serum has become 
a reliable indicator of tumor status in patients with ovarian cancer Concentrations of CA 125 exceed 
a cut off value of 35 arb umts/mL in >80% of patients with epithelial ovarian cancer (Bast et al 
1983) Rising, stable, or falling values correlate with tumor progression stability, or regression, 
respectively in > 90% of cases (Niloff et al 1984) CA 125 concentrations are predictive of the chance 
of clinical recurrence (Niloff et al 1984, Schilthuis et al 1987) At present ongoing studies are 
evaluating the use of the CA 125 assay as an adjunct for screening apparently healthy women for 
ovarian cancer (Zurawski et al 1987,1988, Jacobs et al 1988) 
We have recently developed a two-site immunofluorometric assay (IFMA) for CA 125 using 
europium-labeled OC 125 monoclonal antibody (MAb) as the tracer (Boerman et al 1987) While 
using this in house assay concurrently with a commercially available CA 125 immunoradiometnc 
assay (IRMA), we noted falsely increased concentrations of CA 125 in several samples determined 
with the IFMA, as compared with the IRMA results Here we report on the heterophilic antibodies 
present in human serum samples that caused the spuriously increased concentrations of CA 125 
Materials and Methods 
Serum samples 
Serum samples from 30 patients with gynecologic neoplasms and from 93 healthy female 
controls were included m the present study The following nonimmune serum pools were used for 
supplementation in the CA 125 assays normal mouse serum 1 (NMS1), normal mouse serum 2 
107 
CHAPTER β 
О 
E 
η 
'с 
е> 
< 
200 
160 
120 
40 80 120 160 200 
CA 125 IRMA Çarb. units/mL;) 
В 
E 
от 
•4-» 
С 
3 
xi 
ι-
ΰ/ 
,_ (Λ 
2 
Ζ 
< 
2 
\± 
ю 
CM 
^ 
< 
о 
200 
160 
120 
80 
40 
0 
Figure 1 Orthogonal regression analysis of CA 125 (IRMA) - CA 125 (IFMA) results A. Samples 
(n = 137) were assayed concurrently in the CA 125 ¡RM A and the CA 125 IFMA Four samples 
with CA 125 levels > 200 arb units/mL arc not shown B. Samples (n = 137) were rc-assaycd 
with the IFMA with an assay buffer supplemented with NMSl (100 mL/L) Three samples 
with CA 125 levels >200 arb units/mL are not shown 
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Table 1 CA 125 determinations with IRMA and IFMAa in four selected serum samples (arb. 
unils/mL) 
Sample no. 
171 
189 
204 
192 
IRMA 
24 
B9 
14 
200 
none 
410 
310 
85 
250 
IFMA 
supplemented 
NMS1 
91 
180 
56 
18 
with 
NMS2 
32 
100 
63 
15 
a
 Assay buffers were supplemented wilh normal serum (100 mL/L) from different mouse serum pools Data represent 
the mean of two separate duplicate determinations SD < 13% of the mean for all determinations 
Table 2 CA 125 determinations (arb. units/mL) with IRMA (χ) and IFMA (y) in 37 discordant scrum 
samples 
IFMA 
supplementation3 
None 
NMS1 
NMS2 
NRaS 
NGS 
NShS 
Slope 
1 55 
1 00 
0 98 
1 10 
1.13 
1 21 
Intercept 
20 
25 
3 0 
0.47 
14 
93 
Syx 
48 3 
14 1 
136 
23 3 
28.7 
26 4 
r 
0 565 
0 955 
0 957 
0 886 
0 829 
0863 
X 
35 
35 
35 
35 
35 
35 
У 
74 
38 
37 
39 
54 
52 
" Assay buffer supplementations (100 mUL) to suppress heterophilic antibody reactivity 
(NMS2), normal rat serum (NRaS), normal goat serum (NGS), and normal sheep serum (NShS) 
NMS1 was obtained from Swiss mice kept in the Central Animal Facility of the University of Nijmegen 
The other normal animal sera were obtained from Organon-Tekmka-Cappel, Turnhout, Belgium 
CA 125 immunoradiometric assay 
The CA 125 IRMA (Centocor Ine, Malvern, PA) was used according to the manufacturer's 
instructions In this assay the MAb OC 125 is used both as capture and tracer antibody in a 
simultaneous "sandwich" format (Klug et al 1984) Serum (100 ¿iL) is added to the OC 125-coated 
polystyrene bead in a 25 well tray, then the tracer antibody (5 to 10 ng of125l-labeled OC 125 in 100 
iuL of assay buffer containing a nonspecific murine MAb) is added. After overnight incubation at 
room temperature the beads are washed and counted in a gamma counter In our hands, the lower 
detection limit of the IRMA for CA 125 is 1 4 arb. units/mL. 
CA 125 immunofluorometric assay 
We performed the IFMA according to the two-step "sandwich" protocol as described previously 
(Boerman et al 1987) In brief, we added 100 μΐ of serum and 100 /<L of assay buffer (per liter, 50 
mmol of Tris-HCI (pH 7.75), 154 mmol of NaCI, 5 0 g of albumin, and 7.5 mmol of NaNa) to the OC 
125 coated 12-well strips (Eflab Oy, Helsinki, Finland). After overnight incubation at room 
temperature, we washed the wells, added 200/iL of europium-labeled OC 125 (100 ng/mL) as tracer, 
and incubated for 90 min at room temperature. After washing, we added fluorescence enhancement 
solution (Pharmacia-Wallac Oy, Turku, Finland), and measured the fluorescence intensity in a 1230 
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Arcus fluorometer with time-resolution (Pharmacia-Wallac Oy) We determined 1 5 arb units/mL as 
the lower detection limit of the IFMA in our laboratory 
Statistical methods 
The results of the CA 125 determinations from the different immunoassays were compared by 
orthogonal regression analysis (Cornbleet & Gochman 1979) We calculated the slope and the y-axis 
intercept of the regression lines, the standard error of estimate (Syx), the mean values of χ and y, 
and the Spearman rank correlation coefficient (r) 
Samples were considered to display high values for CA 125 in the IFMA if 
CA 125 (IFMA) - CA 125 (IRMA) > 3 V ((SEIFMAY + (SEIRMA ) 2 ) , where SEIFMA and SEIRMA 
represent the standard errors of CA 125 (IFMA) and CA 125 (IRMA), respectively (both assumed to 
be 15%) 
HAMA determinations 
Serum samples were assayed for the presence of human anti-mouse antibodies (HAMA) by the 
Enzygnost-HAMA-enzyme immunoassay (Behnngwerke AG, Marburg, FRG) according to the 
manufacturer's protocol In brief, either nonspecific mouse immunoglobulins, OC 125 MAb (1 0 
/ig/mL), or phosphate-buffered saline was incubated in wells (1 h, 37 °C) that had been precoated 
with goat anti-mouse antibodies After washing, 10-fold dilutions of serum samples were incubated 
for 1 h at 37 °C in the wells, together with the HAMA positive and HAMA-negative control samples 
In this test, two conjugates of goat-anti-human immunoglobulin (specifically directed against either 
human IgG or IgM) and horseradish peroxidase (EC 1 11 1 7) are used as the tracers After the 2-h 
incubation with tracer, we washed the wells, and determined the amount of bound tracer by 
incubation with excess enzyme substrate (3 mmol H2O2 per liter in the presence of 3',3',5',5'-tetra-
methylbenzidme) To stop the color reaction, we added 100/<L of 0 25 mol/L H2SO4, then measured 
the absorbance at 450 nm with a Titertek Multiskan spectrophotometer (Flow Labs, Herts, U К ) 
Results 
CA 125 determinations 
We assayed 123 serum samples for CA 125 simultaneously in the CA 125 IRMA and the CA 125 
IFMA The results are plotted in Figure 1A Orthogonal regression analysis gave the equation 
CA 125 (IFMA) = 1 35 CA 125 (IRMA) + 3 0 arb units/mL 
(Syx - 30 7, r = 0 655, mean χ = 30 1 arb units/mL, mean у = 43 5 arb units/mL) The slope of 
1 35 and the positive y-mtercept indicate that the mean I FM A results were higher than those obtained 
with the IRMA This demonstrates a discordance between the two assay methods Next, we 
re-assayed the serum samples in the IFMA with the addition of NMS1 (100 mL/L) to the assay buffer 
The CA 125 (IFMAN M S 1) versus CA 125 (IRMA) plot is shown in Figure 1B Orthogonal regression 
analysis revealed the equation 
CA 125 (IFMAN M S 1) - 0 95 CA 125 (IRMA) - 0 15 arb units/mL 
(Syx = 10 7, r - 0 947, mean χ = 30 1 arb units/mL. mean у = 28 3 arb units/mL), indicating a 
good correlation and concordance between the IFMA and the IRMA results 
Without the addition of NMS1 to the IFMA reagent 37 (I e 34 from healthy controls and 3 from 
patients with malignancies) out of 123 serum samples showed falsely elevated CA 125 (IFMA) values, 
on the basis of the statistical criterium stated in the materials and methods section In contrast, 
assaying the 123 samples in the presence of NMS1 yielded only four samples with discordant IRMA 
versus IFMAN results Table 1 lists the CA 125 levels of these four samples as determined with 
the IRMA, IFMA, IFMAN M S 1 and IFMAN M S 2 To exclude methodological errors these samples were 
run twice in each immunoassay The false elevation of two of these four samples (patient 171 and 
189) could only completely be prevented by adding normal mouse serum from another mouse 
serum pool (NMS2) The spuriously elevated CA 125 (IFMA) concentration of the third sample 
(patient 204) was only partly reduced by the addition of normal mouse serum of either pools The 
last one of these four samples (patient 192) gave high values in both IRMA and unsupplemented 
IFMA (200 and 250 arb units/mL, respectively) and yielded a significantly lower IFMA value with 
110 
Discussion 
both mouse serum supplementations. Thus the IRMA result of this particular sample suggested a 
falsely elevation due to the presence of heterophilic antibodies that were not blocked by the 
monoclonal IgG contained in the IRMA assay buffer. Supplementation of the IRMA assay buffer with 
NMS1 (100 mU/L) resulted in a CA 125 (IRMA) concentration (20 arb. units/mL) comparable with 
the CA 125 (IFMA 1) concentration of this sample. CA 125 (IRMA) values of other samples were 
not significantly affected by this modification. 
We investigated whether the interfering antibodies could be suppressed by adding other 
nonimmune serum pools. The 37 samples giving falsely elevated CA 125 (IFMA) results as compared 
with the CA 125 (IRMA) results, were re-assayed with the IFMA using assay buffers supplemented 
with, respectively, NMS2, NRaS, NGS, orNShS (100 mL/L). The results of the orthogonal regression 
analysis are shown in Table 2. In these calculations, the CA 125 (IFMA) levels (y) were expressed 
as a function of the CA 125 (IRMA) levels (χ). Without any serum supplementation in the IFMA reagent 
orthogonal regression analysis revealed high values of the slope (a = 1.55), y-axis intercept (b - 20), 
standard error of estimate (Syx=48.3), mean y-value (74.3 arb. units/mL), and a poor correlation 
(r = 0.565). Addition of NMS1 or NMS2 (100 mL/L) to the IFMA assay buffer greatly reduced the 
discordance between the IRMA and the IFMA results. Furthermore, the data listed in Table 2 show 
that NRaS more effectively suppresses false elevation of CA 125 (IFMA) levels than the addition of 
NGS or NShS, but less effectively than NMS1 and NMS2. 
HAMA-determinations 
We further analyzed the heterophilic antibodies contained in the serum samples by assaying the 
remaining 17 out of the 37 discordant serum samples in the HAMA assay. The other 20 samples 
were exhausted. Ten out of these 17 samples proved to be positive for human anti-murine 
immunoglobulins, irrespective of whether nonspecific murine antibodies or the MAb OC 125 were 
used as catcher antibodies in the HAMA assay. Application of the heavy chain specific (mu or 
gamma) anti-human antibodies as tracer demonstrated that nine of the sera contained HAMAs 
belonging to the IgM immunoglobulin class, while one of the samples contained IgG-class HAMAs. 
Unexpectedly, we obtained identical results if phosphate-buffered saline was added instead of 
catcher antibodies, suggesting that the HAMAs also react with the goat antibodies pre-coated to 
the plates by the manufacturer. In addition, seven serum samples showing concordant CA 125 
(IRMA) versus CA 125 (IFMA) results did not respond in the HAMA. 
Discussion 
Interference by human anti-immunoglobulin antibodies in immunoassays has previously been 
reported in several studies (Howanitz et al. 1982, Clarck & Price 1987, Brennan et al. 1987, Zweig 
et al. 1988). Few studies have been undertaken to determine the incidence of heterophilic antibodies 
in sera from normal human individuals. Measuring creatine kinase isoenzymes in sera from 1008 
healthy blood donors Thompson et al. (1986) found interfering heterophilic antibodies in 92 samples 
(9.1%). Boscato et al. (1986) using an assay specifically designed to detect the heterophilic 
antibodies demonstrated their presence in 40% of 668 normal serum samples. Courtenay-Luck et 
al. (1987) reported anti-murine antibody immune reactivity in all the sera from the healthy controls 
(n = 24) included in their study. The high variability of the reported incidences of heterophilic 
antibodies may be a result of the varying sensitivities of the assays used. 
The present study gives 37 out of the 123 serum samples with falsely elevated CA 125 levels in 
the IFMA. The spurious elevations obtained with the CA 125 IFMA could be suppressed by adding 
normal mouse serum (or 0.5 g/L irrelevant murine IgGl MAb, data not shown) to the probes, 
suggesting the presence of heterophilic antibodies. These antibodies can mimic the CA 125 antigen 
in the OC 125-based "sandwich" assay by cross-linking the tracer antibody with the solid phase 
antibody. 
In ten out of 17 discordant samples human anti-murine antibodies could be demonstrated by an 
enzyme immunoassay primarily designed to detect HAMA in sera from patients who receive murine 
MAbs for diagnostic or therapeutic purposes. Only one of the HAMA-positive patients displayed an 
IgG HAMA-response whereas the other nine serum samples contained heterophilic antibodies 
belonging to the IgM subclass, in line with the observations of other investigators (Bock et al. 1985, 
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Clarck & Price et al. 1987, Courtenay-Luck et al. 1987, Mc Carthy et al. 1987) However, also IgG 
antibodies against murine immunoglobulins have been demonstrated in human serum samples 
(Boscatoi Stuart 1988). 
The effect of heterophilic antibodies was not noticed in our previous study (Boerman et al 1987) 
since for the IRMA-IFMA method comparison we used serum samples from 30 ovarian cancer 
patients with a mean CA 125 value of 93 arb units/mL. The present study demonstrates that spurious 
elevations are most striking in samples with relatively low CA 125 concentrations, since the 
differences between CA 125 (IFMA) and CA 125 (IRMA) results were generally less than 25 arb 
units/mL 
The effect of the heterophilic antibodies could be suppressed only in part with normal sera from 
other species (i e rat, sheep and goat), suggesting that the interfering heterophilic antibodies 
present in human sera are also directed against murine-specific epitopes Moreover, the spurious 
CA 125 (IFMA) elevation of one particular sample could only be suppressed completely by adding 
normal murine serum from one particular mouse strain, suggesting strain-specific anti-im-
munoglobulin immune reactivity The contradictory CA 125 results in the IRMA and IFMA in 
three samples (patient 171, 189, 204) may be ascribed to the presence of heterophilic antibodies 
directed against epitopes not present on the murine immunoglobulins contained in the NMS1 We 
therefore suggest that interfering heterophilic antibodies are best prevented by adding pools of 
immunoglobulins from various strains from the same species as the applied catcher and tracer 
antibody Thus, MAbs obtained from the same fusion experiment may also prove to be suitable 
additives Apart from the source, the amount of immunoglobulins added is important as has been 
discussed in detail in other reports (Boscato & Stuart 1987, Barlett et al 1986) 
During a study including 496 blood donors (Green et al 1986), a patient serum was discovered 
that contained highly specific human anti-idiotypic antibodies to the MAb OC 125 (Klug et al 1988). 
Since anti-idiotypic immune reactivity cannot be blocked with nonspecific immunoglobulins the 
addition of murine antibodies does not prevent the appearance of false-positive CA 125 levels in all 
cases 
The present study shows that in immunoassays such as the CA 125 assay nonspecific antibodies 
should be included in the assay reagent to block interference by heterophilic antibodies In addition 
the source of the nonimmune immunoglobulins seems most critical We think it is advisable to add 
at least immunoglobulins from the same species and strain as the reagent antibody 
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Summary 
The ovary Is a complex structure with both reproductive and endocrine function It is composed 
of a coelomic epithelium, a supporting stroma and functional germ cells Each of these tissues can 
give rise to malignant neoplasms, though the epithelial tumors account for approximately 90% of 
all ovarian malignancies 
In Western countries more than 13 cases of ovarian cancer are diagnosed per 100,000 women 
per annum, making it the fourth most frequent cancer in women after cancer of the breast, colon, 
and uterine cervix The poor survival rate (overall 5-year survival rate ±30%) has been ascribed to 
the fact that the means of an early diagnosis are extremely limited Given the difficulties in 
diagnosing, treating and monitoring the disease there is a continued search for markers of ovarian 
cancer This thesis describes the development of monoclonal antibodies (MAbs) directed against 
ovarian cancer-associated antigens (OCAAs) that may serve as markers for ovarian cancer 
Monoclonal antibodies against OCAAs are potentially powerful tools in the diagnosis and 
management of ovarian cancer patients Firstly, they may be useful adjuncts in the surgical 
pathological practice for the accurate histologic typing and grading of ovarian tumors Secondly, 
an antibody directed against an OCAA which is shed or secreted into the bloodstream, may facilitate 
the quantitative determination of the OCAA in patients sera OCAA serum levels may provide 
information about the tumour status of the patient Thirdly radiolabeled anti OCAA antibodies may 
be used for radioimmunodetection of unsuspected tumor lesions Linked to appropriate drugs 
toxins, or radionuclides, anti OCAA MAbs have in addition therapeutic potential, with the likelihood 
that such therapy could be more tumor directed and thus more specific than has hitherto been 
possible 
Monoclonal antibodies against OCAAs have been developed in several laboratories Chapter 1 
reviews the antibodies that have been developed until now The clinical potential of these anti OCAA 
MAbs is discussed 
Chapter 2 describes the development and immunohistochemical characterization of seven new 
anti OCAA MAbs (OVTL 16 17,19,22 23 24 and 27) raised by mtrasplemc immunization with cyst 
fluids from ovarian carcinomas The antibodies stained sections of most (67 96%) ovarian car 
cinomas examined (n - 49) while little reactivity with non gynecologic tumors and normal human 
tissues was found It was shown that a panel of these MAbs (including OV TL 16 or OV TL 23) can 
be a useful adjunct in the discrimination between ovarian and non ovanan carcinomas In addition, 
the antibodies OV-TL16,17 and 19 belonging to the IgG immunoglobulin class and directed against 
epitopes localized on the tumor cell surface may be useful tools for in vivo application 
Chapter 3 describes the development and characterization of three other anti OCAA MAbs 
OV-TL 15 30 and 31 These MAbs were raised against a tumor extract prepared from an undifferen 
tiated ovarian carcinoma OV-TL 15, 30 and 31 were reactive with the major proportion (84% 84% 
and 74%, respectively) of the ovarian carcinoma specimens examined (n = 76) The antibodies were 
shown to be directed against distinct cell surface antigens (OA 15, OA30and OA31) OV-TL 15 30 
and 31 were only poorly reactive with non ovarian carcinomas Most interestingly the three 
antibodies were hardly reactive with benign ovarian tumors Immunoradiometrical determination of 
antigen levels in cyst fluids from ovarian carcinomas and benign ovarian tumors confirmed the 
carcinoma specific expression of the antigens recognized by OV-TL 15 and 31 Therefore, the 
expression of OA 15, OA 30 and OA 31 is thought to be triggered during the process of malignant 
transformation However, a clear-cut relation between the expression level of these antigens and 
the differentiation grade of the tumor could not be assessed 
Since treatment and prognosis of cancer patients depend on the origin and spread of the tumor, 
reliable histopathological typing of tumors is essential Although the histopathological differential 
diagnosis between ovarian and non-ovarian cancers is feasible in most cases, about 10% of poorly 
differentiated ovarian tumors cannot be positively identified on the basis of morphological criteria 
(Osborn & Weber, 1983) MAbs against OCAAs may be helpful in these cases A comparative 
immunohistochemical study was undertaken (chapter 4) to assess the gynecopathological value 
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of four MAbs against OCAAs OC 125 (Bast et al 1981), OV-TL3 (Poelsetal 1986), MOv 18 (Miotti 
et al 1987), and OV-TL 23 (Boermanetal 1989) OC 125, OV-TL3 and MOv 18 reacted positively 
with approximately 90% of the ovarian carcinoma samples (n = 80) and thus a negative reactivity 
with these antibodies In a section of an adenocarcinoma makes it unlikely to be an ovarian 
carcinoma However, the occasional reactivity of OC 125 and OV-TL 3 with carcinomas of the breast, 
colon and lung limits their use in differential diagnosis MOv 18 was found less reactive with 
non-gynecologic carcinomas OVTL 23 positively stained fewer ovarian carcinoma samples (76%) 
than the other antibodies On the other hand OV-TL 23 was the only antibody being only poorly 
reactive with endometrial carcinomas and completely unreactive with non gynecologic carcinomas 
Therefore, a positive reactivity in an adenocarcinoma section with OV-TL 23 indicates its likelyhood 
as ovarian carcinoma 
MAbs against tumor-associated antigens are currently used to non-mvasively assess the disease 
status in cancer patients (Goldenberg 1987) Recently, a clinical trial was initiated to evaluate the 
applicability of 111ln-labeled OVTL 3 F(ab')2 for imaging cancer lesions in ovarian cancer patients 
Preliminary results are most promising (Claessens et al 1989) To investigate the in vivo potential 
of OV-TL 3, OV-TL 16 and OV-TL 30 we studied the in vitro cell binding characteristics of the antibodies 
and their biodistribution in tumor bearing mice The well-characterized antibody OC 125 (Bast et al 
1981 ) was used as a reference in this study (chapter 5) Label uptake into the xenografted ovarian 
tumors 48 h after injection of radioiodmated OV-TL 3 and OV-TL 16 was 2 3 times higher than the 
tumor uptake obtained with 1 2 5 l labeled OC 125 and OV-TL 30 The higher tumor localization of 
OV-TL 3 and OV-TL 16 as compared to OC 125 could not be ascribed solely to differences in the 
affinity constants the immunoreactive fractions of the antibodies or the expression levels of the 
MAb-defmed antigens It is suggested that because the antigens recognized by OVTL 3 and OV-TL 
16 are not shed from the tumor cells these antibodies may be better tools for radioimmunodetection 
of ovarian carcinomas than OC 125 
To determine the optimal tumor imaging agent based on the monoclonal antibody OVTL 3, the 
in vivo behavior of four different formulations of OV TL 3 was studied (chapter 6) OV-TL 3 whole IgG 
and its F(ab')2 fragments labeled with either I 125 or ln-111 were injected in human ovarian 
carcinoma xenograft bearing mice and the pharmacokinetics of the radiolabels were determined 
The ln-111 label was retained in the body undergoing slow fecal and urinary excretion as compared 
to the 1-125 label Especially the liver kidneys and spleen showed high persisting uptake of In 111 
The F(ab')2 fragments of OV TL 3 cleared the blood and the tissues more rapidly than the intact IgG 
As a result, highest tumor/tissue label uptake ratios were obtained with the 1 2 5 l labeled F (ab )2 
fragments of OV-TL 3 suggesting a use lor 123l-OV-TL 3 F(ab )г in clinical immunoscmtigraphy 
However, the quality of images with I-123 will be degraded due to its short physical halflife 
The monoclonal antibody-based serum assay for CA 125 has become a reliable indicator of 
tumor status in patients with ovarian cancer Various clinical applications of the assay have been 
studied, including detection of disease prior to second-look surgery (Niloff et al 1986), monitoring 
patients' response to therapy (Lavm et al 1987) and differential diagnosis of pelvic masses 
(Malkasian et al 1988) CA 125 concentrations in serum have been measured in most cases with 
the immunoradiometnc assay (IRMA) (Klug et al 1984) in which 1 2 5 l labeled MAb OC 125 is used 
as a tracer In chapter 7 the development of an immunofluorometric assay (IFMA) for CA 125 
determinations is described, using europium labeled OC 125 as a tracer The lower detection limit 
of the IFMA was as good as the lower detection limit of the IRMA The IFMA was shown to be a 
convenient alternative to the IRMA because of short counting times, the use of non-radioactive, 
stable reagents, and an extended measuring range 
Using the IFMA simultaneously with the IRMA for the CA 125 determination in patients' sera 
demonstrated falsely elevated CA 125 levels in several samples when measured in the IFMA It could 
be shown that the falsely elevated CA 125 (IFMA) levels were caused by heterophihc antibodies 
present a proportion of the serum samples (chapter 8) These heterophilic antibodies mimic the CA 
125 antigen by cross-linking the tracer to the catcher antibody The falsely elevated CA 125 (IFMA) 
levels could be prevented by the additon of nonspecific irrelevant murine antibodies to the assay 
reagent Normal sera from rat, goat and sheep were less effective in blocking the interference of the 
heterophihc antibodies in the IFMA, indicating that the interfering antibodies were also directed 
against species-specific epitopes Further characterization of the heterophihc antibodies in a HAMA 
assay showed that in the majority of cases they belonged to the IgM immunoglobulin class 
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Samenvatting 
De functie van het ovarium in het lichaam Is tweeledig Naast de produktie van geslachtscellen 
produceert het orgaan verschillende hormonen Het ovarium bestaat uit rijpende geslachtscellen, 
een bekledende laag van mesotheelcellen en ondersteunend stroma Uit leder van deze weefsel-
componenten kunnen tumoren ontstaan Ovariumcarcmomen vormen meer dan 90% van de 
maligne ovarium tumoren en ontstaan waarschijnlijk uit de mesotheelcellen 
In westerse landen is ovariumkanker na borst-, dikke darm- en baarmoederhalskanker de meest 
voorkomende vorm van kanker bij de vrouw In Nederland werd m 1985 per 100 000 vrouwen bij 
meer dan 18 vrouwen de diagnose ovariumkanker gesteld Ongeveer twee van de drie vrouwen 
met ovariumkanker overlijdt aan de gevolgen van de ziekte Deze slechte prognose wordt vooral 
veroorzaakt door het feit dat de ziekte meestal pas in een gevorderd stadium geconstateerd wordt 
Als gevolg van de problemen bij het diagnostiseren, behandelen en vervolgen (monitoring) van de 
patiënten met ovariumkanker wordt er gezocht naar stoffen die kunnen dienen als markers voor 
deze ziekte 
In dit proefschrift wordt de ontwikkeling van monoclonale antilichamen (MAbs) tegen ovarium-
carcinoom geassocieerde antigenen (OCAAs) beschreven, die zouden kunnen dienen als markers 
voor ovariumkanker leder antigeen dat tot expressie komt op ovariumcarcinoom cellen en met of 
in mindere mate op normale (met getransformeerde) cellen kan in principe dienen als marker voor 
ovariumkanker 
Monoclonale antilichamen specifiek gericht tegen OCAAs kunnen een belangrijke rol spelen bij 
het diagnostiseren en behandelen van patiënten met ovariumkanker Deze antilichamen kunnen 
worden gebruikt bij de histopathologische analyse van tumoren na operatie Immunohistochemi-
sche kleuring met behulp van anti-OCAA MAbs zou de histologische typering en gradering van 
tumoren kunnen verscherpen (weefseldiagnostiek) Als het OCAA waartegen het monoclonale 
antihchaam gericht is, wordt afgescheiden in de circulatie, kan een kwantitatieve bepaling van de 
OCAA bloedspiegel informatie geven over het verloop van de ziekte (serodiagnostiek) Bovendien 
kunnen radioactief gelabelde anti-OCAA antilichamen gebruikt worden om tumorlesies in het 
lichaam non-mvasief te locahseren (immunoscintigrafie) Volgens hetzelfde principe zouden anti-
OCAA MAbs gekoppeld aan cytostatica, toxines of geschikte radionucliden ingezet kunnen worden 
bij de behandeling van kanker (antihchaam geleide therapie) 
Op verschillende laboratoria zijn monoclonale antilichamen tegen OCAAs ontwikkeld Hoofdstuk 
1 geeft een overzicht van de tot nu toe in de wetenschappelijke literatuur beschreven antistoffen 
De waarde van deze antilichamen bij verschillende klinische toepassingen wordt besproken 
In hoofdstuk 2 wordt de ontwikkeling en immunohistochemische karakterisering van zeven 
nieuwe anti OCAA MAbs (OV-TL 16, 17, 19 22, 23, 24 en 27) beschreven Deze antistoffen werden 
opgewekt door muizen te immuniseren met cystevochten van ovariumcarcmomen Aangetoond 
werd dat deze antistoffen gericht zijn tegen antigene determinanten die voorkomen op de meeste 
(67 96%) ovariumcarcmomen, en met of nauwelijks op met-gynaecologische tumoren en normale 
humane weefsels Combinaties van deze antistoffen bleken geschikt voor het immunohistoche-
misch onderscheiden van ovarium en met ovarium carcinomen 
In hoofdstuk 3 wordt de ontwikkeling en karakterisering van drie andere anti OCAA MAbs (OV-TL 
15, 30 en 31) beschreven Deze antilichamen werden verkregen door muizen te immuniseren met 
een extract van een ongedifferentieerd ovariumcarcinoom OV-TL 15, 30 en 31 reageerden met de 
meeste ovariumcarcmomen (84%, 84% en 74%, respectivelijk) en nauwelijks met andere tumoren 
Aangetoond werd dat de antistoffen gericht zijn tegen verschillende oppervlakte antigenen (OA 15, 
OA 30 en OA 31) Opvallend was dat de antistoffen, in tegenstelling tot de tot nu toe in de literatuur 
beschreven anti-OCAA MAbs, met reageerden met benigne ovanumtumoren Immunoradiometris-
che bepalingen van OA 15 en OA 31 in cystevochten van ovanumtumoren bevestigden de 
carcmoom-specifieke expressie van deze antigenen 
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Een juiste hlstopathologische classificatie van tumoren is van wezenlijk belang met het oog op 
de behandeling en de prognose van patiënten met ovarlumkanker Een deel van de ovariumtumoren 
(± 10%) kan niet met zekerheid geclassificeerd worden op grond van morfologische criteria In deze 
gevallen zouden Immunohlstochemlsche kleuringen met anti-OCAA MAbs uitkomst kunnen bieden 
Hoofdstuk 4 beschrijft een studie waarin de waarde van vier verschillende monoclonale an-
tilichamen OC 125, OV-TL 3, MOv 1 θ en OV-TL 23 voor toepassing inde gynaecopathologie wordt 
onderzocht OC 125, OV-TL 3 en MOv 18 reageerden ieder positief met meer dan 90% van de 80 
geteste ovanumcarcinomen Van een adenocarcinoom dat een negatieve reactie geeft met deze 
MAbs moet dus betwijfeld worden of het een ovanumcarcinoom is OV-TL 3 en OC 125 reageerden 
echter ook positief met enkele van de borst-, colon- en longcarcmomen MOv 18 vertoonde 
nauwelijks reactiviteit met met-gynaecologische tumoren OV-TL 23 reageerde weliswaar met 
minder ovanumcarcinomen (76%) dan de andere antilichamen, maar vertoonde een hogere 
specificiteit OV-TL 23 reageerde namelijk met met met-gynaecologische carcmomen en bijna met 
met endometrlumcarcinomen Een adenocarcinoom dat een positieve reactie vertoont met OV-TL 
23 zal dus waarschijnlijk een ovanumcarcinoom zijn 
In verschillende klinische trials wordt de mogelijkheid onderzocht om met behulp van MAbs 
tegen tumor geassocieerde antigenen tumorlesies bij patiënten te localiseren Onlangs werd een 
studie gestart waarin de bruikbaarheid van ^In-OV-TL 3 F(ab')2 voor dit doel wordt onderzocht 
De eerste resultaten van deze studie zijn veelbelovend Teneinde de toepasbaarheid van OV-TL 3, 
OV-TL 16 en OV-TL 30 in de immunoscmtigraf ie te vergelijken werd de interactie van deze antistoffen 
met ovariumtumorcellen in vitro en in vivo bestudeerd (hoofdstuk 5) De antistoffen werden 
gemarkeerd met 1-125 en Intraveneus ingespoten in tumordragende proefdieren De opname van 
I-125 label in de tumoren 48 uur na injectie van OV-TL 3 en OV-TL 16bleek2à3 maal hoger dan na 
injectie met OV-TL 30 en OC 125 Het verschil in tumoropname kon met louter worden toegeschreven 
aan verschillen m immunoreactieve fractie, affimteitsconstante van de MAbs, of expressieniveau van 
de OCAAs Wellicht is de relatief hoge tumorlocalisatie die gevonden werd met OV-TL 3 en OVTL 
16 een gevolg van het feit dat deze antilichamen gericht zijn tegen antigenen die met door de 
tumorcellen worden afgescheiden 
Teneinde de meest geschikte formulering van OV-TL 3 voor radioimmunodetectie van ovarium-
tumoren te bepalen, werd het in vivo gedrag van vier verschillende immunoconjugaten van OVTL 
3 bestudeerd (hoofdstuk 6) OV-TL 3 (intact IgG danwei F(ab')2) werd gemarkeerd met 1-125 of In 111 
en intraveneus ingespoten in tumordragende proefdieren Het In 111 label bleek relatief langzaam 
uit het lichaam te worden uitgescheiden Met name lever, nieren en milt vertoonden een relatief hoge 
en persisterende opname van ln-111 De F(ab')2 fragmenten van OV TL 3 werden veel sneller uit het 
bloed en de met-tumor weefsels geklaard dan het intacte IgG, terwijl de tumorlocalisatie van F(ab')2 
OV-TL 3 nauwelijks lager was Deze resultaten geven aan dat het gebruik van 123l-OV-TL 3 F(ab')2 
voor radioimmunodetectie van ovanumcarcinomen overwogen kan worden 
Het CA 125 gehalte van het bloed kan belangrijke informatie geven over de status van patiënten 
met ovarlumkanker CA 125 bepalingen worden in het algemeen uitgevoerd met een immu 
noradiometnsche assay (IRMA) In deze test wordt 1-125 gemarkeerd OC 125 gebruikt als tracer In 
hoofdstuk 7 wordt een immunofluorometnsche assay (IFMA) beschreven voor CA 125 bepalingen 
In deze assay wordt gebruik gemaakt van de unieke fluorescentie eigenschappen van europium 
chelaten De IFMA, waarin Eu gemarkeerd OC 125 als tracer gebruikt wordt bleek een goed 
alternatief voor de immunoradiometnsche assay De detectiegrens van de IFMA (1,4 U/mL) was 
vergelijkbaar met die van de IRMA De voordelen van de IFMA waren langere houdbaarheid van 
de reagentia, bredere meetrange, kortere teltijden en geen stralingsrisico's Vooral in sera van 
gezonde individuen, gaf de IFMA als beschreven ¡n hoofdstuk 7 echter significant hogere CA 125 
waarden dan de IRMA Aangetoond werd dat heterofiele antilichamen aanwezig In humane sera 
verantwoordelijk waren voor deze vals verhoogde resultaten (hoofdstuk 8) Toevoeging van met-
specifieke Immunoglobulinen van de muis aan de assay buffer voorkwam de storende invloed van 
heterofiele antistoffen In de CA 125 IFMA Normaal serum van de rat, de geit en het schaap 
onderdrukte het storende effect van de heterofiele antistoffen minder effectief Verdere analyse van 
de heterofiele antistoffen In een HAMA assay toonde aan dat de meeste heterofiele antistoffen tot 
de IgM Immunoglobuline klasse behoren 
119 

Dankwoord 
Dit proefschrift kwam tot stand dankzij de enthousiaste inzet van velen Allen die een bijdrage 
hebben geleverd wil ik graag danken 
De medewerkers van de afdeling Celbiologie en Histologie voorde prettige samenwerking Kardien 
Makkink, die met een nimmer aflatende nauwgezetheid een groot deel van de experimenten heeft 
uitgevoerd Paul Jap voor zijn veelzijdige inbreng Mare du Mame Ruud de Wildt, Antoinette 
Keurntjes en Ingeborg Bol voor het werk dat zij in het kader van hun HLO opleiding voor dit 
onderzoek hebben verricht 
De medewerking en gastvrijheid die ml) op het laboratorium voor Endocrinologie en Voortplanting 
werd geboden door Tijn Segers, Rob van den Berg, Ton van der Zande en Henk Ariaens heeft de 
voortgang van het onderzoek enorm bespoedigd 
Dankzij Wim van den Broek heb ik me als gast van de afdeling Nucleaire Geneeskunde nooit een 
gast hoeven voelen 
Niels de Jonge die mij vanuit Leiden als vriend en adviseur bi] statistische problemen terzijde stond 
dank ik voor zijn enthousiaste en onzelfzuchtige bijdragen 
Nol van Uden Cees Nicolasen, Günther Klickerman en Theo Hafmans verzorgden de figuren en 
foto's van dit proefschrift accuraat en vakkundig 
De medewerkers van het Centraal Dierenlaboratorium, Jan Koedam Henme van Wezel, Monique 
Derks, Gerne Grutters en Henme Eikholt wil ik bedanken voor de assistentie en het onderricht tijdens 
de dierexperimenten 
Nu de richtlijnen met betrekking tot de dankbetuigingen in een proefschrift gewijzigd zijn wil ik met 
nalaten op deze plaats mijn beide promotores uitbundig te bedanken 
Vrienden en familieleden dank ik voor hun belangstelling en steun tijdens de afgelopen jaren Henry 
Geerts, onze bijkans rituele lunches zal ik missen 
Prisca, Bram en Daan het was prachtig om temidden van jullie aan dit boekje te werken 
121 
Curriculum Vitae 
Otto Christіаап Boerman werd op 27 mei 1959 geboren te Lochem Na het behalen van het VWO 
diploma in 1977 aan de Rijksscholengemeenschap te Lochem, werd begonnen met de studie 
scheikunde aan de Katholieke Universiteit Nijmegen In oktober 1980 werd het kandidaatsexamen 
scheikunde (S2) afgelegd Het doctoraalexamen, behaald in oktober 1984, omvatte het hoofdvak 
Biochemie (Prof Dr H Bloemendal) en de bijvakken Milieukunde (Dr DW Schoof) en Cyto-His 
tologie (Prof Dr Chr Jerusalem) 
Van oktober 1984 tot april 1986 is hij werkzaam geweest als wetenschappelijk assistent aan het 
laboratorium voor Parasitologie (Prof Dr A M Deeider) van de Rijksuniversiteit Leiden Van mei 
1986 tot december 1989 was hij als wetenschappelijk assistent verbonden aan de afdeling Cel­
biologie en Histologie (Prof Dr A M Stadhouders) van de Katholieke Universiteit Nijmegen In de 
werkgroep van Dr L G Poels werd in het kader van het Praeventiefondsproject 'Vroegdetectie van 
curabele ovanumcarcinomen' (projectleiders Prof Dr Ρ Kenemans, Prof Dr Τ К А В Eskes, Dr 
L G Poels) het m dit proefschrift beschreven onderzoek uitgevoerd Van december 1989 tot april 
1990 is hij als wetenschappelijk assistent in dienst bij de afdeling Pathologische Anatomie (Prof Dr 
G Ρ Vooijs) van de Katholieke Universiteit Nijmegen Vanaf mei 1990 is hij als 'fellow' in dienst van 
de Nederlandse Kankerbestrijding 
122 
Publications 
G A M Berbers, OC Boerman, H Bloemendal, WW de Jong Primary gene products of bovine 
/3-crystallin and reassociation behaviour of its aggregates Eur J Biochem 128,495-502,1984 
J Ρ Rotmans, О С Boerman, A Burgers Identification of sex-linked antigens of Schistosoma 
mansom by Immunoelectrophoresis and immunoblotting J Chem Ecol 12,1817-1832 1986 
A M Deelder, N de Jonge, О С Boerman, YE Filile, G W Hilberath, J Ρ Rotmans, M J Gerntse, 
D W О A Schut Sensitive determination of circulating anodic antigen in Schistosoma mansom 
infected individuals by an enzyme-linked immunosorbent assay using monoclonal antibodies Am 
J Trop Med Hyg 40, 268-272, 1989 
N de Jonge, OC Boerman, A M Deelder Time-resolved immunofluorometric assay (TR-IFMA) for 
the detection of the schistosome circulating anodic antigen Trans Royal Soc Trop Med Hyg 83, 
659-663, 1989 
OC Boerman, С M G Thomas, M FG Segers, Ρ Kenemans, Τ Lovgren, VR Zurawski Jr H J 
Haisma, L G Poels Time-resolved immunofluorometric assay for the ovarian carcinoma-associated 
antigenic determinant CA 125 in serum Clin Chem 33,2191 2194 1987 
ОС Boerman, M FG Segers, L G Poels, Ρ Kenemans C M G Thomas Heterophihc antibodies in 
human sera causing falsely increased results in the CA 125 immunofluorometric assay Clin Chem 
(in press) 
O Boerman, К Makkink, L Massuger, С Thomas, Ρ Kenemans, Τ Hanselaar L Poels Monoclonal 
antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids 
Anticancer Res 9, 551-559, 1989 
О С Boerman, W К Makkink, С M G Thomas, A G J M Hanselaar, С A Yedema Ρ Kenemans, L G 
Poels Monoclonal antibodies that discriminate between human ovarian carcinomas and benign 
ovarian tumours Eur J Cancer Clin Oncol (in press) 
ОС Boerman, С С van Niekerk. WK Makkink A G J M Hanselaar, Ρ Kenemans, L G Poels A 
comparative immunohistochemical study of four monoclonal antibodies directed against ovarian 
carcinoma-associated antigens Int J Gynecol Pathol (in press) 
О С Boerman, L Massuger, W К Makkink, С M G Thomas, Ρ Kenemans, L G Poels Comparative 
m vitro binding characteristics and biodistribution m tumor-bearing athymic mice of anti-ovarian 
carcinoma monoclonal antibodies (submitted) 
L FA G Massuger, О С Boerman, W van den Broek, R A M J Ciaessens, L G Poels, Ρ Kenemans, 
FH M Corstens Biodistnbution of lodine-125 and lndium-111 labeled OV-TL 3 intact and F(ab')2 
fragments m tumor-bearing athymic mice (submitted) 
J L V Broers, M Klein Rot, E Mijnheere, G Schaart, A Sijlmans, O Boerman, FC S Ramaekers 
Novel antigens characteristic of neuroendocrine malignancies (submitted) 
123 
Abbreviations 
Ab antibody 
arb U arbitrary units 
BSA bovine serum albumin 
CA 125 cancer antigen 125 
CHAPS cholamidopropyldimethyl ammoniopropanesulfonate 
Ci Cune 
cpm counts per minute 
cps counts per second 
EDTA ethylenediammetetraacetate 
EIA enzyme-linked immunoassay 
PCS fetal calf serum 
FIGO Federation Internationale de Gynécologie et Obstetnque 
FITC fluorescein isothiocyanate 
HAMA human anti mouse antibody 
HAT hypoxanthine-aminoptenn-thymidine 
% ID/g percentage of the injected dose per gram of tissue 
ι ρ intraperitoneal (ly) 
ι ν intravenous(ly) 
I EM immunoelectron microscopy 
IFA immunofluorescence assay 
IFMA immunofluorometric assay 
Ig immunoglobulin 
IPO immunoperoxidase assay 
IRMA immunoradiometric assay 
Ka affinity constant 
MAb monoclonal antibody 
NMS normal mouse serum 
OCAA ovarian carcinoma-associated antigen 
PBS phosphate-buffered saline 
PLPG periodate lysine paraformaldehyde glutaraldehyde 
PMSF phenylmethylsulphonylfluonde 
RIA radioimmunoassay 
s с subcutaneous(ly) 
SDS sodiumdodecylsulphate 
SLL second look laparotomy 
TR-IFMA time-resolved immunofluorometric assay 
Tris tris(hydroxymethyl)aminomethane 
U/mL units per milliliter 
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STELLINGEN 
behorend bij het proefschrift 
Development and Application of Monoclonal Antibodies against 
Ovarian Cancer. 
ι 
Heterofiele antilichamen zijn aantoonbaar in sera van meer dan 30% van gezonde individuen en kun­
nen in iedere sandwich immunoassayeen storende factor vormen 
(dit proefschrift) 
II 
Het feit dat de affmiteitsconstante van een monoclonaal antilichaam afhankelijk blijkt van de bij de bepa 
ling gebruikte cellijn toont de relatieve waarde van deze parameter 
(Masuhoetal Cancer Res 44,2813 2819, 1985) 
III 
Het is van belang bij in vivo targeting studies antwoord te krijgen op de vraag in hoeverre accumulatie 
van anti tumor antilichamen in tumoren het gevolg is van andere mechanismen dan specifieke 
antihchaam-antigeen interacties 
IV 
De follow-up van kankerpatiënten met behulp van tumormerkstoffen dient terughoudend te geschie-
den, zolang een effectieve tweede-lijns therapie ontbreekt 
V 
De waarneming van Ward et al dat in prokaryotische expressie vectoren geproduceerde variabele do 
meinen van immuunglobulmen, antigeen bindende eigenschappen hebben biedt nieuwe mogelijk 
heden voor het produceren van 'achter de tekentafel ontworpen vehikels voor immunotargetmg 
(Wardetal Nature 341, 544-546, 1989) 
VI 
BIJ het 'humaniseren' van monoclonale antilichamen kan in plaats van het humane Fc-fragment ook ge-
kozen worden voor humaan albumine 
VII 
De aanwezigheid van circulerend anodisch antigeen (CM) in serum of urine is voldoende bewijs voor 
het aantonen van een actieve Schistosoma infectie en hoeft derhalve met bevestigd te worden door het 
aantonen van eieren in de ontlasting 
VIII 
Stimulering van methionine afbraak via de transaminermgsroute is waarschijnlijk een zinvolle therapie 
bij homocystemuria 
IX 
Het is onwaarschijnlijk dat de bij Kearns Sayre patiënten gevonden deleties in het mitochondriële DNA 
dit syndroom veroorzaken. 
X 
Bij het licht-gestimuleerd anisotroop oplossen van halfgeleiders wordt de kinetiek en de vorm van de 
geëtste structuren vooral bepaald door galvanische effecten en niet zozeer door lokale fotochemische 
processen. 
XI 
Om te voorkomen dat goede radioprogramma's in Nederland een zachte dood zullen sterven, dient de 
financiering van radio- en televisieprogramma's strikt gescheiden te blijven. 
XII 
De huidige vrees voor de eugenetica berust vooral op een overschatting van de mogelijkheden van de 
DNA-technologie. 
XIII 
De verdeling van formatieplaatsen voor promovendi binnen een faculteit dient plaats te vinden op 
grond van een open competitie met wetenschappelijke spelregels. 
XIV 
De ondernemers van de West-Indische Compagnie hebben niet kunnen vermoeden dat hun activiteiten 
zouden bijdragen aan de kwaliteit van het nederlandse voetbal. 
XV 
Het is goed dat onderzoekers het land uit worden gestuurd. 
Nijmegen, 25 april 1990 Otto С. Boerman 


